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Apoptosis is an important homeostatic mechanism for the regulation of cellular 
differentiation and proliferation. Within the immune system in particular, a failure of 
apoptotic regulation leads to lymphoproliferative disease and / or autoimmunity. A 
number of molecules have been identified with an important role in regulating apoptosis, 
including both pro-apoptotic and anti-apoptotic proteins. One important pro-apoptotic 
receptor, Fas (CD95 / Apo-1) was identified as responsible for the autoimmunity and 
lymphoproliferative disease in the MRL-lprApr mouse. The autoimmune disease in this 
mouse has a striking resemblance to human Systemic Lupus Erythematosus (SLE). As a 
result, the Fas gene was an important candidate for analysis in human SLE.
However, to study Fas biology in human disease more information was required about 
Fas function in normal human physiology. Therefore, a major objective was to establish 
useful reagents to enable further analysis of the role of Fas in the maintenance of 
lymphocyte homeostasis. With these reagents, a putative ligand (FasL) for the Fas 
receptor was identified on activated T cells, thus establishing a basis for further analysis 
of Fas-FasL interactions. As a result, a soluble FasL was also created in vitro, which 
contributed further to our understanding of Fas mediated apoptosis. The ability of a 
soluble ligand to induce apoptosis has also been confirmed by recent studies with 
naturally produced soluble FasL.
Finally, an analysis of the role of Fas was carried out in patients with SLE using genetic 
and functional approaches. PCR-SSCP analysis of the Fas gene cDNA revealed one 
patient with a mutation in the cytoplasmic region of Fas, suggesting that no major defect 
of Fas exists in the SLE population as a whole. However, functional data suggested 
enhanced in vitro apoptosis following Fas engagement on SLE T cells. The clinical 
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Homeostasis refers to the essential process of check and balance that is operative 
within the human body, and in fact in all living systems. Cell numbers are essentially 
maintained by a balance between proliferation and death, both of which occur 
simultaneously and continuously within the normal human body. Examples of 
homeostasis can be seen in the cellular turnover of the skin, the gastointestinal tract, 
and particularly in the immune system.
Cell death is known to take two forms; namely necrosis and apoptosis (Kerr et al, 
1972). Apoptosis is frequently also referred to as programmed cell death. Cell death by 
apoptosis is different from necrosis mainly in the highly organised nature of the 
process (reviewed by Cohen, 1993). Whereas necrotic cells undergo early swelling 
and enlargement followed by membrane rupture and spillage of the intracellular 
contents, apoptotic cells develop characteristic cytoplasmic shrinkage and membrane 
blebbing followed by nuclear condensation and fragmentation.
An important functional correlate of apoptosis is that this form of cell death is not 
usually associated with an inflammatory response because there is no extrusion of 








Figure 1.1: Morphologic cellular changes in Apoptosis and Necrosis.
Cells undergoing death by necrosis usually swell and rupture to release intracellular 
contents which induce an inflammatory response. In contrast apoptotic death is 
characterised by a shrinking cytoplasm, membrane blebbing and nuclear condensation. 
Membrane-bound apoptotic blebs are rapidly phagocytosed thus preventing the non­
specific induction of an inflammatory reaction.
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Rapid phagocytosis of the apoptotic membrane-bound cellular contents by 
macrophages prevents the induction of an inflammatory cascade. Macrophages and 
other phagocytes have highly specific and sensitive receptors for apoptotic particles 
(reviewed by Savill et al, 1993) and it may be the rapid nature of the mopping up 
process which has led to the failure to detect apoptosis as a ubiquitous process in 
standard histochemical sections in the past. As a result, the vigilant observations of 
Wyllie and Kerr only really induced a greater interest in apoptosis amongst the 
scientific community approximately twenty years after its first description (Kerr et al, 
1972). Subsequently the scale of interest in apoptosis both in biology and in the 
context of disease has led to an escalation in the pace of research such that a number of 
improved techniques have become available for the detection of apoptosis (Studzinski, 
1995).
Apoptosis can be induced by a variety of stimuli, including ultraviolet irradiation, 
toxins, viral infections, drugs (particularly cytotoxic anti-cancer agents), growth factor 
withdrawal as well as specific apoptosis-inducing proteins like TNFa and CD95/Fas. 
Most of these factors usually involve the stimulation of a cascade of intracellular events 
leading to the morphologic manifestations described. A number of surface and 
intracellular molecules have been identified with important functions in the apoptotic 
process. These may take part in induction or inhibition of apoptosis either directly or 
through a network of complex intracellular interactions with other proteins or genes. 
This is a rapidly advancing field and could not justifiably be reviewed completely in 
detail here, but relevant areas will be discussed in relation to Fas-mediated apoptosis 
later.
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1.1.2) Apoptosis in Lymphocytes
Control of cell number and cellular differentiation is an example of homeostasis within 
the immune system. Immune cells such as T cells and B cells undergo continuous 
modification from the time of development within the thymus and bone marrow, 
respectively, until they are no longer required for function within the body. Large 
numbers of immune effector cells are destroyed or inactivated during development 
within the thymus and bone marrow, and the evidence suggests that this process of 
negative selection occurs through apoptosis (Kappler et al, 1987).
In addition to central tolerance, there is also a need to control activated T and B cells 
once they are circulating in the periphery, particularly when they have carried out their 
primary function in the immune response. If this peripheral control fails then 
homeostasis can be dangerously upset in favour of autoimmune disease states or 
malignancy. Apoptosis is therefore considered to play a significant role in the control 
of peripheral activated immune cells (Singer and Abbas, 1994). However, apoptosis is 
by no means the only homeostatic control and other regulatory mechanisms such as 
anergy and clonal ignorance are also thought to operate in the maintenance of 
peripheral tolerance (Abbas et al, 1997).
Apart from the regulation of central and peripheral tolerance, apoptosis of lymphocytes 
also serves important functions in the regulation of cytotoxic lymphocyte function, NK 
cell function and acitvation induced cell death (reviewed by Cohen and Duke, 1992).
10
1.1.3) Apoptosis in Disease
Apoptosis in disease states may be either increased or decreased (Figure 1 .2 ). 
Examples of reduced apoptosis include lymphoid malignancies and autoimmune 
diseases (Krammer and Debatin, 1992), whilst enhanced lymphocyte apoptosis has 
been associated with conditions like AIDS (Meyaard et al, 1992). Many anti-cancer 
drugs and glucocorticoids mediate their effects through enhancing apoptosis of 
lymphocytes and other cell types (Kerr et al, 1994). Similar patterns may be found in 
other disease states not involving lymphocytes. For example decreased apoptosis is 
seen in carcinomas associated with p53 mutations, hormone-dependent breast and 
prostatic tumours, and viral infections with Herpesvirus, Adenovirus or Poxviruses, 
whilst increased apoptosis has been associated with neurodegenerative diseases like 
Alzheimer’s disease, Amyotrophic lateral sclerosis, Cerebellar degeneration, and 
reperfusion ischaemic injury following myocardial or cerebral infarction.




















Figure 1.2: Examples of diseases associated with 
altered apoptosis.
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1.1.4) Signalling pathways in Apoptosis
1.1.4.1) Caspases
The signalling mechanisms for apoptosis are still being deciphered but current evidence 
suggests a common committed pathway of intracellular events leading to the 
cytoplasmic and nuclear changes characteristic of apoptosis. This involves a series of 
proteases called Caspases (cysteine proteases that cleave after an aspartate residue), 
which act in a cascade type reaction to ultimately lead to the nuclear and morphologic 
changes characterising apoptosis (Martin and Green, 1995). Caspases are currently 
grouped into three families based on their amino acid sequence recognition but it is as 
yet unclear if they always function by sequential activation in a cascade-like reaction. 
However in the case of Fas it is now believed that sequential activation occurs of 
Caspase 8 (FLICE), Caspase 1 (ICE), and Caspase 3 (PRICE) (Los et al, 1995; 
Armstrong et al, 1996; Duan et al, 1996; Enari et al, 1996; Muzio et al, 1996; Anel et 
al, 1997).
Caspases have been shown to mediate apoptosis following a variety of stimuli (Sarin et 
al, 1996). The essential nature of this signalling function is highlighted by the ability of 
soluble inhibitors of Caspases, like Z-VAD-FMK (Cbz-Val-Ala-Asp(OMe)- 
fluoromethylketone), to completely block apoptosis (Sarin et al, 1996). A stimulus- 
dependant and hierarchical response is indicated by the Caspase-1-deficient mice, 
where a defect is seen in CD95-mediated apoptosis but dexamethasone and y- 
irradiation maintain the ability to induce cell death by apoptosis (Cleveland and Ihle,
1995).
The Caspases mediate cleavage of various cellular substrates including fodrin, PARP, 
topoisomerase and various others (Labeznik et al, 1994; Martin and Green, 1995). The 
exact position of the Caspases within the signalling pathway to death in relation to 
surface stimuli is still being mapped out.
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1.1.4.2) Mitochondrial function in apoptosis
The inner mitochondrial membrane has an asymmetric distribution of ions resulting in 
the inside being negatively charged. This transmembrane potential is disrupted at an 
early stage of cellular commitment to apoptosis, and can be detected using various 
cationic lipophilic fluorochromes (Idziorek et al, 1995). The process of disruption of 
the membrane potential is known as permeability transition (PT), where mitochondrial 
proteins leak out into the cytoplasm. PT can be induced by a variety of apoptotic 
stimuli, including CD95 (Castedo et al, 1996). Included amongst the mitochondrial 
proteins which leak out during PT are cytochrome c and the pro-apoptotic protein, AIF 
(apoptosis inducing factor) (Liu et al, 1996a ; Zamzami et al, 1996). It is interesting 
that AIF can proteolytically activate caspase 3 (Susin et al, 1997). The exact role of 
mitochondria and hierarchical interactions with the caspase cascade remains to be fully 
defined, but it is intriguing that most of the Bcl-2 gene family are localised to the outer 
mitochondrial membrane where they may regulate mitochondrial function (reviewed by 
Cory 1995).
1.1.4.3) Bcl-2 as a negative regulator o f apoptosis
The Bcl-2 gene was first identified from follicular B cell lymphomas (Bakhshi et al, 
1985), and has been regarded as a prototypic cell death repressor gene responsible for 
the prolonged cell survival in these lymphomas. During the course of the last five years 
a large number of family members belonging to the Bcl-2 gene family have been 
isolated including both anti-apoptotic (Bcl-XL and BAG-1) and pro-apoptotic 
molecules (BAX, BAK, Bcl-Xs, and BAD) (Boise et al, 1993; Takayama et al, 1995; 
Oltvaiet al, 1993; Simonian et al, 1997; Gajewski and Thompson, 1996). Homo- or 
hetero-dimerisation of the various family members can take place and the combination 
of molecules within this dimeric structure appear to determine the cellular outcome
13
(Cory, 1995). The exact mechanisms by which Bcl-2 family members mediate their 
functions is currently being deciphered, but it appears that three major mechanisms 
may be operative. These include influence on the Caspase pathway via interactions 
with CED-4 (Spector et al, 1997), regulation of the release of cytochrome c from 
mitochondria (Yang et al, 1997a), and regulation of the Bcl-2 proteins by 
phosphorylation (Chang et al, 1997).
An understanding of the molecular interactions which determine the ultimate outcome 
with respect to apoptosis and identification of key regulators of the process should 
allow more targeted intervention in an attempt to control some of the diseases 
mentioned above. One pro-apoptotic player in this cellular process of death is Fas (CD 
95), which will be outlined in more detail now.
1.2) FAS BIOLOGY
1.2.1) Identification and characterisation o f Fas
Of the large number of molecules now identified to play a role in apoptosis, CD95/Fas 
is thought to have an important pro-apoptotic function. Fas was named as such by 
Yonehara et al in 1989 when a monoclonal antibody was raised with reactivity to 
"fibroblast associated surface" antigen derived from a human diploid fibroblast cell line 
FS-7 (Yonehara et al, 1989). An independent group in Germany simultaneously 
published another monoclonal antibody called anti-Apo-1 which was developed 
following immunisation of mice with a human B lymphoma cell line (Trauth et al, 
1989). Subsequent cloning and characterisation of Fas and Apo-1 revealed identical 
sequences (Oehm et al, 1992) and CD95 became the assigned cluster of differentiation 
(CD) number for Fas / Apo-1 at the Human Leucocyte Differentiation Workshop in 
Boston in 1993 (Schlossman et al, 1995). Except where Apo-1 is specifically referred
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to, the term Fas will be used in this dissertation as interchangeable and synonymous 
with CD95.
Anti-Fas antibody (CH 11) was developed by immunising mice with human diploid 
fibroblast cells FS-7 (Yonehara et al, 1989). Cell lines were stained with the antibody 
and lymphoma cells (KT-3) were found to expresss large amounts of Fas. Using 
cDNA libraries from KT-3 cells, Itoh et al in 1991 cloned and identified the cDNA for 
human Fas which consisted of 2534bp with a polyadenylation signal (ATTAAA) at 
the 3' end. A long open reading frame (1005 nucleotides) from the initiation codon at 
nucleotide positions 195-197 to the termination codon TAG at position 1200-1202 was 
found to code for a protein of 335 amino acids. Hydropathy analysis indicated the 
presence of a signal sequence at the N-terminal end, and predictions from analysis of 
typical peptide cleavage sites suggested that the mature Fas protein had approximately 
319 amino acids with a calculated Mr of 36000. Amino acid analysis predicted that Fas 
contained an extracellular domain of 157 amino acids, a membrane-spanning domain 
of 17 amino acids, and a cytoplasmic domain of 145 amino acids. The extracellular 
domain is rich in cysteine residues (18 of 153 amino acids) and the cytoplasimc 
domain is relatively rich in charged amino acids (24 basic and 19 acidic out of 143 
amino acids). Western blotting analysis confirmed a specific band of apparent Mr 
43000, where the difference from predicted was explained by glycosylation at two 
sites in the extracellular domain (Yonehara et al, 1989).
1.2.2) Fas and the TNF receptor superfamily.
Comparison of the Fas sequence revealed similarity to the TNF-receptor (TNF-R) 
family of proteins with overall identity to other family members being 24 -30 % (Itoh 
et al, 1991). The TNF-R family consists of a number of type 1 membrane proteins 
including the TNF receptors type 1 and 2, CD40, CD30, CD27, OX 40, 4-IBB and
15
including the TNF receptors type 1 and 2, CD40, CD30, CD27, OX 40, 4-IBB and 
the NGF-R. The family as a whole is characterised by cysteine rich extracellular 
domains with their homologous regions confined to the extracellular region (reviewed 
by Smith et al, 1994). There was no evidence to suggest that anti-Fas or TNF could 
transmit their effects by binding to each others receptors (Owen-Schaub et al, 1992). 





FAS TNF-R1 TNF-R2 NGF-R CD40
Figure 1 .2 .2: The TNF-NGF receptor family of proteins.
A schematic diagram is shown with only some representative members of the 
family of TNF-R like proteins. Amongst a growing family these include 
CD27, CD30, 0X40, and 4-IBB. They all have cysteine rich extracellular 
domains as indicated but Fas and TNF-R 1 differ from the others in the highly 
homologous death domain (approximately 80 amino acids in length and indicated 
by the red boxes) situated in the cytoplasmic region of the molecule. Despite the 
homologous extracellular and death signalling regions of Fas and TNF-Rlthey 
do not cross-transduce apoptotic responses.
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1.2.3) The early evidence for apoptosis following Fas engagement.
Anti-Fas antibody was shown to induce apoptosis by DNA laddering patterns and 
ultrastructural electron microscopic changes which first became visible by 3 hours after 
exposure to monoclonal CH11 (Itoh, 1991). CH 11 being an IgM antibody did not 
require cross linking in order to mediate apoptotic changes unlike the Apo-1 antibody 
(Dhein et al, 1992). As mentioned above a German group working on anti-Apo-1 
identified an antibody with reactivity to activated lymphocytes and they subsequently 
cloned the gene (Oehm et al, 1992) which was found to be identical to the Fas 
sequence. The original monoclonal anti-Apo-1 antibody showed restricted expression 
on malignant lymphocytes (Trauth et al,1989). Anti-Apol also induced apoptosis and 
tumour regression in mouse models. The issue of resistance or insensitivity to Fas- 
mediated apoptosis was briefly mentioned in this paper but no attention was dedicated 
to the phenomenon of resistance to apoptotic cell death at that stage. Apo-1 expression 
was also found on resting lymphocytes but upregulation occurred on activation with 
phorbol ester. It was interesting that Apo-1 expression was found on freshly isolated 
lymphocyte subpopulations from leukaemic patients probably reflecting their in vivo 
activation in this disease (Trauth et al, 1989).
1.2.4) Fas expression on human cells
Using the monoclonal CH 11 anti-Fas antibody, Fas expression was first seen by 
FACS analysis of human T and B cells but not on NK cells (Miyawaki et al, 1992). In 
this study no Fas expression could be seen on T cells, B cells or NK cells of neonates 
but Fas expression did increase with age. Fas expression was also upregulated on 
activation of T cells (PHA) and B cells (S.aureus Cowan 1 + IL-2) but it must be 
noted that these experiments were conducted using neonatal blood which does not 
show any Fas expression at baseline, hence an apparently marked maximal expression
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occurring on day 5 after activation. It was noted however that Fas expression on 
mature T cells were largely seen on activated memory CD45Ro+ cells and not on naive 
CD45Ro~ cells.
A similar pattern of staining for Fas occurred in B cells displaying activation or 
memory phenotypes where surface expression of slgD is lost (naive B cells express 
slgD and slgM and lose expression of slgD on activation). Cell lines originally derived 
from leukaemia and lymphoma patients (Jurkat and KT-3, respectively) were also 
tested for Fas expression and found to have very high levels of constitutive Fas on 
their surface. Whilst Jurkat and KT-3 cell lines underwent apoptosis (measured by 
propidium iodide staining), freshly isolated memory T cells and B cells from adults did 
not show Fas sensitivity, nor did 5 day activated neonatal T and B cells (Miyawaki et 
al, 1992).
The Fas death pathway has now been shown to be active in many cell types other than 
lymphocytes, including neutrophils (Liles et al, 1996), eosinophils (Tsuyuki et al,
1995), monocytes (Shinohara et al, 1995), hepatocytes (Galle et al, 1995), muscle 
cells (Seino et al, 1996), a variety of brain cells (Dowling et al, 1996; Dsouza et al,
1996), synoviocytes (Kawakami et al, 1996; Matsumoto et al, 1996), keratinocytes 
(Sayamaet al, 1994), and thyroid cells (Giordano et al, 1997). In fact, Fas-mediated 
apoptosis appears to occur in virtually any cell type that expresses Fas under the 
appropriate conditions, hence placing Fas as a molecule whose role extends beyond 
just the maintenance of lymphocyte homeostasis.
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1.2.5) The signalling cytoplasmic region o f  Fas
1.2.5.1) Identification o f  the critical cytoplasmic domain
A further advance in our understanding of the apoptosis mediated by Fas came with the 
work of Itoh et al in 1993 where they described cytoplasmic deletion mutants and 
demonstrated the importance of a cytoplasmic death domain in the human Fas gene. 
Mature human Fas has 319 amino acids with 157 extracellular and 145 cytoplasmic 
amino acids.
The cytoplasmic region was shown to contain a cell killing domain of 68 amino acids 
closely conserved with TNF-RI (p55, =24% identity). In the case of Fas the 130 
amino acid stretch between 175 - 304 includes this conserved region and deletion 
mutants generated in this region resulted in impaired apoptosis. Deletion of the C- 
terminal 15 amino acids resulted in enhanced apoptosis implying a regulatory role for 
this domain (Figure 1 .2 .5 .1 ). The C-terminal domain in other proteins have also 
been shown to play a role as regulators of function, for example tyrosine kinase 
receptors like PDGF receptors and G-protein coupled receptors like adrenergic
receptors. Itoh et al (1993) also generated a human Fas mutant resembling the Ipr cg
mouse model (Ile-225 to Asn-225) but in the case of human Fas the equivalent amino 
acid Val-238 was mutated to Asn-238 and shown to have a major defect in Fas-







Ec = 157 aa
Tm = 17 aa
Figure 1.2.5.1: Schematic representation of the Fas protein
The 319 amino acid (aa) Fas transmembrane protein is depicted in the diagram 
with the extracellular (Ec), transmembrane (Tm) and cytoplasmic (Cyt) regions as 
shown. Within the cytoplasmic signalling region is a 130 aa death inducing 
domain (red hatched) essential for apoptosis and which has a 68 aa homology 
with the death domain of the type 1 TNF-R. The terminal 15 aa of the Fas 
cytoplasmic tail (blue boxes) plays a regulatory role in preventing uncontrolled 
apoptosis
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1.2.5.2) Factors that associate with the Fas death domain.
In an attempt to trace the signalling events following Fas engagement, many groups 
have been isolating a variety of proteins that interact directly or indirectly with the Fas 
cytoplasmic domain. Current evidence suggests that FADD (Fas-associated death 
domain binding protein), binds to the death domain of Fas by means of an 
homologous region (Chinnaiyan et al, 1995; Muzio et al, 1996). Following the FADD 
- Fas interaction, another protein, FLICE is recruited to the death domain. FLICE has 
Caspase activity and may either directly activate a downstream cascade of Caspases or 
may depend on other Caspases for its activation ( Enari et al, 1996; Muzio et al, 1996).
More recently death domain associating proteins have been identified which influence 
the cellular path to death. Daxx (Yang et al, 1997b) appears to bind to the death domain 
at a site different from FADD, and promotes apoptosis just like FADD but in addition 
also stimulates JNK signalling. FLIP is a protein with homology to a viral FLIP 
previously identified and has been shown to block apoptosis by binding to either 
FLICE or FADD thereby preventing Caspase activation at a very early point in the 
Caspase death pathway (Irmler et al, 1997). Independantly cloned molecules have been 
found to be identical to FADD (MORT-1) (Boldin et al, 1995) and FLICE (MACH) 
(Boldin et al, 1996). Other family members like the TNF-R also use similar death 
domain associated proteins to transduce their effects. TNF-R signalling at this stage 
appears to be more complex with divergence of signalling pathways for death (TRADD 
(Hsu et al, 1995), FADD, FLICE, Caspases) and survival (TRAF, NF-kB) (Liu et al, 
1996b).
A number of other death proteins have been identified including DR3AVsl (Chinnaiyan 
et al, 1996), TRAIL (Wiley et al, 1995), TRAMP (Bodmer et al, 1997), RIP (Stanger 
et al, 1995), REAPER (Golstein and Depraetere, 1995) and Apo-2 ligand (Marsters et 
al, 1996) but how these interact with Fas is not clear as yet. The latter proteins may be 
alternative mechanisms for apoptosis rather than factors that directly influence Fas-
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mediated death. Bcl-2 and Bcl-xL have been shown in many in vitro and in vivo 
experiments to inhibit Fas-mediated apoptosis (Memon et al, 1995; Reap et al, 1995; 
Martin et al, 1995). The exact mechanism by which the inhibition occurs is not entirely 
clear but based on the effects of the homologous Ced9 inhibiton it is most likely at the 
level of the mitochondria (Kroemer et al, 1997) (Figure 1.2.5.2).
1.2.5.3) Other signalling mechanisms implicated following Fas 
engagement.
Many other signalling mechanisms have been implicated following Fas stimulation, 
including protein tyrosine kinases (Eischen et al, 1994), reactive oxygen intermediates 
(Hug et al, 1994), calcium (Oshimi and Miyazaki, 1995; Vito et al, 1996), Fas- 
associated serine-threonine kinases(Tian et al, 1995), phosphatases (FAP (Cleveland 
and Ihle, 1995) and HCP (Su et al, 1995), Ras (Gulbins et al, 1995), Lyn and p59fyn 
kinase (Wang et al, 1996), sentrin (Okura et al, 1996), and JNK (Verheij et al, 1996; 
Chen et al, 1996; Nishina et al, 1997) and ceramide generated from sphingomyelinase 
activity (Cifone et al, 1994; Gulbins et al, 1995).
Exactly how these fit into the puzzle is not entirely clear, and it may be that some of 
these are epiphenomena related to phosphorylation changes induced in intracellular 
proteins following Fas receptor stimulation and Caspase activation. The experimental 
data presented for many of these signalling molecules suggest an ability to influence 
apoptotic outcome in the models studied but it is difficult to allocate a hierarchical 
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Figure 1.2.5.2 : Some signalling mechanisms induced by Fas.
Diagram showing some of the intracellular signalling mechanisms mediating apoptosis. 
Following Fas engagement by ligand , trimerisation occurs which is followed by 
binding of FADD to the death effector domain of Fas. The formation of this complex 
then attracts binding of intracellular FLICE (caspase 8) in order to generate a death 
inducing signalling complex (DISC). The signalling pathways that follow are not 
clearly defined but a series of caspases are activated possibly in a cascade like reaction 
as depicted by the arrows. Caspases are thought to mediate the final morphological 
changes which characterise apoptosis through their proteolytic activity, and may infact 
function in close association with mitochondrial factors. Bcl-2 and other family 
members are thought to influence apoptosis by their action on the mitochondrial 
function (inhibitory activity of Bcl-2 is indicated here by the red T-shaped bar). Other 
inhibitory molecules also play an important role and FLIP (FLICE inhibitory protein) is 
shown in the figure to block the interaction of FADD and FLICE and hence the DISC 
complex. Other complicated interactions are being defined as new molecules are 
identified and their functions characterised.
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1.2.5.4) Fas modulation by IL-2
Studies by Owen-Schaub et al (1992) showed that IL-2 in culture resulted in 
upregulation of Fas expression over 7 days and also increased the percentage 
lymphocytes expressing Fas on the surface (similar to other stimuli for T cell activation 
like CD3, PH A and superantigen). In contrast, lymphocytes cultured in vitro without 
any stimulation lost Fas expression progressively. Anti-Fas-induced apoptosis could 
be restored in insensitive lymphocytes with IL-2 exposure (usually required for 4 days 
prior to anti-Fas exposure) (Owen-Schaub et al, 1992).
Other factors have also been identified which alter sensitivity to Fas-mediated 
apoptosis. It was previously documented that CD3 stimulation of T cells (thymocytes, 
peripheral CD4 and CD8 cells, and T cell clones) could result in apoptosis (Russell et 
al, 1992). IFN-y did not have the same enhancing effect on CD3-mediated apoptosis 
of T cells as it had on the colon cancer cell line HT-29 which displayed upregulation of 
Fas on the surface on stimulation with IFN-y (Itoh et al, 1991).
1.2.5.5) Fas function modulated by Bcl-2.
The interaction of anti-apoptotic proteins like Bcl-2 was investigated in relation to Fas 
(Itoh et al, 1993). Using a transfectant model with double transfectants (Fas and Bcl-
2), Fas-induced apoptosis (measured by trypan blue and DNA fragmentation) was 
shown to be reduced in the presence of Bcl-2. Similar results were obtained in a 
transfected T cell line WR19L (murine). Further independent evidence for an 
interaction between Bcl-2 and Fas was found in a human B cell chronic lymphocytic 
leukaemia line where malignant lymphoblasts with upregulated Fas as well as Bcl-2 
were protected from Fas-mediated apoptosis in vitro (Mapara et al, 1993). Other
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studies have, however, suggested that Fas/CD95 signalling is not regulated by Bcl-2 
(Moreno et al, 1996; Chiu et al, 1995; Strasser et al, 1995). Thus at present there is no 
final consensus about the influence of Bcl-2 and its family members on the outcome 
following Fas engagement.
1.2.6) Fas function and lymphocyte homeostasis.
1.2.6.1) Central and peripheral tolerance
The consensus appears to be that Fas plays a greater role in peripheral than in central 
mechanisms of lymphocyte homeostasis as relates to both B and T cells (Daniel and 
Krammer, 1994; Gilette-Ferguson and Sidman, 1994; Rothstein et al, 1995). 
Peripheral deletion of T cells depends on the activation state of these cells but may also 
depend on other factors including the cellular environment (Akbar and Salmon, 1997), 
and factors like Bcl-2 (Lacronique et al, 1996), Bcl-xL (Van Parijs et al, 1996), TGF- 
B (Cerwenka et al, 1996; Kawakami et al, 1996), IL-2 (Foumel et al, 1996; Van Parijs 
et al, 1996), as well as a growing range of death domain associated proteins (Cascino 
et al, 1996; Chinnaiyan et al, 1995 and Muzio et al, 1996). It has been suggested that 
this process of “activation-induced cell death” may play an important role in eliminating 
T cells that have been activated to mount a natural immune response to a variety of 
foreign antigens (Nagata and Golstein, 1995).
In addition to peripheral tolerance of T cells Fas has been shown to be important in the 
elimination of activated B cells, where appropriate CD40 ligation is an important 
determinant of outcome (Rothstein et al, 1995; Rathmell et al, 1995; Cleary et al, 1995; 
Garrone et al, 1995; Schattner et al, 1995; Rathmell et al, 1996).
1.2.6.2) Fas-m ediated cytotoxicity
25
Fas was not only shown to play a role in death of activated B and T cells (both CD4+ 
and CD8+ ) but also in cytotoxicity reactions (Rouvier et al, 1993). Cytotoxicity 
usually has a Ca2+ -dependent and a Ca2+ -independant component. Fas-mediated 
cytotoxicity was shown to constitute the Ca2+ -independent component (10-20%). In 
fact most of the latter was attributable to Fas, supported by the finding that the 
cytotoxic effect could not be reproduced on Ipr thymocytes defective in Fas but was 
normal on gld thymocytes (Walsh et al, 1994a).
Further research has confirmed the role of Fas in cytotoxicity mechansims (Stalder et 
al, 1994; Ju et al, 1994; Hanabuchi et al, 1994; Anel et al, 1994), and as yet there is no 
evidence of any cytotoxicity pathways other than the perforin-granzyme and Fas 
pathways. Cytotoxicity experiments done in perforin or Fas knockout mice support the 
latter argument (Walsh et al, 1994b; Kataoka et al, 1996). It has been suggested that 
the two pathways complement each other in that the perforin-granzyme pathway may 
be important in cytotoxic cell death of viral infected or tumour cells where no target cell 
cooperation is required, whilst the Fas-mediated cytotoxicity via either CD4+ or CD8+ 
cytotoxic lymphocytes may be more important in maintaining homeostatic control of 
activated lymphocytes (Carter and Dutton, 1995; Podack, 1995). In the latter case 
more target cell cooperation is required, and may be more influenced by cytokine 
modulation.
1.2.6.3) Fas and co-stimulation o f  T cells.
In contrast to apoptotic effects of anti-Fas antibody reports were emerging of 
costimulatory effects of certain new monoclonal anti-Fas antibodies (Alderson et al,
1993) like M38 immobilised on plastic plates with CD3. A similar B cell proliferative 
response was seen in one patient with a B cell lymphocytic leukaemia (BCLL) on 
exposure to anti-Apo-1 following stimulation in vitro with SAC and IL-2 (normally 
this stimulation would make the BCLLs more susceptible to apoptosis) (Mapara et al,
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1993).The suggestion that Fas could act as a costimulator of cellular responses could 
not be confirmed by other investigators (Van Parijs et al, 1996) (including ourselves). 
One paper did show NF-kB activation following Fas engagement (Ponton et al, 1996) 
but this does not necessarily confirm a proliferative effect and the whole area of Fas 
costimulation needs further clarification.
1.2.7) Diseases associated with dysregulation o f  Fas.
Whilst research work progressed in vitro, Fas-mediated apoptosis was being 
demonstrated in vivo in the mouse where anti Fas (Jo-2 antibody ) injected into mice 
(Balb/c, Mrl +/+, C3H/HeJ ) intraperitoneally resulted in rapid and fulminant hepatic 
cell death (Ogasawara et al, 1993). This suggested not only a role for Fas in fulminant 
hepatitis but also provided a cautionary note against the premature use of anti-Fas 
reagents in the manipulation of immune responses.
Although many papers have suggested a role for Fas in disease pathogenesis, this has 
often been based on surface expression patterns in these conditions and no clear proof 
exists for a direct role for Fas. Very few genetic studies, if any, have been reported in 
diseases thought to be related to Fas dysfunction. However, the evidence appears 
much stronger in the case of diseases like Hashimoto’s thyroiditis (Giordano et al,
1997), Hepatitis (Kondo et al, 1997), lymphoproliferative disease (Kondo et al,
1994), and a recently identified childhood equivalent of the murine Ipr model, known 
either as the Canale-Smith-syndrome or Autoimmune lymphoproliferative disorder 
(Fisher et al, 1995; Rieux-Laucat et al, 1995; Le Deist et al, 1996; Drappa et al, 1996).
In addition there are good experimental models showing a role for Fas in “immune 
privilege” (Bellgrau et al, 1995; Griffith et al, 1995). This phenomenon describes the 
ability of some tissues such as the eye, testis, and brain to tolerate foreign grafts
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without the problems of graft rejection. A similar type of “immune evasion” may 
protect some tumour cells from destruction by lymphocytes (both immune privilege 
and immune evasion will be discussed later in the section on Fas ligand). Also much 
work is ongoing in the haematology field where Fas is being studied not only in the 
context of drug resistant tumours but also as a possible additional tool in the fight 
against cancer (Friesen et al, 1996).
1.2.7.1) Soluble Fas
A soluble form of Fas resulting from splice variants was reported by Kimura et al 
(1994) in the rat liver. Soon thereafter a report appeared describing soluble Fas in 
humans (Cheng et al, 1994), suggesting that increased levels of soluble Fas may 
inhibit Fas-mediated apoptosis. Murine soluble Fas variants have also been reported 
(Hughes et al, 1995), but not all research groups working on soluble Fas have been 
able to reproduce the results and the controversy continues as to whether soluble Fas 
plays a major role in altering cellular outcome following Fas engagement. A very 
recent suggestion has been that it may not be the serum levels of soluble Fas that are 
important but rather the shift toward production of splice variants following activation 
(Kovacs et al, 1997). The controversy surrounding soluble Fas in SLE will be 
discussed further in chapter 5.
1.2.8) The Ipr mouse and Fas
A major milestone in Fas biology which heralded the huge proliferation of research 
into Fas was the identification by Watanabe-Fukunaga et al that the Ipr mutation in 
mice corresponded to a defective Fas gene (Watanabe-Fukunaga et al, 1992). It would 
therefore be prudent to provide some background about the Ipr mouse model in order 
to appreciate the importance of the identification of the Ipr - Fas defect.
28
Ipr refers to "lymphoproliferation" and describes the phenotypic changes of 
lymphadenopathy occurring in mice of various strains (MRL/Mp, C3H/HeJ, 
BALB/cBy, AKR/J, C57BL/6 and SJL/J) that carry the homozygous Ipr gene. The Ipr 
gene usually has autosomal recessive expression but heterozygotes also manifest some 
lymphoproliferation and autoimmune features (Morse et al, 1985). The autoimmune 
features of Ipr mice will be discussed in a later section on SLE. The 
lymphoproliferation in the MRL-lpr llpr mouse is profound with a two hundred fold 
increase in cell number compared to wild type MRL +/+ mice (Cohen and Eisenberg, 
1991). Lymphoid infiltrates are seen in all lymph node groups and can also be found in 
the spleen and other organs including salivary and lacrimal glands.
The lymphoid infiltrates consist of an increase in the total number of CD4+ and CD8+ 
cells but there is also a disproportionate increase in the very curious double negative 
(DN) T cells which characterises the Ipr phenotype. DN T cells in these Ipr mice are 
CD4- CD8- Thy 1+ and thus appear to bear a superficial resemblance to developing 
DN T cells in the thymus. Further analysis however revealed the presence of surface 
markers that are not usually present on developing thymic T cells, including a number 
of B cell antigens such as B220. The DN T cells do not simply reflect defective 
apoptosis and subsequent leakage into the peripheral lymphoid circulation. These DN 
T cells have been reported to have quite a variety of defects amongst which are 
included abnormal cellular responses, T cell receptor rearrangements, T cell receptor 
coupling and signalling defects, and abnormal oncogene expression (Cohen and 
Eisenberg, 1991).
The source of the DN T cells has proved elusive and there is no indication of active 
proliferation of these DN T cells in peripheral lymph nodes. Two favoured hypotheses 
include the generation of DN T cells in the liver (Ohteki et al, 1990) and the 
differentiation into DN cells from previously expanded single positive CD4+ or CD8+ 
cells (Cohen and Eisenberg, 1991). Defective cellular function in Ipr mice is not limited
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to the DN T cell population. Abnormal function has also been demonstrated in B cells, 
CD4+ T cells and macrophages derived from Ipr mice and there is also evidence for 
deranged cytokine activity.
The biological consequences of the Ipr mutation are clearly quite multiple and varied, 
and may reflect some influence of background genes on the Ipr mutation, but 
excitement in the Ipr model mounted following the identification by Watanabe- 
Fukunaga (Watanbe-Fukunaga et al, 1992) that Ipr encodes the structural gene for 
murine Fas. The excitement centred around the potential benefits for cancer and 
autoimmunity research given the striking resemblance of the Ipr lymphoproliferation 
and autoimmune features to human lymphoma and SLE, respectively.
1.2.8.1) Retroviral insertion in the Fas gene o f the Ipr mouse
Adachi et al from the same Japanese research group subsequently demonstrated that the 
Ipr Fas gene defect was due to an insertion of a retroviral transposable element into 
intron 2 which gave rise to aberrant mRNA splicing and premature termination before 
exon 3 (Adachi et al, 1993). The poly(A) site of the early transposable element (Etn) 
was thought to be responsible for the premature gene termination. Wu et al (1993) 
confirmed similar findings but also showed that when the abnormal Fas gene is placed 
under the control of the CD2 promoter in transgenic mice then the Etn expression is 
reduced in thymic cells and Fas expression is increased. The dynamic interplay of 
retroviral Etn expression with other gene promoters or enhancers was previously 
reported (Keshet et al, 1991) and (Watson et al, 1992).
Any doubt about the role of retroviral influence on Fas gene expression in the Ipr 
mouse was laid to rest when a third group independently identified a further Etn 
insertion (Chu et al, 1993) with a similar retrotransposon to Wu et al (1993). The 
former paper also showed quantitative differences in Fas expression in Ipr compared to
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wild type mice with 10 fold lower expression in Ipr. It is interesting to note that 
heterozygous Ipr defects are also associated with some decrease in Fas mRNA and 
autoimmune features (Carlsten et al, 1990).
1.2.8.2) The Ipr c8 allelic variant
An allelic variant of the Ipr gene was known for some time and was called Ipr cg
because it complemented the defect found in another genetically different but 
phenotypically similar gld mouse (cg being "complementary to gld"). Following the
cloning and identification of the Fas gene it was rapidly discovered that the lprcg
phenotype was due to a point mutation in the murine Fas gene within the cytoplasmic 
domain so critical for Fas-mediated cytolysis (Watanabe-Fukunaga et al, 1992). A 
point mutation at position 786 with a nucleotide transition from T to A results in an 
amino acid change from isoleucine to asparagine and subsequent failure to respond to 
anti-Fas antibody. The gld mouse model will be discussed in the section on Fas- 
ligand. Figure 1.2.1 shows the sites of genetic alteration within the Fas gene in the
Ipr and Ipr CS mouse.
1.2.9) Fas biology in relation to this thesis
When our research into Fas began, it was clear that whilst the human Fas gene was 
cloned and identified at the outset, most of the research that followed concentrated on 
the Ipr mouse model. We therefore aimed to study the role of the Fas gene in human 
Fas biology using new molecular techniques for the generation of appropriate reagents. 










T to A (nt786)
De-225 to Asn-225
Figure 1 .2 .1 : Changes within the Fas gene of the Ipr
The genomic outline is shown for the wild type (WT) and Ipr Fas genes with 
exons indicated as black boxes. The Ipr mouse has a ±5.3Kb retroviral transposon 
inserted (ETn indicated by red box) between exons 2 and 3 which results in 
premature termination of the Fas transcripts and impaired function.
A very similar functional defect of Fas is found with a single point mutation 
within the cytoplasmic region of the coding sequence of Fas in the Ipr cg mouse. 
The cDNA for Fas is shown with the site of the point mutation (nucleotide 786) 
and the resultant amino acid transition is indicated.
Abbreviations: Ec = extracellular coding region, Tm = transmembrane region,
Cyt = cytoplasmic coding region, lie = isoleucine, Asn = asparagine.
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1.3) FAS LIGAND BIOLOGY
A H istorical perspective
1.3.1) The gld mouse model
The natural ligand for Fas was not identified for some years after the Fas gene was 
first cloned. It was however, well known that the gld mouse had the phenotypic 
picture of the Ipr mouse (lymphoproliferation and autoimmune disease) but the gld 
gene was not allelic to Ipr (Matusuzawa et al, 1990). The gld gene was also found to 
be an autosomal recessive gene like Ipr but it was localised to chromosome 1 whilst Ipr 
localised to chromosome 19 (Roths et al, 1984 and Watanabe-Fukunaga et al, 1992). 
It was thus suggested that Ipr and gld represented two different enzymes that probably 
acted in a common metabolic pathway of T cell differentiation and function (Davidson 
et al, 1985).
1.3.2) Cellular expression o f Fas Ligand inferred from the gld model
Both mature gld T cells as well as wild type B6 derived T cells displayed normal 
proliferation and cytokine responses to CD3 stimulation but the gld cells did not 
undergo apoptosis on exposure to antigen (CD3, TCR, APC presented or SEA) 
(Russell and Wang, 1993). This suggested that within the gld phenotype there was 
uncoupling of the normal relationship between the TCR and a gld derived T cell 
molecule responsible for inducing apoptosis after antigen exposure. Russell et al
(1992) also demonstrated that the gld factor responsible for the death pathway was 
present on T cells rather than APCs. These findings led to much speculation at the 
time that gld probably represented a defect of Fas ligand.
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Further ideas about the ligand for Fas came from the cytotoxicity work of Rouvier et al
(1993) where they used cytotoxic clones derived from a rat - mouse hybridoma (PC60- 
dlOs) as effector cells to induce apoptosis in Fas positive target thymocytes. They 
found that apoptosis of Fas expressing target cells could also be achieved with other 
stimulated effector T cells (stimulated with PMA / ionomycin) or antigen specific 
stimulated effector cells. This work hence suggested the presence of Fas ligand on 
these activated T cells and on the dlOs cytotoxic hybridoma cells. The idea that a Fas 
ligand may have been expressed on activated T cells was supported by the data 
showing that no cytotoxic effect was inducable on Ipr thymocytes which lacked 
functional Fas receptors. CD8+ lymphocyes have also been known to undergo cell 
death on exposure to high doses of cognate peptide (Su et al, 1993). It was interesting 
to note in this paper that cell death was prevented if cell to cell contact was inhibited in 
agarose gel microdroplets hence indicating a need for a cell surface ligand to mediate 
cell death. It would have been interesting to postulate a role for Fas ligand in this 
system.
The evidence thus pointed to a pattern of cell surface expression of the putative ligand, 
with a suggestion that T cells were implicated. Given that T cells are regarded as 
important regulators of the immune response in general, it was not unreasonable to 
postulate that a T cell may express a ligand for Fas in order to kill Fas positive target 
cells by a cell-cell interaction on completion of an immune response. Could activated T 
cells expressing ligand therefore be able to kill not only Fas expressing B cells and 
monocytes recruited to sites of immune responses but also other activated T cells 
expressing Fas? Such downregulation of the immune response by a Fas-FasL 
interaction may explain how peripheral deletion of activated lymphocytes occurred. In 
a project aimed at studying the role of Fas in SLE, it was clearly important to 
understand the natural ligand for the Fas receptor, hence as part of this project we 
aimed to identify the natural human ligand for Fas using a molecular approach outlined
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in chapter 3. However, during the course of this work other researchers succeeded in 
cloning the FasL gene and some of these data will be discussed.
1.3.3) Cloning of the rat FasL gene
Following compelling evidence from the dlOs cytotoxicity model of Rouvier et al 
discussed above, Suda et al (1993) in fact used the same dlOs cell line after repeated 
sorting on FACS to clone a rat FasL. They used a recombinant murine Fas-Fc which 
was used to identify the "ligand expressing" cells. Expression cloning of a cDNA 
library from the "high" expressing dlOs cells eventually revealed the first clone of Fas 
ligand, which turned out to be a rat ligand derived from the rat component of the 
genome in the hybridoma cell line. Gene analysis of the cloned rat ligand for Fas 
revealed a gene of 1623 nucleotides encoding a protein of 278 amino acids with a 
calculated Mr of 31,138.
The features of the protein suggested a type II transmembrane structure, lacking a 
signal sequence at the N-terminus and containing a proline rich region,a 
transmembrane anchor of 22 hydrophobic amino acids, and a 179 amino acid carboxyl 
region defining the extracellular domain. There were four potential N-glycosylation 
sites in the extracellular region. Biochemical characterisation of immunoprecipitated 
Fas ligand revealed a Mr of 38-42 Kd, and it was interesting to note that they found 
differences in the Mr of Fas ligand precipitated from dlOs cells and transfected COS 
cells, which were explained on the basis of glycosylation differences. Although Fas 
ligand expression was limited to the surface of the dlOs cells it was found that 
transfection of COS cells with cDNA for Fas ligand resulted in both surface expression 
and secretion of soluble Fas ligand into the culture medium, perhaps by cleavage from 
the cell surface.
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1.3.4) FasL is a member o f the TNF family
Amino acid alignment analysis showed Fas ligand to be a member of the TNF / NGF 
family, with homologous regions being restricted to the carboxyl terminus which 
encodes the extracellular receptor-interacting domain of the proteins. Homology was
highest with TNFa and TNF(3 (27.8% and 28.7%) rather than with other family
members like CD40L, CD27L and CD30L (figure 1.3). Despite the homology with 
TNF, Fas ligand could not bind the TNF-receptor p55 nor activate mouse TNF 







FasL TNF CD27L CD30L CD40L
Figure 1.3: The TNF family of proteins
FasL was identified to be a type II transmembrane protein with 25-30% homology 
to the other TNF family members (homologous regions shown as shaded area in 
the extracellular region). Not all family members are represented here.
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1.3.5) Murine Fas ligand gene and the gld mutation
Subsequently, the FasL genes for mouse and human were also cloned using 
expression cloning techniques (Takahashi et al, 1994b and Lynch et al, 1994). The 
mouse ligand was localised to chromosome 1 and corresponded to the gld 
chromosomal localisation (Suda et al, 1993). Independant observations confirmed the 
gld mutation to be a single base change at position 847 (amino acid transition T to C 
resulting in leucine replacing phenylalanine at position 273) (Takahashi et al, 1994a 
and Lynch et al, 1994). A variety of experiments confirmed that the gld mutations 
resulted in impaired apoptosis of Fas positive target cells (Ramsdell et al, 1994 ; 
Takahashi et al, 1994a and Lynch et al, 1994), and the defect could be corrected in 
chimeric marrow transplant experiments (Sobel et al, 1995 and MacDonald et al,
1995).
The data presented on FasL can therefore also be seen to originate largely from 
experimental mouse models. Whilst human diseases often teach us much about the 
biology of newly discovered molecules and animal models provide useful information 
about their in vivo relevance, it remains important to establish the “normal biology” of 
these molecules as much as possible within the human context. With this in mind our 
strategy in generating reagents that could be used to study the biology of FasL in 
human peripheral blood will be outlined in chapter 4.
Fas Ligand  -  more recent developments
1.3.6) Soluble Fas ligand
The gld model provided data on cytotoxicity and cell-cell interactions between Fas and 
FasL (Matusuzawa et al, 1990). Given that the prototype family member, TNF, was
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mainly secreted following cleavage from the cell surface, the same was considered to 
be true for FasL. In vitro expression of FasL in Cos cells suggested that FasL was also 
secreted into the culture medium (Suda et al, 1994). This was confirmed by other 
groups in Jurkat and hybridoma experiments (Brunner et al, 1995; Ju et al, 1995; 
Dhein et al, 1995; Martinez-Lorenzo et al, 1996), and it is thought that release from the 
cell surface occurs by similar metalloproteinase activity (Kayagaki et al, 1995) as is the 
case with TNF. The identification of soluble FasL led to the suggestion that Fas-FasL 
interactions were important not only in the context of cell-cell interactions as mentioned 
above but also in autocrine and paracrine cell death (Brunner et al, 1995; Ju et al, 1995; 
Dhein et al, 1995). Also further studies have shown that high levels of soluble FasL 
could be found in some haematological malignancies like LGL leukaemia and NK cell 
lymphoma and may be implicated in their pathogenesis (Tanaka et al, 1996).
1.3.7) Diseases associated with altered FasL expression
Upregulated surface expression of FasL has also been implicated in Lyme arthritis 
(Vincent et al, 1996), HIV (Westemdorp et al, 1995) and immune evasion by tumour 
cells. Tumour cell expression of FasL appears to allow them to kill Fas positive 
lymphocytes that would normally play a role in tumour surveillance, and this has been 
shown for hepatocellular carcinoma (Strand et al, 1996), melanoma (Hahne et al,
1996), colon carcinoma cell lines (O’connell et al, 1996), as well as the NK cell 
lympoma and LGL leukaemia (Tanaka et al, 1996).
1.3.8) Immune privilege
The expression of FasL by immune privileged tissue has been shown in experimental 
models (Bellgrau et al, 1995; Griffith et al, 1995). Immune privilege refers to the areas 
where transplanted foreign cells are protected from attack by immunocytes such as
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cytotoxic lymphocytes or NK cells. The eye and the testicle have been known for some 
time to be protected from such immune attack, as has the brain. Whilst the latter site 
has immune privilege largely conferred by the impermeable blood-brain barrier, the 
experimental evidence clearly suggests a major role for FasL-mediated destruction of 
Fas positive host lymphocytes in the case of the eye and testicular tissue. In the eye 
FasL expression has also been suggested to play a role in dampening inflammatory cell 
responses after infections so as to minimise the risk of collateral damage to ocular 
tissue from non-specific inflammatory mediators (Griffith et al, 1995).
Will FasL prove to be the magical molecule in transplantation? A warning against 
extending the “immune privilege”-FasL hypothesis for generalised use in 
transplantation comes from two papers. Yagita et al (1996) showed that an attempt to 
express FasL on grafted tissue resulted in a severe inflammatory reaction, thought to 
be mediated by FasL-induced death of Fas-positive host neutrophils with a resultant 
release of inflammatory mediators.
The other lesson was learnt when an attempt was made to prolong islet cell survival by 
creating FasL transgenic NOD mice in the hope that FasL expression by the islet cells 
would protect them from lymphocyte-mediated destruction. The islet B cells in this 
case upregulated Fas expression and thereby became even more susceptible to FasL 
killing from both the transgenic FasL expressing cells as well as cytotoxic T cells 
(Chervonsky et al, 1997). Clearly we have a lot more to learn about the regulation of 
the Fas-FasL molecules before they can be exploited for therapeutic purposes.
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1.4) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
1.4.1) Autoimmunity
The immune system has the ability to discriminate between self and non-self antigens. 
Autoimmunity refers to an immune response to self antigens which results in varying 
degrees of organ damage. Examples of autoimmune diseases include diabetes, 
Grave's disease, Hashimoto's thyroiditis, myasthenia gravis, autoimmune 
thrombocytopaenia, haemolytic anaemia, and a number of rheumatic diseases including 
rheumatoid arthritis, scleroderma and SLE. Autoimmune diseases are usually 
characterised by the presence of autoantibodies and self reactivity of T cells (Eisenberg 
and Horsfall, 1993). However, multiple interacting factors may contribute to the 
development of autoimmunity including genetic factors (both MHC and non-MHC), 
gender, microbial infections, and a variety of functional defects of antigen presenting 
cells and lymphocytes (reviewed by Abbas et al, 1997).
1.4.2) Central and peripheral control o f  immune responses
The immune system has a number of mechanisms for controlling a response to self 
antigens (figure 1.4). This includes central and peripheral mechanisms of control of 
T cells. Central tolerance occurs by thymic deletion of T cells responding to self 
antigens presented by MHC (Ashton-Rickardt et al, 1994). Peripheral control becomes 
important in the elimination of autoreactive cells which may have slipped through the 
thymic net but is also particularly important following immune responses to foreign 
antigen (Newell et al, 1990). A large number of activated T cells must be removed after 
an immune response to foreign antigens and this peripheral deletion is known to occur 
through apoptosis. The exact mechanisms are still being determined but both Fas and
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TNF have been implicated in this “activation-induced cell death” (Shi et al, 1990). 
Other mechanisms o f peripheral tolerance apart from apoptosis include anergy and 
clonal ignorance (Jones et al, 1990 and Schwartz 1990) (Figure 1.4). Anergy 
differs from apoptosis in that peripheral T cells are not killed but remain in a state of 
unresponsiveness which can often be rescued by IL-2 in culture. The in vivo relevance 
of anergy is as yet uncertain but it has been suggested that a molecule called CTLA-4 
(CD 152) may play an important role in this regard (Bluestone 1997). The in vivo 
significance o f clonal ignorance is even more uncertain and is based largely on 
experimental murine work. It is thought that a breakdown in peripheral tolerance 






Figure 1.4 : Mechanisms of Peripheral Tolerance
T cells activated on exposure to self antigen may be regulated by a number of 
mechanisms as outlined. Apoptosis o f activated cells is thought to occur mainly 
via Fas and TNF receptors , whilst the regulation of Anergy has largely been 
ascribed to CD28 and CTLA-4 expressed on T cells. The mechanisms underlying 
clonal ignorance are as yet undefined.
Self antigen
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1.4.3) The Ipr mouse, Fas, and peripheral tolerance
From the Ipr mouse model it appears that Fas plays an important role in peripheral 
tolerance. It is very interesting that a single gene defect represented by the Ipr mouse 
has such a dominant effect on the autoimmune manifestations (Wu et al, 1994). In fact 
transgenic correction of the Fas defect in T cells of the Ipr mouse resulted in complete 
correction of the autoimmune features including the glomerulonephritis, arthritis, 
autoantibody production and also the lymphoproliferative disorder The latter model 
supports the argument that T cells play a central role in the autoimmune response 
because correction of only T cell Fas defects under a CD2 promoter also resulted in 
correction of B cell function in that autoantibody and immunoglobulin levels were 
normalised (Wu et al, 1994).
1.4.4) Clinical Features o f SLE
SLE is a multisystem disease often quoted as a prototypic autoimmune disorder. The 
most common sites affected include the skin, joints and serosal surfaces but the 
disease can be associated with devastating complications when it affects the kidneys, 
lung, heart, and brain. Amongst a variety of haematological features, lymphopaenia 
and thrombocytopaenia occur commonly and have largely been ascribed to antibody 
mediated cellular destruction (Eisenberg and Horsfall, 1993). SLE has been associated 
with both MHC (DR2 and DR3) and non-MHC genes (Complement C2 and C4) and 
occurs more commonly in females (ratio of 10:1).
SLE is characterised by autoantibodies to double stranded DNA (dsDNA) but it is 
often associated with a variety of autoantibodies directed at functional nuclear or 
cytoplasmic antigens (figure 1.4.2) (Galperin et al, 1996). These include anti- 
nuclear antibodies, anti-Sm, anti-Ro / La, anti-cardiolipin, anti-phosphatidylserine,
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anti-platelet, anti-red cell, anti-neutrophil, anti-histone, and anti-ulRNP antibodies 
amongst many others. Whilst it is clear that immune complexes resulting from the 
interaction between autoantigens and autoantibodies in SLE account for much of the 
tissue damage, recent research has suggested that direct autoantibody penetration of 
cells may play a role too (Elkon 1994 and Tsai et al, 1993). Autoantibody production 
is associated with altered B cell function but this is in turn subject to regulation by 
helper T cells. It is known that B cell differentiation and antibody production is 
dependent on CD40 function which is tightly coupled to the ligand of CD40 expressed 
on T cells (Grewal et al, 1996 and Van Essen et al, 1996). Similarly, T cells express 
Fas ligand which can regulate Fas-mediated apoptosis of activated B cells. We 
therefore hypothesised that a breakdown in Fas-mediated apoptosis could account for 
some of the pathology seen in SLE.
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Figure 1 .4 .2  : Functions of common autoantigens in SLE
43
1.4.5) The role o f Apoptosis in SLE
Evidence from mouse models such as the MRL-lpr /Ipr mouse suggested that 
decreased apoptosis accounted for the phenotypic changes including the 
lymphoproliferation and autoimmune features. At the time of commencement of our 
project no human data existed on the role of apoptosis in SLE. More recently 
experimental evidence from one group suggested that a soluble Fas molecule may be 
increased in SLE which could result in reduced Fas-mediated apoptosis (Cheng et al,
1994). This has not been reproducible experimentally by independant researchers 
(Knipping etal, 1995 and Goel et al, 1995), and the validity of an ELISA based on a 
mutant splice variant of Fas brings into question the issue of what the measurement 
actually reflected as regards normal Fas biology.
Thus it was clear at the outset that the role of apoptosis in the pathogenesis of human 
SLE was poorly defined. Whilst the MRL-lpr/lpr mouse provided useful insights about 
defective apoptosis and autoimmunity there was no indication of any defective Fas 
function in humans. Also the Fas gene had not been studied in human SLE except for 
the splice variant described above. Genetic and functional studies on Fas and apoptosis 
in human SLE have subsequently been completed by a number of investigators and 
will be discussed in relation to our results in chapter 5.
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AIMS AND OBJECTIVES OF THE PROJECT
The Ipr mouse model of SLE was identified to have a single gene defect, i.e. the Fas 
gene. Correction of the Fas gene defect in T cells of these mice abrogated most of the 
autoimmune and lymphoproliferative features, but there was no indication if the Fas 
gene played such a dominant role in the equivalent human disease. In addition the 
emphasis of research into Fas was focused on murine biology. Given this scenario a 
number of objectives were determined for this project:
1) To generate Fas reagents for the study of human Fas biology.
2) To identify a human ligand for Fas.
3) To generate FasL reagents in order to study its role in human disease.
4) To study the Fas gene in human SLE.
5) To investigate for functional defects of Fas-mediated apoptosis in human SLE.
In order to meet the objectives a molecular approach was used to generate the 
necessary reagents and various apoptosis assays as well as SSCP polymorphism 
analysis had to be established. The results chapters that follow integrate the 






Reagents were purchased from a variety of suppliers as indicated with each method but 
the majority of standard chemical reagents were obtained from Sigma Chemical Co. A 
list of all suppliers with telephone numbers appears in appendix 1 of the thesis.
A variety of cell types were used in this project with some differences in the culture 
medium requirements (culture medium from Life Technologies). CHO transfectants 
were all grown in Glutamine - free DMEM (methods from Sansom et al, 1993) ; COS- 
7 cells and lymphocytes including the transformed cell lines Jurkat and H9 were all 
grown in RPMI medium, and various supplements were added into the medium as 
shown in table 2.1. All cell culture work was carried out under sterile conditions in a
Class II Biological Safety cabinet and cells were grown in incubators at 37°C with 5% 
CO2 in a humidified atmosphere.
2.1.1) Recipes for culture media:
1). Glutamine - free DMEM.
To 400 ml of autoclaved distilled deionised water the following were added:
2.1) CELL CULTURE
Dulbecco’s MEM (10 X)
Foetal calf serum (FCS)
Penicillin / Streptomycin (10 000 u/ml, 10 000 ug/ml) 
Sodium bicarbonate (7.5 %)
Sodium pyruvate (lOOmM)














The nucleosides were added to 50 ml of distilled deionised water, filter 




Penicillin / Streptomycin (10 000 u/m l; 10 000 ug/ml) 5 ml
L-Glutamine (200 mM) 5 ml
2.1.2) Cell culture technique
2.1.2.1) Culture of CHO transfectants /  COS-7 cell transfectants
Both cell lines were adherent lines requiring regular (3-4 days) subculture in the 
relevant medium. For this the culture medium was removed from the tissue culture 
flask, and 5 ml of PBS was added to the flask for a washing step of approximately two 
minutes (to ensure removal of medium before the addition of trypsin). Trypsin-EDTA 
(1:250) (Life Technologies Ltd) was added to the culture flask in a volume of 2.5 - 3
ml and incubated at 37°C for 3 minutes to remove adherent cells from the flask 
surface. Trypsin was immediately neutralised with 10 ml of appropriate medium, and 
cells passaged from the cell suspension for future use at 2:10. Remaining cells were 
used for relevant experiments, frozen for storage in liquid nitrogen, or discarded after 
chlorination.
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Table 2.1: Medium requirements of cells used.
CELL TYPE
CHO Transfectants Cos cells, Lymphocytes, 
Jurkat cells , H9 cells.










Sodium Pyruvate ImM nil
Penicillin 100 units/ml 100 units/ml
Streptomycin 100 ug/ml 100 ug/ml






Additional Reagents 500 ng/ml
Hygromycin for Fas 
transfectant selection.
500 ng/ml Neomycin for 
Fas-L transfectant selection. 
10 Units/ml IL-2 for 
lymphocyte culture.
Media and supplements from Life Technologies Ltd 
Nucleosides from Sigma Chemical Co.
PBS (phosphate buffered saline) tablets from Unipath Ltd. 
All tissue culture plastics from Falcon Ltd.
2.1.2.2) Culture of Jurkat cells, JLW cells and H9 T cells
Jurkat cells, JLW cells and H9 T cells are transformed T cell lines which are non- 
adherent and were cultured in RPMI medium supplemented as shown. Cells were 
passaged every week by removal of three quarters of the culture medium containing the
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cells in suspension and replenishment with fresh RPMI medium. Cells removed from 
the culture were either used in apoptosis experiments, signalling experiments and RNA 
extraction or disposed of following chlorination if not required at the time. Cells were
grown at densities of 1 X 106 / ml.
2.1.2.3) Cryogenic storage of cells
To ensure a continued supply of cell lines for future experimental use a regular store of 
each cell line including the new transfectants was created in liquid nitrogen. Cells were 
washed after passage in medium and centrifuged at 350 g for 5 minutes and the 
medium removed. Cells were resuspended in 2 ml of 40% FCS in RPMI 1640 and 
placed on ice. An equal volume of 20% DMSO (Sigma) in RPMI medium was added 
to the cell suspension drop by drop with gentle mixing and the cells were then
subdivided into cryogenic storage vials at lxlO6 cells/vial. Vials were then cooled in an
insulated cooling box at -80°C for 24-48 hours before being placed in long term liquid 
nitrogen storage.
To recover cells from cryogenic storage, the cells were brought to 37°C rapidly and the 
contents transferred in aseptically to a tube containing 10 ml of pre-warmed medium
(37°C). Cells were centrifuged at 350g for 5 minutes and the supernatant was 
discarded. Cells were then resuspended in their appropriate pre-warmed medium and
placed in culture at 37°C with 5% C 02.
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2.1.3) Purification of peripheral blood mononuclear cells (PBMC) and 
T cells from peripheral blood.
2.1.3.1) Peripheral blood mononuclear cells (PBMC)
Peripheral blood samples were drawn from randomly selected SLE patients attending 
our Connective Tissue Diseases clinic at the Royal National Hospital for Rheumatic 
Diseases in Bath. On the same day a healthy normal volunteer from amongst staff at 
the hospital or the Rheumatic Diseases Institute was asked to donate a blood sample for 
concurrent separation and analysis so as to minimise any variation in the results 
secondary to differences in sample handling . Heparinised blood samples were diluted 
1:1 (volume:volume) in sterile PBS before being layered onto 15 ml of Ficoll (Heparin 
from CP Pharmaceuticals Ltd and Ficoll from Nycomed UK Ltd). Following 
centrifugation at 420 g for 30 minutes the layer of mononuclear cells (PBMCs) was
recovered from the gradient (containing PBMC 1-2 X 106 / ml of blood). The PBMCs 
were washed twice in PBS to remove any residual Ficoll and then a third time in 
complete RPMI medium. PBMCs were then either used directly for various 
experiments or separated further into purified populations of T cells as described 
below.
2.1.3.2) T cell purification
Monocytes were removed by adherence to tissue culture plastic petri dishes by
culturing the PBMCs in 10 ml of RPMI medium supplemented with 10% FCS at 37°C 
for 1 hour. All non-adherent cells (which included B cells, T cells and some residual 
monocytes) were recovered by gentle washing in RPMI. Monocytes adherent to the 
plate were gently scraped off the surface of the petri dish for FACS analysis for FasL 
expression. To purify the remaining lymphocytes, the cell suspension was incubated 
with a number of antibodies in order to deplete non-T cells. Antibodies used were anti­
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monocyte (anti-CD 14, 500ul of lOug/ml UCHM1 hybridoma supernatant), anti-B cell 
antibodies (anti-CD 19 1:10 dilution of ascites from BU12), and antibody to L243 
(anti-HLA DR) at 500 ul of a 10 ug/ml hybridoma supernatant (to remove activated T 
cells, B cells, monocytes and macrophages). The cell suspension with added
antibodies was incubated for 1 hour at 4°C on a spiramix rotating platform (Jencons 
Scientific Ltd), then washed in RPMI to remove unbound antibody and incubated in a 
2ml suspension containing 50 ul of sheep anti-mouse-IgG-coated magnetic beads
(Dynal; diluted 1:10 in medium) at 4°C on a rotator for a further hour. Cells were then 
washed in RPMI and adhered to a magnetic particle concentrator applied to the outside 
of the tube (repeated 2-3 times). Cells remaining in suspension were pooled as the 
purified T cell population which were 95% pure by FACS analysis for the CD2 
marker.
2.1.3.3) Generation of T cell blasts
Either PBMCs or purified T cells were used depending on the experiment in question.
Cells were suspended in RPMI at 1 x 106 cells/ml and incubated with PMA (lOng/ml ; 
Sigma) + ionomycin (luM ; Sigma) or SEB (lOug/ml ; Sigma) for 5 days. Fresh 
medium containing IL-2 (gift from Glaxo-Wellcome) at 10 Iu/ml was added at this time 
and cells cultured for a further period to increase cell numbers as required for the 
relevant experiment. IL-2 was added every two or three days with fresh medium 
depending on cellular requirements as judged by the change in colour of the medium.
2.1.4) Preparation of cells for FACS analysis.
Cells were resuspended at l-2xl05 cells / tube and washed in medium (Omerod, 
1990). Where Fc receptor blocking was required human IgG was used at 50ug/ml and
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cells were incubated for half an hour at 4°C. Cells were washed in 2ml of medium and 
resuspended in 50ul of the relevant antibody (at lOug/ml in medium) for further
incubation at 4°C for an hour. Any unbound primary antibody was washed away in 
PBS and cells were resuspended in a FITC-conjugated secondary antibody at lOug/ml 
in a volume of 50ul (either IgG or IgM depending on primary antibody used) for a 30
minute incubation at 4°C. Cells were then washed in PBS and analysed in FACS 
sheath fluid (Becton Dickinson) on a FacStar Plus analyser (Becton Dickinson). 
Information about cellular forward scatter (FSC), side scatter and the fluorescence 
intensity of labelling (FL1) was obtained using a LYSIS II programme.
2.1.5) Transfection of CHO or COS-7 cells by Electroporation.
A number of cell transfectants were generated in this project. CHO cells were used for 
the surface molecules like Fas and CD28 and COS-7 cells for the soluble Fas-Fc and 
Fas ligand expression. As both cell lines were immortal adherent lines the conditions 
for transfection were the same (Chu et al 1987). Cells were prepared in culture by
growing to 50-75% confluence in a large 175 cm2 Falcon flask. Following 
trypsinisation as described in 2.1.2.1 cells were washed in HeBs saline (recipe below)
and resuspended in HeBs saline at 5xl06 / ml. Salmon sperm DNA was added (20 ul 
of lOmg/ml stock added to 1ml HeBs ) to the HeBs cell suspension as carrier DNA. 
Plasmid containing the DNA for transfection was added at 50 ug/ml of DNA (prepared 
by Promega column purification). A final volume of 500 ul of cell suspension in HeBs 
containing salmon sperm DNA and plasmid DNA was pipetted into a 0.4cm BioRad
electroporation cuvette. A BioRad electroporator (BioRad Gene PulserTm) was used at 
a capacitance of 250uF and voltage of 300V to provide an electrical discharge to the 
cells with a time constant of between 3-5 ms. Cells were allowed to recover in 1ml of 
medium at room temperature for 10 minutes before being seeded into petri dishes with
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15 ml of appropriate culture medium and incubated at 37°C with 5% CO2. Cells were 
analysed by FACS at 24-48 hours for transient expression and cultured in selection 
medium (hygromycin 500ug/ml for Fas transfectants and neomycin 500ug/ml for FasL 
transfectant selection) before further sorting by magnetic beads and/or FACS sorting.
Recipe for HeBs saline:










made up in sterile MilliQ water to 500ml.
2.1.6) Chromium release assay
Fas positive target cells (Jurkat cells) were washed in RPMI medium and resuspended 
at 5xl06 cells/ml in medium. One hundred ul of isotonic 51Cr (Amersham) was added 
to the cell suspension and incubated at 37°C for 2 hours. The cells were washed in 
RPMI medium three times and then allowed to rest at 37°C for lhour before pipetting 
into a 96 well round bottomed plate at 2xl04 cells per well (triplicates for each 
stimulation). Stimulations were carried out as described in the results (section 3.2.3.4) 
for 18 hours before harvesting and counting on a y-counter (Wallac) programmed for 
the measurement of 51Cr. NP-40 (Sigma) was used to induce maximal release of 51Cr 
from the Jurkat cells, and PMA and ionomycin (Sigma) was used at 40ng/ml and luM, 
respectively, to stimulate FasL upregulation on the effector Jurkat cells.
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2.2) DNA and RNA manipulation
All the molecular techniques except RNA extraction have been based on the Laboratory 
Manual of Molecular Cloning edited by Sambrook et al (1989). Enzymes were 
handled on ice and added as the last step of any reaction described.
2.2.1) RNA extraction
(Chomczynski and Sacchi, 1987)
Reagents:
Denaturing Solution (solution D): 4 M guanidinium thiocyanate (Sigma)
The solution D was dissolved in the manufacturer's bottle at 65°C and stored in
the fridge at 4°C. 2-mercaptoethanol was added to an aliquot of the stock 
solution prior to use (72ul 2-ME to 10ml stock solution).
Other reagents used were:
Phenol (water saturated) (Appligene)
2M Sodium acetate pH 4 (Sigma)
Chloroform - isoamyl alcohol (49:1) (Sigma)
Isopropanol (Sigma)






To minimise handling of guanidinium thiocyanate a stock solution was 
prepared as follows : 250 g guanidinium thiocyanate
293 ml water (DEPC treated). 
17.6ml 0.75M sodium citrate pH7 
26.4ml 10% Sarcosyl
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Protocol for RNA extraction :
RNA is very sensitive to degradation by RNAse enzymes, hence there was a need to 
observe strict procedures with bench cleansing using alcohol, separate RNA pipettes, 
equipment, and solutions and regular change of gloves. All pipette tips and eppendorf 
tubes were autoclaved before use, and as far as possible no DNA work was conducted 
simultaneously. The steps involved in the RNA extraction from cells which were 
washed in PBS were as follows:
1) Cells were resuspended and disrupted in fresh solution D (between 1-2 x 106 cells / 
100 ul solution D) in a final volume of 500 ul in a 1.5ml microfuge tube.
2) The following were sequentially added with mixing by inversion between each:
50 ul 2M sodium acetate pH4 
500 ul phenol (water saturated)
100 ul chloroform-isoamyl alcohol (49:1)
3) Samples were shaken vigorously for 10 seconds (vortexing) and chilled on ice for 
15 minutes.
4) Tubes were spun at 13000g in a microcentrifuge for 10 minutes.
5) The top aqueous layer containing RNA was removed gently by pipetting and 
transferred to a fresh tube where an equal volume of chloroform-isoamyl alcohol was 
added. Samples were vortexed briefly and spun for 5 minutes at 13000g.
6) One more extraction was performed with chloroform-isoamyl alcohol as above 
before the final aqueous layer was precipitated with an equal volume of isopropanol
(samples were then stored at -20°C for 1-24 hours).
7) Samples were spun at 13000g for 10 minutes and the supernatant removed.
8) The pellet was redissolved in solution D (150 ul) and 150 ul isopropanol was added
before samples were again stored at -20°C between 1-24 hours.
9) The samples were spun at high speed for 10 minutes and the supernatant discarded.
10) The RNA pellet was washed once with 70% ethanol and once in absolute alcohol 
before drying down under vacuum for 15 minutes (GyroVap vacuum dryer, HOWE).
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11) The RNA pellet was dissolved in 50 ul DEPC water and the RNA quantitated by 
spectrophotometry (Ultrospec II, LKB) at 260nm using the equation:
A260 x 40 x dilution = ug/ml DNA, 
where A = absorbance, the dilution of RNA was 1/100, and 40 represents a constant 
for ssRNA. An OD26O : OD28O of 1.8 - 1.9 indicated good purity RNA.
12) RNA was routinely electrophoresed on agarose to check for degradation before 
use in RT-PCR reactions.
2.2.2) Reverse transcription (RT) and cDNA production.
To generate cDNA total RNA was reverse transribed for 1 hour at 37°C . The reactions 
were carried out in autoclaved siliconised eppendorf tubes (Sigma) to minimise 
adherence of cDNA to the tube. The reverse transcription reactions were set up as 
follows:
Total RNA 350 ng 5 ul
M-MLVRT buffer (5X) (Life Technologies) 6 ul
M-MLV RT enzyme (Life Technologies) 2 ul
DTT (0.1 M) ( Sigma) 3 ul
dNTP mix (lOmM) (Pharmacia) 1.5 ul
Oligo-dT (45 uM) (Pharmacia) 1 ul
RNAse inhibitor (Pharmacia) 1.5 ul
DEPC water (Sigma) make up to 30 ul.
After incubation at 37°C for 1 hour the reaction was terminated by heating to 95°C for 
10 minutes and the tubes then placed on ice. cDNA generated by the latter reaction was
either used immediately for PCR reactions or stored at -20°C.
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2.2.3) PCR (polymerase chain reaction)
PCR was either carried out with template cDNA as generated above or with plasmid 
containing the DNA sequence of interest (as outlined in the various results sections). 
Reactions were set up as follows in 0.65 ml eppendorf tubes:
cDNA (or plasmid DNA diluted to lOng/ul) 2 ul
Taq polymerase buffer (1 OX) (Promega) 10 ul
MgCl2 (25 mM stock) (Promega) 6 ul
Taq polymerase enzyme (Promega) 0.5 ul
dNTP (2 mM stock) (Pharmacia) 10 ul
Oligonucleotide primers 5' and 3'
(from Pharmacia; luM final concentration) 1 ul each
water ( milliQ) upto 100 ul.
All volumes were scaled down appropriately if reactions were carried out in 25 - 50 ul 
final volume for "test runs" on new reactions.
PCR reactions were all carried out on a Perkin Elmer Cetus thermal cycler and a typical 
programme would have 25 - 30 cycles o f :
95°C for 1 minute (denaturing)
55°C for 1 minute (annealing) (varied according to Tm of oligonucleotides)
72°C for 1 minute (extension)
72°C for 10 minutes at the end of all the cycles followed by 4°C until the
samples were retrieved for analysis.
In order to ensure complete strand separation and oligonucleotide denaturation, the
PCR samples were heated to 95°C for 3 minutes before the Taq polymerase enzyme 
was added. Samples were then layered with mineral oil (Sigma) before PCR reactions 
were commenced. For radiolabelling of PCR fragments either for probe generation or
SSCP analysis 2 ul of a 1:10 dilution of a 32P-dCTP (10uCi/ml)(Amersham) was 




Restriction digests were carried out frequently for a variety of reasons including the 
preparation of DNA for ligation, screening of recombinant plasmid clones, restriction 
mapping of cloned and subcloned DNA fragments, and excision of cDNA fragments 
for radiolabelled probe generation for southern blotting. In general enzyme choices 
were determined by the requirements of the experiment in question and much of this 
has been outlined with the relevant results. Restriction digests were carried out in 
autoclaved eppendorf tubes in a volume of 20 ul unless larger amounts of DNA were 
required for gel excision for further DNA manipulation when reactions were carried 
out in 100-500 ul volumes. A typical restriction digest was as follows:
Plasmid DNA (0.5 ug/ul) 5 ul
buffer (10X) (for relevant enzyme) 2 ul
restriction enzyme (3-5 u / ug DNA) 1 ul
water to volume of 20 ul.
Where double digests were required the appropriate buffer was used or two separate 
digests carried out if no single appropriate buffer was available. Enzyme reactions 
were conducted in a water bath heated to the appropriate temperature for the enzyme in 
use, and most restriction enzymes were purchased from New England Biolabs or 
Promega. Samples were electrophoresed on 1% (w/v) agarose gels for analysis on a 
UV transilluminator.
2.2.5) Ligation reactions
DNA ligation was necessary for generation of recombinant plasmid DNA in the variety 
of cloning experiments undertaken in this project. This was achieved using the 
following type of reaction:
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Plasmid DNA (with appropriate restriction sites) (50 ng/ul) 1 ul
cDNA or restriction fragment with compatible restriction sites
(50 ng/ul see calculation formula below) 1 ul
ligase buffer (10X) (New England Biolabs ; NEB) 1 ul
Ligase enzyme (T4 DNA ligase 400,000 u/ml) (NEB) 1 ul
water ( milliQ) 6 ul
10 ul
Ligation reactions were carried out in eppendorf tubes at 16°C for 4-16 hours 
depending on the nature of the ligated ends. Cohesive end ligations are more efficient 
and require shorter incubation periods whilst blunt end ligations were left for 16 
hours. To facilitate the cloning of blunt Fas fragments into pEe6, polyethylene glycol 
(PEG-8000 15% w/v; Sigma) was added to the ligation reactions.
To achieve optimal ligation a vector: insert ratio of 1:3 or 1:5 molar ends of DNA was 
used. With information of the size of vector and size of insert available the amount of 
insert DNA needed for a given amount of plasmid DNA in the ligation reaction ( 50 - 
100 ng) was calculated as follows:
ng of vector x kb size of insert insert
ng of insert = --------------------------------------- X molar ratio of -----------
kb size of vector vector
Ligations were terminated by heating to 70°C for 10 minutes (to inactivate T4 DNA
ligase) before DNA was either used for transformation of bacteria or stored at -20°C. 
Ligation controls were always carried out to help with decisions about transformation 
efficiency of recombinant clones. The ligation controls used were, vector religated to 
itself, unligated vector, and ligation reactions containing only the insert of interest.
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2.2.6) Transformation of bacteria (Electroporation).
In order to identify recombinant clones of insert and vector DNA, bacteria were 
transformed by electroporation (Sambrook et al, 1989) and colonies grown on agar 
plates. Transformation by electroporation is much more efficient than methods like heat
shock. A BioRad Gene PulserTm was used for all the transformation of bacteria with 
DNA. All work was done on ice with a mix of 40 ul of electrocompetent E.coli and 1- 
2 ul of ligation reactions (and controls as described above) in 0.2cm electroporation 
cuvettes (BioRad). Bacterial electroporation was carried out using the pulse controller 
with a resistance of 200 Ohm, capacitance 25 uF, and voltage of 2.5 Kv. Time 
constants were between 3.5 - 4.5 ms. Nine hundred and fifty ul of SOC medium (Bio 
101 Inc via Stratech Ltd) (at room temperature) was immediately placed onto the
transformed bacterial mix which was then incubated at 37°C (slow rotation in a 
bacterial Incubator Shaker, Model G25 from New Brunswick Scientific Co. Inc) for 
thirty minutes before plating (aliquots of 50-100 ul per plate) onto agar containing 
ampicillin.
Reagents required for bacterial transformation:
1) Electrocompetent bacteria.
Whilst commercial sources are available, electrocompetent E.coli are relatively easy to 
produce and remain competent for a considerable time if appropriately stored in liquid 
nitrogen. A variety of host strains of E.coli were prepared for the project because of 
the variety of plasmids used, but essentially all electrocompetent bacteria were 
produced as follows:
a) 10 - 12 ml of bacterial culture was grown in CircleGrow medium (Bio 101 Inc) 
overnight from an inoculate of stock E.coli stored in liquid nitrogen.
b) Sterile autoclaved 400ml CircleGrow medium was seeded with 1ml of the overnight
culture and placed into the Incubator Shaker at 37°C, 250 - 300 rpm.
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c) The optical density (OD) was checked at baseline and then hourly until an OD600 of 
0.55 - 0.6 (takes 2-3 hours and culture becomes cloudy indicating log phase growth).
d) The culture was placed on ice and transferred to cooled 50 ml Falcon tubes for
centrifugation at 4000rpm for 10 minutes at 4°C (Beckman benchtop GPR centrifuge).
e) Supernatant was disposed following chlorination and the bacterial pellet was 
resuspended in 20ml ice cold sterile Milli-Q water, pooled and centrifuged at 4000rpm
at 4°C for 10 minutes.
f) The bacterial pellet was resuspended in 20 ml cold sterile Milli-Q water and spun as 
before.
g) The pellet was resuspended in 2 ml cold sterile Milli-Q water containing 10% 
glycerol (Sigma) and aliquoted into freezing vials for rapid storage in liquid nitrogen.
2) Growth Media:
Circle-Grow bacterial growth medium (Bio 101 Inc via Stratech L td): dissolved 40g in 
500 ml milliQ water and autoclave for 20 minutes. Allow to cool before adding 
antibiotics.
SOB medium (Bio 101 Inc via Stratech Ltd): Dissolved one capsule per 20 ml water 
and autoclaved for 20 minutes.
SOC medium : SOB medium with sterile 1M glucose (Sigma) added at 400mM final 
concentration.
Agar plates : 1% agar w/v (Sigma) was added to CircleGrow medium and autoclaved,
cooled in a water bath to 50°C before ampicillin (purchased from local Hospital 
Pharmacy) was added at 50 ug/ml. The agar was poured in a standard manner onto 
bacterial grade petri dishes.
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2.2.7) Selection of transformant colonies
Antibiotics added to the agar plates help selection of plasmid-encoded antibiotic- 
resistant colonies. Typical concentrations of antibiotics used for selection included 
ampicillin 50 ug/ml, tetracycline 15 ug/ml, and kanamycin 50 ug/ml. In addition colour 
selection using blue/white screening was done with vectors capable of alpha- 
complementation (lacZ gene) in conjunction with the appropriate host bacterial strain. 
Agar plates were spread with 50 ul of 50 mg/ml X-Gal (NBL) and 100 ul of 0.1M
IPTG (NBL) and left to absorb for 30 minutes at 37°C before plating of transformants. 
Recombinant colonies were white in colour due to disruption of the lacZ gene of the 
plasmid but some pale blue colonies also contained inserts. Leaving the agar plates at
4°C for a few hours helped enhance the blue/white colour segregation.
2.2.8) Plasmid minipreps
Colonies chosen either by blue/white colour selection or at random where no colour 
selection was available were picked off the agar plates (flame sterilised loop) and 
placed into 5 ml of CircleGrow medium in 30 ml universal plastic tubes (Fahrenheit)
for shaking in an Incubator Shaker at 37°C overnight. 1.5 ml of the overnight growth 
was transferred to eppendorf tubes for centrifugation at 6 500 rpm in a benchtop 
micro-centrifuge for 5 minutes.The supernatant was suitably disposed of following 
chlorination and the bacterial pellet was handled as follows to extract the plasmid DNA:
1) Add 100 ul resuspension solution (solution I) and mix by vortexing.
2) Add 200 ul lysis solution (solution II) and mix by inversion. The solution clears 
with this step.
3) Add 150 ul neutralising solution (solution III) and mix by vortexing. The solution 
again becomes cloudy with white "floccular" material.
4) Centrifuge at 13 000 rpm for 5 minutes and remove supernatant to fresh eppendorf 
tube.
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5) Add 500 ul of a 1:1 mix of chloroform : phenol (ie, 250 ul of each mixed in a glass 
bottle and added to the tubes in step 4). Tubes were mixed by vortexing and spun in a 
centrifuge at 13 000 rpm for 3-5 minutes.
6) The aqueous (upper) layer was removed carefully from each tube and placed in 
fresh eppendorf tubes. The remaining phenol / chloroform was all pooled for 
appropriate disposal at a later stage.
7) An equal volume of chloroform was added to the aqueous phase in step 6 and mixed 
by vortexing before centrifugation at 13 000 rpm for 5 minutes.
8) The aqueous phase (upper layer) was again carefully removed by pipette into fresh 
eppendorf tubes. Absolute ethanol was added at twice the volume of the aqueous layer 
and mixed by inversion. This would reveal clouding within the solution as the DNA
became precipitated by the ethanol. Samples were stored at -20°C for half an hour to 
allow further precipitation to occur before centrifugation at 13 000 rpm for 10 minutes.
9) The supernatant was discarded and the DNA pellet washed in 70 % ethanol before 
drying under vacuum for 10 -15 minutes.
10) Pellets were resuspended in 25 - 30 ul of TE buffer containing RNAse (20ug/ml). 
The RNAse prevented small molecular weight DNA bands being obscured by RNA 
during agarose gel electrophoresis. Plasmid DNA was then subjected to restriction 
digests with appropriate enzymes as described above (3-5 ul DNA per reaction) for 
screening of recombinant clones.
Reagents used : (all chemicals from Sigma)
Solution I: 50 mM glucose
25 mM Tris-Cl pH 8 
lOmMEDTApH 8 
made up in milli-Q water.
Solution II: 0.2 N NaOH
1 % SDS
made from stock 10M NaOH and 10% SDS before use.
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Solution III: 5M Potassium acetate 60 ml
Glacial Acetic acid 11.5 ml
water 28.5 ml
The resulting solution was 3M for potassium and 5M for acetate
TE buffer: 10 mM Tris-Cl pH 8 
1 mM EDTA
made up with milli-Q water.
2.2.9) Plasmid maxipreps
Following identification of cloned plasmid DNA by restriction mapping of miniprep 
DNA, larger quantities of purified DNA were obtained for transfection and expression. 
Bacterial cultures were set up in 2L Pyrex flasks containing 500ml of autoclaved 
CircleGrow medium with ampicillin 50 ug/ml. Larger flasks allowed better agitation of
the culture in the incubator shaker and was carried out at 37°C overnight from a 
seeding of 1 ml of a relevant miniprep bacterial culture. The turbid overnight bacterial 
growth was handled as follows:
1) 150-200 ml bacterial growth was poured into 250 ml Nunc bottles for centrifugation
in a Beckman J2-21 centrifuge with a fixed angle rotor (JA 14) at 10 000 rpm, 4°C for 
10 minutes.
2) Supernatants were appropriately disposed of following disinfection, and the 
bacterial pellet was resuspended in 100ml STE solution by gentle pipetting. 
Centrifugation was again carried out as above and the pellet resuspended in 20 ml cell 
resuspension buffer (solution I) by gentle pipetting.
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3) 40 ml of freshly prepared Solution II (lysis solution) was added and the contents 
mixed by inversion. This resulted in a clearing of the mixture which sometimes
required 20 - 30 minutes on the bench (facilitated in a 40° water bath).
4) 20 ml of solution III was added and mixed by shaking and inversion to give rise to a
turbid "floccular" solution, which was then centrifuged at 10000 rpm, 4°C for 30 
minutes without the brake on (so as not to disturb the pellet).
5) The plasmid DNA in the supernatant was carefully removed by pipetting to 
minimise transfer of any bacterial debris and transferred into 30 ml Corex tubes.
6) An equal volume of isopropanol was added at room temperature to precipitate the 
plasmid DNA (left on the bench for 15 minutes). Samples were centrifuged at room 
temperature at 10 000 rpm for 10 minutes and the supernatant drained. Pellets were 
washed in 70 % ethanol and dried at room temperature before resuspension in TE 
buffer in a volume of 3 - 5 ml for purification.
7) Plasmid purification was carried out by the method supplied with the Promega 
Wizard purification kit (Promega TB139, Wizard™ plus Maxipreps DNA purification 
system). Purified DNA was quantitated by spectrophotometry using a quartz glass 
cuvette and reading the optical density (OD) at wavelengths of 280 and 260 nm.
A ratio of OD260 : OD28O = 1*7 - 1.8 indicated sufficiently pure quality DNA for 
transfection.
STE solution: 0.1 M NaCl
10 mM Tris-Cl pH 8 
1 mM EDTA pH 8 
made up in milli-Q water.
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2.2.10) Colony screening by hybridisation
Where no colour selection was available and a random selection of 12-24 colonies did 
not reveal any recombinant clones, selection by colony lifting and hybridisation was 
conducted. Agar plates containing approximately 100 - 150 colonies reasonably spaced 
apart were covered by Hybond N membranes (Amersham) until the latter was evenly 
wet (within one minute). Identification points were marked using ink with a sterile 
needle to leave an imprint in both the agar and the membrane for alignment at a later 
stage. Membranes were then evenly lifted off the agar plates and handled as follows:
(agar plates were incubated at 37°C for 6 hours to allow colonies to regrow before
storage at 4°C)
1) Membranes were placed colony side up onto Whattman filter paper pre-soaked with 
denaturing solution for 7 minutes.
2) Membranes transferred onto Whattman filter paper pre-soaked with neutralising 
solution for 3 minutes ; then placed onto fresh filter paper with neutralising solution for 
another 3 minutes.
3) Membrane filters were then washed in 2X SSC solution for a minute and drained on 
a dry piece of Whattman filter paper for a few minutes.
4) Membranes were wrapped in Saran wrap and placed face down on a UV 
transilluminator for 2 - 3 minutes to fix the DNA by cross-linking.
5) Membranes were incubated in 30ml pre-hybridisation buffer in Hybaid bottles at
65°C for 3-6 hours in a Hybaid hybridisation oven (rotated continuously).
6) A radiolabelled probe (50ul) was added to the 30ml pre-hybridisation mix for
further incubation with the membranes overnight at 65°C.
7) The radioactive probe was appropriately stored at -20°C for upto one week for re­
use, and the membranes were washed of non-specific binding as follows:
8) Membranes were washed at 65°C for 15 minutes in a solution containing 2X SSC
and 0.5% SDS, then for another 15 minutes at 65°C in solution containing 0.2X SSC 
and 0.5% SDS. The membrane was tested for radioactive signals by a hand held
67
counter (Mini-Monitor series 900) to determine the duration of the final stringent wash 
in solution containing 0.1X SSC and 0.5% SDS. This final wash was done for 5 
minutes if background radioactivity on monitoring was < 20 counts per second or for 
10-15 minutes for higher levels of radioactivity.
9) Membranes were wrapped in Saran wrap and fixed onto autoradiography casettes 
for exposure to Blue Sensitive Xray film (Genetic Research Instruments Ltd).
10) Autoradiographs were developed in the Xray department of the Royal National 
Hospital for Rheumatic Diseases, and aligned onto the previous postions marked on 
the membranes. Appropriate identification marks were made on the autoradiographs
for alignment on the agar plates previously stored at 4°C, and the colonies which most 
closely aligned to the "hot" spots on the autoradiograph were chosen for further 
miniprep analysis.
Solutions used in this procedure:
SSC: made up as 20X stock as follows:
3 MNaCl (Sigma)
0.3 M Sodium citrate (Sigma)
SDS: made up as 10% solution w/v of lauryl sulphate (Sigma) in distilled water.
Denaturing solution: 1.5 M NaCl
0.5 M NaOH
Neutralising solution: 1.5 MNaCl
0.5 M Tris-HCl pH 7.2 
0.001 M EDTA pH 8
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Pre-hybridisation solution: made up as follows:
Stock solution Final vol. Amount
20 X SSPE













20 X SSPE : 3.6 M NaCl
0.2 M sodium phosphate 
0.02 M EDTA pH 7.7
50 X Denhardt's solution:
2 % w/v BS A 
2 % w/v Ficoll
2 % w/v PVP (polyvinylpyrolidine)
Radiolabelling of probes was done using a Promega Prime-a-Gene kit as 
the following reaction (various components added in sequence as shown):
Nuclease free water to achieve final volume 50 ul 
5 X labelling buffer
dNTP mix (500 uM of each unlabeled dNTP)
DNA (25 ng/ul denatured)
Nuclease free BSA (10 mg/ml)
a _32P-dCTP (50 uCi, 3000 Ci/mmol)












2.2.11) Agarose gel electrophoresis
Agarose gels were made in 1 X TAE buffer as a 1% or 2% solution (w/v agarose from 
Sigma), boiled in a conical flask in a microwave oven until the agarose was completely
in solution and then cooled on the bench (± 50°C) for addition of ethidium bromide (5 
ul of lOmg/ml stock solution to 100 ml of agarose). The gel solution was poured into a 
gel tray and allowed to set at room temperature (low melting temperature gels were set 
in the fridge). All DNA electrophoresis was conducted in IX TAE buffer (containing 
Ethidium bromide) using a standard horizontal electrophoresis tank attached to a power 
source (at 70 - 100 volts).
Gels were analysed over UV light and photographed with a hand-held camera.
TAE buffer: made as 50 X stock as follows:
242 g Trizma Base (Sigma)
57.1 ml Glacial acetic acid (Sigma)
100 ml 0.5 M EDTA pH 8
made up to 1 litre with milli Q water.
2.2.12) TA cloning
This was achieved using a pT7Blue T-Vector Kit (Novagen, catalogue number 69836-
1). TA cloning differs from standard cloning techniques only in the use of compatible 
T and A nucleotide overhangs to facilitate ligation of PCR products (Marchuk et al, 
1990). The pT7Blue T-vector supplied with the kit was prepared by EcoRV digestion 
and addition of single 3’ dT residues at each end. Standard PCR was carried out with 
Taq DNA polymerase (Promega) (section 2.2.3) which leaves single 3’A-nucleotide 
overhangs on the reaction products (Clark, 1988). Ligation reactions were carried out 
using components of the kit (as per ligation reaction outlined in section 2.2.5). 
Subsequent transformation of bacteria and plasmid miniprep analysis was conducted as 
described in the methods above (sections 2.2.6, 2.2.7, 2.2.8).
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2.3) BIOCHEMISTRY / IMMUNOCHEMISTRY
2.3.1) Fas-Fc protein purification from culture supernatants
2.3.1.1) Concentration of supernatants
Fas-Fc transfectant supernatants were pooled and stored at 4°C until approximately 
500 - 1000 ml of supernatant was available. The latter was placed in a large glass 
beaker and placed on a magnetic stirrer. An equal volume of saturated ammonium 
sulphate solution was added to the beaker by dripping through a column (a syringe
barrel attached to a 20 gauge needle). The mixture was left at 4°C for 6 - 12 hours and
centrifuged at 3000 g for 30 minutes (4°C). The pellet was resuspended in PBS at 0.1- 
0.3 X the original start volume of supernatant, transferred to dialysis tubing and
dialysed against PBS at 4°C (three exchanges of PBS at 4-6 hourly intervals). The 
dialysed concentrate was then removed from the dialysis tubing for affinity 
chromatography.
Saturated Ammonium sulphate (Sigma):
761 g in 1 litre distilled water (at room temperature = 4.1M).
PBS: prepared by dissolving 1 tablet per 100 ml distilled water (CP pharmaceuticals 
Ltd).
Preparation of dialysis tubing by boiling:
1) Cut tubing (Sigma) to appropriate lengths.
2) Place tubing in large volume of 5mM EDTA, 200mM sodium bicarbonate and boil 
for 5 minutes.
3) Rinse tubing briefly in distilled water and add a large volume of solution as in (2) 
for a further boiling for 5 minutes. Decant the solution and rinse in distilled water.
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4) Cover tubing in large volume of distilled water and cover with foil for autoclaving 
(10 minutes).
5) Dialysis tubing stored at 4°C with 0.02% sodium azide.
6) Tubing rinsed before use (inside and outside) with distilled water.
2.3.1.2) Affinity chromatography with Protein G sepharose
Dialysed concentrated protein from the pooled cell culture supernatants could be 
purified by affininty chromatography because of the immunoglobulin Fc region 
designed into the Fas-Fc molecule. Essentially a Protein G-Sepharose-4-FastFlow 
column from Pharmacia was set up in a cold cabinet as per the guidelines of Pharmacia 
(Technical help catalogue 18-1022-29).The column was monitored by paper recording
(lmm/min) throughout the procedure. The dialysate was diluted 1:1 in start buffer and
passed throught the column at lml/min (ensuring that the column did not run dry at any 
time). The column was then washed with the start buffer until a stable baseline trace 
was recorded, when elution buffer (pH 2.7) was passed through at lml/min until the 
tracing again returned to baseline. One ml aliquots of eluates were collected in 
eppendorf tubes during the elution peak of the tracing and the eluate in each eppendorf 
tube was immediately neutralised by having a pre-added 20 ul of neutralising buffer 
(1M Tris pH 9.0) within the eppendorfs. Protein concentrations were checked in each 
eppendorf using an OD280 reading on the spectrophotometer, and the appropriate 
protein eluates were pooled for further biochemical characterisation on SDS-PAGE 
gels and immunoblotting.
Start / Wash buffer: 0.02M Sodium phosphate pH 7 made up as follows:
Na2HP04 : 1.42 g in 500 ml dH20  
NaH2P04 : 1.38 g in 500 ml dH20  
Mixed in equal volume to give pH7 start buffer.
Elution buffer: 0.1M glycine-HCl pH 2.7
(3.75g in 500 ml dH20)
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2.3.2) SDS PAGE electrophoresis
Standard vertical electrophoresis apparatus (Hoefer) was used for SDS-PAGE 
resolution of proteins and in general was attached to a power source at constant 
current of 20 - 25 mA over 2-4 hours depending on the size of protein being resolved 
and the percentage acrylamide within the gel. The percentage polyacrylamide in gels 
varied according to requirements but a typical 1mm thick 10% gel was made up as 
follows:
Acrylamide / Bisacrylamide 30% (37.5:1) (NBL) 10 ml
4X gel electrophoresis buffer 7.5 ml
10% SDS 0.3 ml
ddH20 12.1 ml
10% ammonium persulphate (w/v) (NBL) 150 ul
TEMED (Sigma) 10 ul
After polymerisation at room temperature (layered with water saturated butanol) the 
stacking gel was poured with a comb in situ:
Acrylamide / Bisacrylamide 30% (37.5:1) 1.33 ml
4X stacking gel buffer 2.5 ml
10% SDS 0.1 ml
ddH20 6.0 ml
10% ammonium persulphate 50 ul
TEMED 5 ul
Before electrophoresis samples were mixed with an equal volume of 2X SDS sample
buffer and heated at 95-100 °C for 5 minutes, then placed on ice and dispensed by 
pipette into the wells under running buffer.
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Buffers for gel electrophoresis:
Running gel buffer: 1.5 M Tris-HCl pH 8.8 (to 800ml dH20  add 182g Trizma base
and bring pH to 8.8 with HC1, make upto 1L with dH20).
Stacking gel buffer: 0.5 M Tris-HCl pH 6.8 (to 400ml dH20  add 30g Trizma base
and pH to 6.8 with HC1, make upto 500ml with dH20).
Electrophoresis running buffer (made up as 10X stock as follows):
250mM Tris-HCl 
1.9 M glycine 
1% SDS
To 800 ml dH20  add 30.3g Trizma base and 144g glycine and 
lOg SDS. Dissolve and make up to 1L with dH20  and pH to 
8.3 with HC1.
10% SDS: made up by dissolving 10 g SDS (Sigma) in dH20  in a final
volume of 100ml.
2X SDS sample buffer: Tris-Cl pH 6.8 (62.5mM) = 312.5 ul of 1M stock
SDS 2% = 1000 ul of 10% stock
Glycerol 10% = 500 ul of 100% stock
DTT 50 mM = 250 ul of 1M stock
Bromophenol blue 0.1% = 50 ul of 10% solution,
made up with dH20  (2887.5ml) to a final volume of 5
ml and stored at room temperature.
Formula for calculating the percentage acrylamide in a gel:
vol of gel x % gel




Gels were submerged in Coomassie Brilliant blue stain for 30 - 45 minutes with gentle 
agitation at room temperature followed by destaining solution for the same period. The 
destain solution was replenished once to improve resolution of protein bands above 
background over a 1-2 hour period. Gels were then transferred to a layer of Whatman 
paper and covered in Saran wrap before drying on a vacuum gel dryer (RAPIDRY, 
Genetic Research Instruments Ltd).
Coomassie blue staining solution: 50% w/v methanol
10% w/v acetic acid
0.25% w/v Coomassie blue R-250.
Destaining solution: 10% w/v methanol
5% w/v acetic acid
2.3.4) Western Blotting
Proteins from SDS-PAGE gels were transferred to either nitrocellulose or PVDF 
membranes (BioRad) by electrophoresis on a semi-dry blotting apparatus (Sigma). 
PVDF membranes are hydrophobic and required an additional step of wetting in 100% 
methanol before being placed in transfer buffer. All membranes and Whattman filter 
paper were incubated in transfer buffer for at least ten minutes before the blotting 
transfer was set up. Gloves were used at all times to avoid background staining of 
membranes. Four layers of pre-soaked filter paper were placed onto the transfer unit, 
followed by the wet blotting membrane. Air bubbles were removed by rolling a pipette 
over the membrane and the SDS-PAGE gel was placed onto the transfer membrane. 
Air bubbles were again removed by rolling followed by layering another 4 pieces of
75
wet filter paper (one at a time with removal of air bubbles at each stage). The sandwich 
was placed with the membrane on the side of the positive electrode, the semi-dry
blotting apparatus was assembled and connected to a power source at 1mA / cm2 of 
membrane (80mA for an 8 X 10 cm membrane). Electrophoretic transfer took place 
over 1 hour unless a higher percentage gel or higher molecular weight proteins were 
being transferred in which case the transfer took between 90 and 120 minutes.




made up in deionised water.
A 10X stock of transfer buffer without methanol and SDS could be stored and fresh 
IX buffer made up as required.
Following western blot transfer the membrane was subjected to immunoblotting as 
follows. The transfer membrane was incubated with blocking buffer at room 
temperature for one hour with gentle agitation. Blocking buffer was poured off and the 
membrane was incubated with relevant primary antibody (dilution 1:1000 but titrated 
according to background upto 1:10 000) for one hour at room temperature with gentle 
agitation. Membranes were washed in PBS-tween for 15-30 minutes with three 
exchanges of fresh wash buffer before the secondary peroxidase conjugated antibody 
was added at a dilution of 1: 10 000. In the case of Fas-Fc immunodetection direct 
detection of the immunoglobulin tail was possible by using an anti-mouse IgG 
peroxidase conjugate followed by the detection stage. After a lh incubation the 
secondary antibody was also extensively washed in three exchanges of PBS-Tween 
over 30 minutes. The membranes were then incubated with substrate solution 
containing DAB tablets (3,3’-Diaminobenzidine)(Sigma) for colour detection of 
immunoreactive proteins. Later in the project immunoblotting experiments were
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conducted with ECL detection using an Amersham ECL detection system and 
autoradiography.
Blocking solution: PBS with 0.1% (v/v) Tween-20 and 5% (w/v) milk
powder.
Antibody dilution buffer: PBS with 0.1 % Tween-20 (Sigma)
DAB substrate solution: 1 DAB tablet (3,3’-Diaminobenzidine) (Sigma) in
15 ml of Tris-Cl pH 8 and 15ul of 30% hydrogen 
peroxide solution.
2.3.5) Dot blots
For the detection of native undenatured protein dot blot analysis was carried out as 
follows. Antigen was spotted onto marked pieces of nitrocellulose paper (circles 2cm 
in diameter). The membrane spotted with antigen was air dried and soaked in blocking 
buffer as for western blots for 30 minutes. Primary antibody was then incubated with 
the blots for one hour followed by three exchanges of wash buffer (PBS + Tween 
0.1%). Secondary antibody was incubated for an hour followed by three washes and 
then incubation with substrate solution (Tris-Cl pH 8 15ml + DAB tablet + H2O2 15 
ul). Colour visualisation of protein was evident within minutes of incubation with 
substrate solution.
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2.3.6) Protein quantitation by ELISA (BioRad Protein Assay)
Protein quantitation was either carried out by spectrophotometry (OD280) or by a Bio- 
Rad protein quantitation assay as described here. Bovine serum albumin was used as a 
standard and diluted from a stock solution of 25 mg/ml as follows:
1/16 = 1.5 mg/ml
1/20 = 1.2 mg/ml
1/28 = 0.9 mg/ml
1/50 = 0.5 mg/ml
1/125 = 0.2 mg/ml
All standards and samples were dispensed in 5 ul aliquots (duplicate) into a 96 well 
ELISA plate (Maxi Sorp, Nunc, Denmark). Twenty ul of reagent S was added to 1ml 
of reagent A and mixed by inversion before dispensing 25 ul per well, followed by 
200 ul of reagent B per well. Plates were left at room temperature for 15 minutes 
(stable for upto 1 hour) and read on a Dynatech MR 5000 plate reader at an absorbance 
of 750nm. The plate reader was programmed to plot a linear curve of Abs (750nm) 
from the standards using the known concentrations and measure protein concentrations 
of the samples from the resulting curve. Results were plotted as absorbance and 
concentration values in mg/ml.
2.3.7) Immunoprecipitation
Whole cell lysates were used for immunoprecipitation experiments. Cultured cells were 
washed in PBS to get rid of any residual medium before resuspension in lysis buffer
(between 5xl06 and 40xl06 cells per ml of lysis buffer). The 1ml lysates were 
transferred to 1.5ml eppendorf tubes and placed on ice for 10 minutes, vortexed briefly 
and left on ice for a total of 30 minutes. Tubes were spun at 13 000 rpm in a cooled
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benchtop microcentrifuge (4°C) (BioFuge Fresco, Heraeus) for 10 minutes to separate 
nuclear debris and membranous material before the lysate was transferred to a fresh 
eppendorf tube for protein quantitation by one of the methods mentioned above (Bio- 
Rad quantitation by ELISA). Equal quantities of protein were then transferred to 
eppendorf tubes for addition of 30 ul of protein G-sepharose beads (Pharmacia) and
incubation on a rotating platform at 4°C for 1 hour. Samples were spun at 13000 rpm 
for 2 minutes and the pre-cleared lysate removed by pipette into fresh eppendorf tubes 
for incubation with the primary antibody on ice for 1 hour. Fas-Fc was regarded as a 
primary antibody in the immunoprecipitation of FasL in chapter 3. After incubation on 
ice for one hour 30 ul of protein G sepharose was added to the lysate-antibody mix and
rotated at 4°C for 2 hours. Antibodies of most species bind to protein G sepharose 
beads so that a gentle centrifugation of the lysate at this stage produced a pellet of 
beads with antibody-bound proteins from the lysate which could be resolved on SDS- 
PAGE electrophoresis. To remove non-specifically bound proteins the sepharose 
beads were washed in the lysis buffer 3 times with gentle centrifugation (short pulse 
on a microcentrifuge) before mixing with an equal volume of SDS sample buffer for 
heat denaturation and loading onto a gel.
Lysis buffer: (all made up fresh from stock solutions, chemicals all from Sigma):
1) General lysates: NaCl 150 mM
NP-40 1%





made up in milli-Q water.
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2) Lysis buffer for Kinase / signalling experiments:




Ortho vanadate (Na3V0 4 ) 1 mM
Triton X - 100 1 %
Glycerol 10%
leupeptin 2 uM
soybean trypsin inhibitor 10 ug/ml
PMSF 400 uM
made up in milli-Q water.
2.3.8) In vitro Jun kinase (JNK) assay
In vitro kinase reactions for Jun kinase were established using the method of Kyriakis 
et al (1994). Lysates from stimulated cell cultures were made and quantitated for 
protein content by ELISA as described. Each lysate was incubated with 10 ul (2.5 ug)
GST-cJun (coupled to sepharose beads) on a rotating platform at 4°C for 4-6 hours 
before being washed with lysis buffer three times. Between each wash the beads were 
gently pelleted in a cooled benchtop microcentrifiige at low speed (10 second pulse 
only). The beads were drained of lysis buffer by a 19 gauge needle which does not 
allow the beads to be aspirated (with insulin syringe) and then added to an in vitro 
kinase reaction as follows:
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Lysate (GST-cJun bound beads) 10 ul
10 x kinase buffer 4 ul
gamma-32P ATP (1 uCi / ul) 
milli-Q water 
Total volume 40 ul
24 ul
2 ul
Gamma 32P-ATP was from Amersham and diluted 1:10 from a 10 uCi / ul stock in 
milli-Q water before use.
The reaction mix was incubated at 37°C for 30 minutes before adding an equal volume
of SDS sample buffer and heat denaturation of the proteins at 95°C for 5 minutes. 
Samples were held on ice before loading onto an SDS PAGE gel (12.5 %). Gels were 
dried after washing in milli-Q water for 5 minutes and autoradiographs were developed 
and read on image analysis software (Imagedok and Phoretics).
Kinase reaction buffer 10X:
Preparation of GST-cJUN:
GST-cJun protein (1-173) was prepared from a plasmid kindly donated by Dr S Ward. 
E.coli were transformed with the plasmid by electroporation and a colony was chosen
for a miniprep culture which was grown over 6 hours at 37°C. Ten ml of the miniprep 
culture was seeded into a 2 litre flask containing 400 ml of CircleGrow culture medium 
containing ampicillin 50 ug/ml and grown to an OD600 of 0.6 - 0.8 (maximum 0.9). 
Expression of the recombinant GST-cJun was induced by IPTG (Sigma) added to the 
culture at this point to a final concentration of 0.4mM (160 ul of a 1M stock added to a
Hepes pH 7.5 250 mM (Life technologies)
Magnesium acetate 100 mM (Sigma)
Mg-ATP 500 uM (Sigma)
made up in milli-Q water.
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400 ml culture). The bacterial culture with IPTG was incubated in the incubator shaker
for a further 3-5 hours at 37°C and the culture was then transferred to centrifugation
bottles and spun at 4°C, 4000 rpm for 20 minutes (Beckman J2-21 centrifuge, JAM 




SP1 (small peptide 
inhibitor) 1 ug/ml
made up in PBS.
Resuspension was facilitated by pipetting the lysate up and down and then transferred
to 50 ml Falcon tubes for overnight storage at -20°C. Samples were next sonicated 
four times for 40 seconds with one minute intervals on ice between sonication (power 
setting 50%). Sonicated lysates were transferred to 30 ml corex tubes and centrifuged
at 10 000 rpm, 4°C for 10 minutes (Beckman J2-21 centrifuge). Supernatants were 
transferred to 15 ml Falcon tubes and incubated with 1 ml of 50% glutathione agarose
beads (Pharmacia) per 10 ml at 4°C, on a spiramix rotating platform for 1-2 hours 
(Note that the glutathione beads were washed in PBS prior to their use in order to
remove any alcohol from the storage mixture). Incubated samples were spun in a 4°C 
centrifuge by gentle pulsing only and allowed to settle on ice before doing a wash in 
lysis buffer once, followed by three washes in PBS containing 2mM EDTA. A final 
wash in PBS was done before mixing with storage buffer containing:




For the last wash in storage buffer samples were spun at 2 000 rpm for 1 minute and 
left to settle on ice for at least ten minutes before removing the supernatant. Beads were
then transferred to eppendorf tubes and stored in 50 % storage buffer at -20°C ready 
for use. GST cJun protein coupled to the agarose beads were checked and quantitated 
on SDS PAGE gels before use in immunoprecipitations and in vitro kinase assays.
2.3.9) Sphingomyelinase assay
Cells stimulated as required were washed in cold PBS before incubation with lysis 
buffer (as shown in 2.3.7) on ice for 30 minutes. All stimulations were carried out in a
37°C water bath and rapidly terminated by immersion in liquid nitrogen. Samples were
spun at 13000 rpm, 4°C for 10 minutes and the supernatants quantitated for protein by 
the Bio-Rad ELISA assay (section 2.3.6). Fifty ug of lysate from each stimulation was 
incubated in an in vitro sphingomyelinase assay (Wiegmann et al, 1994) as follows:
50 ug Lysate
250 mM Sodium acetate (Sigma)
1 mM EDTA pH 5 (Sigma)
1.1 uCi/ml 14C sphingomyelin (Amersham)
made up to a final volume of 50 ul in milli-Q water.
The samples were incubated at 37°C for 2 hours before a phase extraction with 250 ul 
water and 800 ul of a 2:1 mix of chloroform:methanol. The upper aqueous layer was 
used with 5 ml aqueous scintillation fluid (Optiphase Hisafe 3, Wallac) in miniature 
polyethylene vials for liquid scintillation counting (Packard Instrument Co) and 
radioactivity measured on a Liquid Scintillation Counter (1209 Rackbeta, LKB 
Wallac). Results were expressed as a percentage change from baseline unstimulated 
cells at time point zero (chapter 3).
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2.4) Single Stranded Conformational Polymorphism (SSCP)
Blood was taken from patients and controls as described in 2.1.3 and stimulated with 
PMA / ionomycin to upregulate Fas expression (see results 5.2.1). RNA was extracted 
as described (section 2.2.1) and RT PCR conducted using the oligonucleotide primers 
shown in figure 5.1.2. Radiolabelled PCR (Orita et al, 1989) was carried out for 30 
cycles as described in 2.2.3 above and the PCR samples were handled as follows. 
Five ul of the PCR mix was removed and mixed with 5 ul of SSCP stop solution/ 
loading buffer comprising:
Formamide 95% (Sigma)
EDTA 20 mM (Sigma)
NaOH 10 mM (Sigma)
Bromophenol blue 0.05 % (Sigma)
xylene cyanol 0.05 % (Sigma)
The PCR + SSCP stop solution was heat denatured at 95°C for 5 minutes and kept on 
ice for loading onto a non-denaturing polyacrylamide gel. TBE-PAGE gels were 
poured as 20 x 40 x 0.05 cm, 6% acrylamide gels made up in TBE buffer using 
Appligene electrophoresis apparatus. The gel plates were attached to a Haake K15 
cooling unit (Fisons) when polymerised and denatured samples were loaded in 2 ul
aliquots per well (remainder stored at -20°C). Electrophoresis was carried out at 12 W 
constant power for 20 hours in 1 x TBE buffer, following which gels were carefully 
removed and dried under vacuum before being subjected to autoradiography.
Buffers: TBE IX: 90 mM Tris-borate pH 8.3 (Sigma)
4 mM EDTA pH 8 (Sigma)
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A 6% acrylamide gel comprised of:
5 x TBE buffer 10 ml
milli-Q water 29.5 ml
Acrylamide (30%) 10 ml
TEMED 50 ul
Ammonium persulphate 500 ul
Gel conditions were optimised using mutant PCR products. Gels run at room 
temperature required the addition of glycerol 10% to the gels for resolution of bands
but the best differentiation of polymorphic bands was found at 4°C with no added 
glycerol. Autoradiographs were visualised on a light box for polymorphic bands and 
any polymorphism was confirmed by independent PCR and SSCP gels. Sequence 
analysis was conducted for the polymorphic samples by automated cycle sequencing at 
the Blood Transfusion Service in Bristol but all primer and template material was 
provided in a ready-to-go PCR tube as for a standard PCR reaction.
2.5) APOPTOSIS ASSAY
A variety of in vitro assays of apoptosis were established and the methods are outlined 
below.
2.5.1) JAM assay
This is a method based on DNA labelling with 3H-thymidine (Matzinger, 1991) where 
apoptotic fragmented DNA is reflected by decreased thymidine retention compared to
non-apoptotic DNA. Target cells were labelled with 3H-thymidine (ICN) by co-culture
overnight at 37°C in a CO2 incubator with 1.5 uCi/ml of 3H-thymidine (from 20 uCi /
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ml stock made up in culture medium). Labelled cells were washed in medium and left 
in an incubator for 6-8 hours before being plated out in a u-bottomed 96 well plate at
1 x 105 cells per well (in triplicate). Stimulations were carried out in a final volume of 
200 ul per well for between 6 - 20 hours depending on the experiment in question and 
cells were then harvested on filter mats using a Skatron semi-automatic cell harvester. 
The filter mat was dried in a microwave oven for 2 minutes between hand paper towels 
and individual filters were punched out into scintillation polypropylene vials. Five 
hundred ul of scintillation fluid (Optiscint Hisafe, Wallac) was added to each vial 
before analysis on a Rackbeta scintillation counter programmed for reading triplicate 
samples.
2.5.2) Annexin V-FITC assay
The Annexin assay (Martin et al, 1995) depends on detection of exposed phosphatidyl- 
serine on the surface of apoptotic cells. A kit (Annexin V-FITC from Nexins Research) 
was used for the detection of phosphatidyl-serine on apoptotic cells. Cells were 
stimulated as required with anti-Fas antibody or sFasL and washed in ice-cold PBS at 
the end of the stimulation. Cells were then suspended in ice-cold diluted binding buffer
at lOMO6 cells / ml ( in a volume of ± 445 ul). Five ul of freshly diluted Annexin V- 
FITC (1:10 dilution in binding buffer) and 50 ul propidium iodide (100 ug/ml in 
culture medium) was added to the 445 ul cell suspension and the tube incubated on ice 
(in the dark) for 10 minutes before FACS analysis on a Becton Dickinson flow 
cytometer. All the components were provided in kit form (Nexins Research B.V.) 
except the propidium iodide which was purchased from Sigma.
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2.5.3) Detection of apoptotic DNA by TdT-mediated dUTP nick end 
labelling (TUNEL).
This was carried out by means of the TUNEL kit from Boehringer Mannheim.
TUNEL provided an additional method for detecting the DNA strand breaks of 
apoptosis by measuring the 3'-OH labelling of strand breaks in apoptotic DNA using 
an enzymatic reaction catalysed by terminal deoxynucleotidyl transferase (TdT). The 
fluorescein labelled dUTP incorporated into the strand breaks is detectable on FACS
(Negoescu et al, 1996). Cells (approximately 1 x 106 per stimulation) were stimulated
as usual and washed in PBS /1%  BSA at 4°C. Suspensions of 100 ul in FACS tubes 
had 100 ul of 4% paraformaldehyde / PBS added and incubated at room temperature 
for 30 minutes. Cells were washed in PBS / 1% BSA and resuspended in 100 ul 
permeabilisation solution (0.1 % Triton X-100 in 0.1 % sodium citrate) and incubated 
on ice for two minutes. Cells were washed twice in PBS 11% BSA and resuspended 
in 50 ul TUNEL reaction mixture. Cells were incubated in the dark in a humidified
atmosphere at 37°C for one hour, and then washed twice in PBS before analysis by 
FACS in PBS solution.
2.5.4) Cytospin analysis for nuclear morphology in apoptosis
Cells stimulated via the Fas receptor and control samples were spun onto slides at a
density of 5 x 104 cells per slide on a Cytospin 3 apparatus (Shandon). Slides were air 
dried and fixed in acetone solution for 5 minutes before air drying again. Propidium 
iodide was added to the slides at 50 ug/ml and incubated at room temperature for 10 - 
15 minutes before washing in PBS and analysing the slides on a fluorescent 




All statistical analysis was conducted on a Statview programme (Abacus, Macintosh 
version) using data imported from Microsoft Excel version 5.0. Analysis included 
calculation of descriptive statistics like mean and standard deviations and comparison 
of groups was done by a Mann-Whitney U test for non-parametric data. Correlations 
were done by Spearman's rank correlation coefficient. Data from the JAM assays are 




FAS / CD95 
A molecular approach to reagent generation
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INTRODUCTION .
As stated earlier, research into murine Fas biology accelerated after the discovery that 
the Ipr defect in mice was due to abnormalities of the Fas gene. The autoimmune 
features found in the MRL-//?r /  Ipr mouse had a striking resemblance to some of the 
manifestations of human SLE (Cohen and Eisenberg 1991), which is generally 
regarded as a prototypic non-organ specific autoimmune disease. With this in mind we 
embarked on this study to look at the role of Fas in human biology, with specific 
reference to human SLE. The project commenced when very little was known about 
Fas function in normal human biology, so that in order to study Fas we had to generate 
the necessary reagents. A molecular approach was taken with the aim of generating 
reagents that would be useful in guiding genetic studies on Fas as well as providing 
tools for use in functional studies of apoptosis. Given that the natural ligand for Fas 
was not identified at the time, we also used a molecular approach to construct a probe 
in order to search for a cell surface ligand for Fas.
R E SU LT S.
3.1) Cloning and expression of Human Fas cDNA
3.1.1) G eneration of Fas cDNA
In order to identify a source of Fas RNA for reverse transcription, various cell lines 
available in the laboratory were screened for surface expression of Fas by FACS 
analysis. Using a monoclonal antibody to human Fas (CH11) cell surface expression 
of Fas was found on the transformed T cell lines, H9 and Jurkat as well as the 
transformed B cell line, Priess. Figure 3.1.1 shows the high levels of Fas expressed
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on H9 cells which were subsequently chosen for total RNA extraction. Purified total 
RNA was therefore used from the Fas expressing H9 cells in a reverse transcription 
PCR (RT-PCR) reaction to generate Fas cDNA.
To achieve this primers were designed from the published sequence data (genbank 
accession n o .: M67454) in order to generate the coding region of human Fas. F igure 
3 .1 .2  shows the published Fas sequence in relation to the oligonucleotide primers 
designed in this experiment to generate a gel fragment of approximately 1000 base 
pairs representing the coding region without the untranslated 5’ and 3’ sequences. 
Oligonucleotide primers 5* (CGGAGGATTGCTCAACAACCATGCTG, nt 177-202) 
and 3' (CACTCTAGACCAAGCTTTGGATTTC, nt 1210-1185) were used in the RT- 
PCR reaction. A fragment of predicted size (±1000 bp) was generated representing 
Fas cDNA and is shown in figure 3.1.3 as an agarose gel band. No PCR fragments 
were evident in the negative control reactions devoid of template DNA. Thus a specific 
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Figure 3.1.1: Fas Expression on H9 T cells
Surface expression of Fas was seen on H9 T cells (shaded histogram) without any 
activation stimuli. Cells were stained with monoclonal anti-Fas antibody (CH 11) at 
lug/ml and detected by anti-mouse IgM FITC. Control antibody (mouse IgM lug/ 
ml) staining is shown (unshaded histogram).
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g a c g c t tc tg gggagtgagg g a a g c g g tt t a cg a g tg a c t tg g c tg g a g c 50
ctca g g g g cg gg ca c tg g ca cggaacacac cc tg a g g cca  g c c c tg g c tg 100
cccaggcgga g c t g c c t c t t c tc c c g c g g g t tg g tg g a c c c g c tc a g ta c 150
gg a g ttg g g g a a g c t c t t t c a c ttc g g a g g  a t tg c tc a a c aaccATGCTKjj 200
GGCATCTGGA CCCTCCTACC TCTGGTTCTT ACGTCTGTTG CTAGATTATC 250
GTCCAAAAGT GTTAATGCCC AAGTGACTGA CATCAACTCC AAGGGATTGG 300
AATTGAGGAA GACTGTTACT ACAGTTGAGA CTCAGAACTT GGAAGGCCTG 350
CATCATGATG GCCAATTCTG CCATAAGCCC TGTCCTCCAG GTGAAAGGAA 400
AGCTAGGGAC TGCACAGTCA ATGGGGATGA ACCAGACTGC GTGCCCTGCC 450
AAGAAGGGAA GGAGTACACA GACAAAGCCC ATTTTTCTTC CAAATGCAGA 500
AGATGTAGAT TGTGTGATGA AGGACATGGC TTAGAAGTGG AAATAAACTG 550
CACCCGGACC CAGAATACCA AGTGCAGATG TAAACCAAAC TTTTTTTGTA 600
ACTCTACTGT ATGTGAACAC TGTGACCCTT GCACCAAATG TGAACATGGA 650
ATCATCAAGG AATGCACACT CjACCAGCAAC ACCAAGTGCA aagaggaaggI 700
1ATCCAGATCT AACTTGGGGT GGtTTTGTCT TCTTCTTTTG CCAATTCCAC 750
TAATTGTTTG GGTGAAGAGA AAGGAAGTAC AGAAAACATG CAGAAAGCAC 800
AGAAAGGAAA ACCAAGGTTC TCATGAATCT CCAACCTTAA ATCCTGAAAC 850
AGTGGCAATA AATTTATCTG ATGTTGACTT GAGTAAATAT ATCACCACTA 900
TTGCTGGAGT CATGACACTA AGTCAAGTTA AAGGCTTTGT TCGAAAGAAT 950
GGTGTCAATG AAGCCAAAAT AGATGAGATC AAGAATGACA ATGTCCAAGA 1000
CACAGCAGAA CAGAAAGTTC AACTGCTTCG TAATTGGCAT CAACTTCATG 1050
GAAAGAAAGA AGCGTATGAC ACATTGATTA AAGATCTCAA AAAAGCCAAT 1100
CTTTGTACTC TTGCAGAGAA AATTCAGACT ATCATCCTCA AGGACATTAC 1150
TAGTGACTCA GAAAATTCAA ACTTCAGAAA IKjAAATCCAA AGCTTGGTCT 1200
acracrtaaaaa a ca a c a a a tt c a g t tc tg a g ta ta t g c a a t t a g t g t t t g a 1250
a a a g a t tc t t a a ta g c tg g c tg ta a a ta c t g c t t g g t t t t t ta c tg g g ta 1300
c a t t t t a t c a t t t a t t a g c g ctgaagagcc a a c a t a t t t g t a g a t t t t t a 1350
a t a t c t c a t g a t t c t g c c t c c a a g g a tg tt ta a a a tc ta g ttg g g a a a a c 1400
a a a c t tc a tc aagagtaaat g ca g tg g c a t g c ta a g ta c c caaataggag 1450
tg ta tg c a g a ggatgaaaga t t a a g a t ta t g c tc tg g c a t c ta a c a ta tg 1500
a t t c t g t a g t a tg a a tg ta a tc a g t g ta t g tta g ta c a a a t g t c t a t c c a 1550
ca g g c ta a cc c c a c t c t a t g a a tca a ta g a a g a a g c ta tg a c c t t t t g c t 1600
g a a a ta tc a g t ta c tg a a c a ggcaggccac t t t g c c t c t a a a t t a c c t c t 1650
g a t a a t t c t a g a g a t t t ta c c a t a t t t c t a a a c t t t g t t t a ta a c tc tg a 1700
g a a g a tca ta t t t a t g t a a a g t a t a t g t a t ttg a g tg c a g a a t t t a a a ta 1750
a g g c tc ta c c tca a a g a c c t t tg c a c a g t t t a t t g g t g t c a ta t t a ta c a 1800
a t a t t t c a a t tg tg a a t tc a catagaaaac a t t a a a t t a t a a t g t t tg a c 1850
t a t t a t a t a t g t g ta tg c a t t t t a c t g g c t ca a a a c ta cc t a c t t c t t t c 1900
tc a g g c a tc a a a a g c a t t t t gagcaggaga g t a t t a c t a g a g c t t tg c c a 1950
c c t c t c c a t t t t t g c c t t g g t g c t c a t c t t a a tg g c c ta a tg c a c c c c c a 2000
aacatggaaa ta tc a c c a a a a a a ta c t ta a ta g tc c a c c a aaaggcaaga 2050
c t g c c c t ta g a a a t tc ta g c c tg g t t t g g a g a ta c ta a c t g c tc tc a g a g 2100
a a a g ta g c tt t g tg a c a tg t ca tg a a c cca t g t t t g c a a t ca a a g a tg a t 2150
a a a a ta g a tt c t t a t t t t t c c c c c a c c c c c g a a a a tg ttc a a ta a tg tc c 2200
ca tg ta a a a c c tg c ta c a a a tg g c a g c tta ta ca ta g ca a tg g ta a a a tc 2250
a tc a tc tg g a t t t a g g a a t t g c t c t t g t c a ta c c c tc a a g t t t c t a a g a t 2300
t t a a g a t t c t c c t t a c t a c t a t c c t a c g t t t a a a t a t c t t tg a a a g t t tg 2350
t a t t a a a t g t g a a t t t ta a g a a a ta a ta t t t a t a t t t c t g ta a a tg ta a a 2400
c tg tg a a g a t a g tta ta a a c tga a g ca g a t a cc tg g a a cc acc taaagaa 2450
c t t c c a t t t a tg g a g g a tt t t t t t g c c c c t t g t g t t t g g a a t ta ta a a a t 2500
ata g g ta a a a g t a c g t a a t t a a a ta a tg t t t t t g 2534
Figure 3.1.2: Human Fas Gene Sequence.
The full gene sequence for Human Fas is shown (GenBank no. M67454) with the coding 
region (nucleotides 195 - 1200) outlined in upper case and the transmembrane encoding 
domain shown in the boxed area. Oligonucleotide primers were designed (underlined 
sequences) to amplify the coding region of human Fas as a PCR fragment of ±1005 bases.
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Ec Tm Cyt
Primers used for PCR (compare figure 3.1.2):
5': CGGAGGATTGCTCAACAACCATGCTG (nt 175-200) and 
3': CACTCTAGACCAAGCTTTGGATTTC (nt 1205-1182)
Figure 3.1.3 : PCR of the Fas coding region.
A line drawing above shows the Fas coding region amplified by PCR 
using oligonucleotide primers underlined in figure 3.1.2 (sequence o f  
oligonucleotides shown below the drawing). An agarose gel is shown 
below where the Fas PCR product o f ± 1031 bases was amplified from H9 
T cells (lane 2) and Priess B cells (lane 3). Molecular weight markers are 
shown in lane 1 (<J)-X 174 Hae III digest).
Ec = Extracellular coding region 
Tm = Transmembrane coding region 
Cyt = Cytoplasmic coding region
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3.1.2) Cloning Fas cDNA into pT7
In order to test if the amplified PCR product was in fact Fas cDNA, it was necessary to 
clone the PCR product into a plasmid vector. This would enable the preparation of 
larger quantities of Fas DNA for analysis by restriction mapping and sequencing if 
necessary.
To achieve this we employed a method of TA cloning (chapter 2.2.12). Ligated PCR 
products of Fas cDNA were transformed into E.coli and grown on agar plates. White 
bacterial colonies were chosen for plasmid minipreps. In all thirty six clones were 
selected for miniprep analysis of which six were found to have an appropriate sized 
insert. Figure 3 .1 .4  shows a representative agarose gel where a restriction digest 
with EcoRl-F\rtl removed an insert of the correct size (± 1090bp) from the vector (gel 
A lane 8). Lane 4 of the same gel shows an example of a clone with no DNA insert 
removable by the Eco R1 -Pst 1 digest. The relatively high frequency of non­
recombinant clones such as these on a given agar plate makes it imperative to screen 
miniprep colonies for an insert before proceeding to restriction mapping of minipreps 
with a larger selection of restriction enzymes. Miniprep screening by restriction 
analysis with a combination of Eco R1 + Pst 1 in this case therefore revealed six clones 
with inserts which could be further analysed by restriction mapping.
In order to characterise the recombinant clones as human Fas cDNA, analysis by 
restriction mapping was conducted. Plasmid clones containing inserts as shown in 
figure 3 .1 .4  were analysed by restriction mapping using a range of restriction 
enzymes. The predicted fragments from a mapping experiment are shown in the same 
figure (3.1.4). Restriction mapping in this case confirmed the presence of a number of 
clones of Fas cDNA PCR products in the pT7 vector (Fas-pT7 clones) in a variety of 
orientations. Amongst the 6 clones analysed by this method one was found to be in the
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appropriate orientation (ie, the 5’ end proximal to the T7 promoter and referred to here 
as sense clones) (lanes 2 and 3 of gel B) and two clones were in the opposite 
orientation (lanes 5, 6, 8, and 9 in gel B referred to here as anti-sense clones). The 
orientation of the Fas cDNA within the pT7 vector was not important from the 
viewpoint of cellular expression (because the pT7 vector is not a mammalian cell 
expression vector) but it was useful to know the orientation for the purpose of sub­
cloning into mammalian expression vectors as will be seen later.
Therefore it was evident that the Fas cDNA was successfully amplified by PCR, the 
















Predicted DNA patterns with restriction 
digests:
Pst I /E co R l : 1090 + 2828 bp
Hind III (sense) : 1064 + 2854 bp
(anti-s) : 57 + 3861 bp
Xba I (sense) : 1053 + 2865 bp
(anti-s) : 30 + 3888 bp
Lane 1-4 = clone 1 
5-8 = clone 2
1 / 5 = uncut DNA
2 / 6 = Eco R1
3 / 7 = Pst 1
4 / 8 = EcoRl + Pstl
GEL B
1 2 3 4 5  6 7 8  9 Lane 1 - 3 = clonea
4 - 6 = cloneb 
7 - 9  = clonec
1 / 4 / 7  = uncut 
2 / 5 / 8  = X b a \  
3 / 6 / 9  = H in d lll
Figure 3.1.4: Cloning of Fas cDNA into pT7 Blue.
A cloning diagram is shown above with selected restriction sites and 
predicted fragment sizes for the chosen restriction enzymes. Agarose gels are 
shown below with Gel A showing screening o f miniprep colonies and Gel B 
showing restriction mapping of three recombinant clones. In Gel A lane 8 
shows a positive clone from which a fragment o f ± 1090 bp was removed by 
a Pst 1 / EcoRl digest. Lanes 2 and 3 o f Gel B show the excision o f ±1050bp 
fragments by Xba 1 and Hindlll, respectively, to represent a 5 ’ to 3 ’ sense 
orientation of clone a, whilst clones b and c were anti-sense clones.
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3.1.3) Cloning Fas into pEe6 expression vector
In order to generate transfectants, Fas cDNA was introduced into a eukaryotic 
expression vector which contained the necessary promoter regions for driving 
transcription. The pT7 vector in which Fas was initially cloned provided a useful 
means to TA clone directly from PCR and amplify and map the human Fas cDNA but 
it lacked the genetic promoter machinery necessary for expression in eukaryotic cells.
It was therefore necessary to subclone the Fas cDNA into an appropriate vector. A 
plasmid which was already available within the laboratory was chosen for this purpose 
(pEe6). pEe6 uses a CMV promoter to drive expression of the inserted gene in 
eukaryotic cells (Cockett et al, 1991). This requires the gene of interest to be correctly 
cloned into the vector in relation to the promoter (5' - 3') (referred to as sense direction 
in this thesis). Sub-cloning the Fas cDNA from the pT7 vector into pEe6 in the correct 
orientation could not be achieved readily since no suitable combination of restriction 
enzymes could excise a full Fas cDNA such that it could be religated to the equivalent 
sites on pEe6.
It was thus decided to use an approach of blunt end cloning. Figure 3 .1 .5  shows 
the strategy where a Pst 1 - Eco R1 fragment from Fas-pT7 was removed and blunt 
ended by a Klenow reaction and cloned into Sma 1 cut pEe6. The ligated Fas-pEe6 
was transformed into E.coli by electroporation. Colony screening following “colony 
lifts” and hybridisation with radiolabelled Fas cDNA as a probe is shown in figure 
3.1.5. Miniprep screening of selected "hot colonies" revealed some clones with larger 
DNA bands thus suggesting the presence of an inserted DNA sequence into the pEe6 
vector (lanes 6, 7, 8, 9, and 10 in the agarose gel of figure 3.1.5).
To identify which clones contained the appropriate Fas insert further restriction 
mapping was carried out as shown in figure 3.1.5 a. As seen in the figure the
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fragment sizes help predict the orientation of Fas within the vector. In the case ofXba 1 
and Hin d III a clear difference in size is evident so that the ± 1050 bp fragments 
generated by both these enzymes (lanes 4 and 5 respectively of figure 3.1.5 a) 
suggested that the clone was in a sense orientation within the vector (ie 5’ end is 
proximal to the promoter within the vector). An antisense clone would have given 
fragments of ± 25-40 bp which would have been very easy to differentiate on an 
agarose gel. Whilst Bam HI cuts twice in the Fas sequence and once in the pEe6 
sequence one of the three fragments generated by this enzyme helped in orientation of 
the clone (sense = 260 bp versus antisense = 797 bp). Lane 6 in figure 3.1.5a shows a 
± 260 bp fragment to support the findings of a sense clone of Fas-pEe6 with tYieXba 1 
and Hin d III digests above.
Thus this experiment shows that Fas was subcloned into pEe6 from pT7 using a blunt 
cloning technique. Miniprep screening was carried out using radioactive hybridisation 
and the restriction mapping confirmed a sense clone of Fas in pEe6 (Fas-pEe6) which 
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oo Lane 1 = pEe6 Hind III
2 = clone 1 uncut
3 = clone 1 Hind III
4-10 = Hind III digests
of clones 2 - 8
Figure 3.1.5: Sub-cloning Fas cDNA into pEe6.
The line drawings show the strategy for ligation o f pEe6 cut with Smal to blunt-ended Fas cDN A excised from pT7. 
Recombinant clones were screened by colony hybridisation on Nylon membranes and radioactive colonies shown on 
the colony screen above represent pEe6 clones containing Fas cDNA. The agarose gel shows restriction enzyme 
screening with Hindlll o f  eight “hot” clones from the colony screen above. Lanes 6, 7, 8, 9 and 10 show bands larger 
than the native pEe6 (lane 1) and represent recombinant clones that require further mapping (figure 3.1.5a). Clones 












Fas - pT7 (blunt ends) 
1090 bp





Predicted restriction fragments 
for Fas - pEe6:
Xba 1: sense =4761 + 1047 bp
anti-s = 5783 + 25 bp
H in d lll: sense = 4688 + 1120 bp 
anti-s = 5768 + 40 bp
BamHl : sense = 507 + 260 + 5041 bp 
anti-s = 507 + 797 + 4504bp
Lanes:
1 = <J)-X 174 
= pEe6 / Smal 
= clone a uncut 
= clone a X bal 
= clone a Hindlll 
= clone a BamHl
Figure 3.1.5a: Restriction Mapping Fas - pEe6.
A cloning diagram is shown for Fas cDN A in pEe6 with selected restriction 
enzyme sites and the predicted sizes for the restriction fragments. The agarose 
gel shows a restriction map for one recombinant clone. Lanes 4 and 5 show  
the excision  o f  appropriate sized fragments with Xbal and Hindlll 
respectively. In lane 6 the vector size is larger than in lanes 4 and 5 and 
supports the suggestion o f a sense orientation for this clone (the smaller 
BamHl fragments are not clearly visible on the image but their positions have 
been outlined by the arrows).
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3.1.4) Expression of Fas-pEe6 in Chinese Hamster Ovary (CHO) cells
In order to express the cloned Fas-pEe6 in CHO cells, transfectants were generated 
using electroporation. Experience with transfecting other DNA into CHO cells in our 
laboratory had shown that transient expression varied depending on the electroporation 
conditions and the type of DNA used, but expression was usually in the order of 5 - 
20% of cells transfected. CHO cells transfected with the Fas-pEe6 initially showed low 
levels of expression of surface Fas on FACS analysis at 24 hours (figure 3 .1 .6 a ) ,  
however this confirmed the ability of CHO cells to express Fas in a recognisable form.
In an attempt to increase the levels of expression and to create stable expressing 
transfectant cell lines for Fas the cells that bound anti-Fas antibody were selected by 
magnetic beads coated with anti-mouse IgM. After cells were recovered and re­
cultured, higher levels of Fas expression was achieved as shown in Figure 3 .1 .6 b . 
FACS sorting was also subsequently used to enrich the Fas expressing CHO 
transfectants. The upper 10% of Fas expressing cells detected on FACS were sorted 
and propagated in culture. Continued growth of the sorted cells under selection with 
hygromycin resulted in a stable population of high Fas expressors (ie a relatively 
homogenous Fas expressing cell line figure 3.1.6c).
Thus the expression of Fas on the CHO cell line demonstrated that the cloned Fas 
cDNA derived from the previous cloning experiments was indeed functionally intact 
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Fig 3.1.6 : FACS analysis of CHO-Fas transfectants at various stages of selection.
FACS histograms are shown for CHO cells transfected with Fas-pEe6 and stained with monoclonal 
anti-Fas antibody CH 11 (lug/m l). Histogram a shows transfected cells 24 hours after electroporation 
whilst histogram b shows Fas staining after two rounds of magnetic bead selection of transfectants. 
Histogram c shows the homogeneous population of high Fas expressing CHO cells obtained after 
FACS sorting cells from b.
3.1.5) Characterisation of Fas function in CHO-Fas transfectants
Apart from demonstrating an immunologically intact Fas molecule on the CHO-Fas 
transfectants by the FACS analysis just described, we also tested the CHO-Fas 
transfectants in various Fas functional assays as follows:
3.1.5 a) Functional apoptosis assays in CHO-Fas cells
To test for apoptosis in general a number of assays were established in the laboratory 
(methods chapter 2.5). CHO-Fas cells were subjected to a JAM assay (section 2.5.1) in 
which monoclonal anti-Fas antibody was tested for the ability to induce apoptosis. This 
showed Fas-mediated apoptotic death in the CHO-Fas cells but not in untransfected CHO 
cells as shown in Figure 3 .1 .7 . In addition there was no death of CHO-Fas 
transfectants when incubated with an isotype matched mouse IgM at equivalent 
concentrations (lug/ml).
The sensitivity of these cells to a recombinant FasL molecule was also tested. CHO-Fas 
cells were also sensitive to Fas-mediated death by ligand as shown in figure 3.1.7 (the 
description of the generation of the soluble Fas ligand follows in chapter 4). As CHO 
cells did not normally express human Fas on their surface, untransfected or mock 
transfected cells provided a useful control in the study of Fas-mediated apoptosis. The 
CHO-Fas transfectants could therefore be used in functional assays because they undergo 
apoptosis on Fas engagement. The results thus suggested that the introduction of Fas into 
CHO cells made them susceptible to Fas-mediated death by apoptosis. The cloned Fas 
cDNA has therefore not only been demonstrated to have immunoreactivity on the cell 
surface of transfectants but is also functionally active in mediating cell death when 
introduced into the CHO cell line. This result suggested that the CHO-Fas system may be 
useful for studies of signalling mechanisms triggered following Fas receptor engagement.
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Figure 3.1.7 : Apoptosis of CHO-Fas transfectants.
A JAM assay is shown using transfected CHO-Fas cells. A reduction in 3H- 
Thymidine incorporation (apoptotic DNA) is represented as a change in % cell 
survival which is evident in histograms b (CH11 antibody lug/ml), c (sFasL 
1:10)*, and d (ssFasL 1:10)*. Controls are shown as unstimulated CHO-Fas 
transfectants (a), transfectants stimulated with istotype matched mouse IgM 
antibody lug/ml (e), and anti-Fas antibody with non-transfected CHO cells (f). 
All results represent triplicate samples.
* sFasL = soluble Fas ligand (generated in this project, section 4.1.2) 
ssFasL = signal sequence Fas ligand (see section 4.1.5, ss representing the 
addition of a B7 signal sequence to the sFasL.
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3.1.5 b) Antibody screening and epitope mapping
It was our intention to use the CHO-Fas transfectants for immunisation and generation of 
our own supply of anti-Fas antibodies. During the course of the project however, 
antibodies became commercially available so that there was no longer a need to spend 
limited time and resources on this. However, we had an opportunity during this project to 
test a soluble Fas ligand against the CHO-Fas transfectants which provided a useful tool 
for testing and validating the ligand (shown in figure 3.1.7 and details discussed in 
chapter 4). This in vitro model system could be useful in future to compare various anti- 
Fas reagents from the point of view of epitope mapping and Fas mutant generation.
3.1.5 c) Signalling in the CHO-Fas cells
3.1.5 c (1) Acidic Sphingomyelinase signalling
To assess mechanisms associated with Fas engagement in the CHO-Fas system where 
Fas can be easily introduced, a number of signalling assays were established. Reports 
were beginning to emerge of sphingolipid signalling following TNFR1 engagement (of 
which Fas is a family member). Thus we attempted to study if sphingolipid signalling 
occurred on Fas engagement.
In order to test sphingomyelinase signalling in the CHO-Fas transfectants the assay was 
first established in T cell blasts where CD28 was also known to activate the acidic 
sphingomyelinase signalling pathway (Boucher et al, 1995). Figure 3 .1 .8a  shows the 
activation of acidic sphingomyelinase following stimulation of the CD28 receptor by its 
ligand, CD80 (B7). There was a rapid and transient activation of acidic sphingomyelinase 
following CD28 stimulation, and similar results were seen following Fas stimulation in 
these T cell blasts. Control antibody stimulation with anti-CD3 or mouse IgM did not 
activate the sphingomyelinase pathway. The CHO-Fas transfectants were tested in the
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same assay and found to have intact sphingomyelinase signalling associated with Fas 
engagement as shown in figure 3 .1 .8b . As a positive control for CHO signalling a 
CHO-CD28 transfectant was used. In both the CHO-Fas and CHO-CD28 transfectants 
there was no activation of sphingomyelinase by control mouse antibody.
To test if the sphingomyelinase activity could be inhibited chloroquine was used in the 
assay. Chloroquine inhibited the Fas-mediated activation of sphingomyelinase as shown 
in figure 3 .1 .8c . Whilst it was well recognised that lysosomotrophic agents such as 
ammonium chloride, monensin and chloroquine inhibited acidic sphingomyelinase activity 
in general, it was nevertheless interesting to see the inhibition of Fas-induced 
sphingomyelinase activity by choloroquine especially because this drug is still widely 
used in the therapy of SLE, albeit in a chemically modified form (hydroxychoroquine). 
This could be an additional mechanism of action for hydroxychloroquine in SLE and will 
be discussed later.
Therefore the sphingomyelinase assay which was established on the background of a 
CD28 based system in the laboratory confirmed that Fas stimulation resulted in acidic 
sphingomyelinase activity both in the CHO-Fas transfectants as well as T cell blasts. This 
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Figure 3.1.8: Acidic Sphingomyelinase signalling in CHO-Fas transfectants.
The percentage acidic sphingomyelinase activity above baseline unstimulated cells is shown over time (minutes) 
following cell stimulation. Rapid upregulation of acidic sphingomyelinase activity can be seen with both CD28 (9.3 
antibody lug/m l) and Fas stimulation (CH 11 lug/ml) both in T cell blasts (a) as well as CHO-Fas transfectants (b). 
Control antibody failed to stimulate acidic sphingomyelinase activity (anti-CD3 lug/m l in {a} and Mouse IgM in {b}). 
Chloroquine(CQ) (lOOnM) inhibited the Fas-mediated acidic sphingomyelinase activation (c).
time (min) time (min)Time (mill)
3.1.5 c (2) Jun Kinase signalling in CHO-Fas transfectants
One of the downstream consequences of acidic sphingomyelinase activation is the 
generation of ceramide. This in turn has been implicated in activation of c-Jun kinase 
(JNK) following stimuli such as ultraviolet irradiation and osmotic stress (Kyriakis et al, 
1994).
To investigate whether JNK activity was induced in the CHO-Fas system, an in vitro 
kinase assay was established using a GST-cJun fusion protein as substrate. F igure 
3.1.9 shows autoradiographs from SDS-PAGE gels of in vitro kinase reactions from T 
cell blasts and CHO-Fas transfectants. As with sphingomyelinase above, both cell types 
showed JNK activation following Fas stimulation. The level of phosphorylation changes 
seen with CHO-Fas transfectants was however less than that seen in T cell blasts which 
may reflect cell specific differences in regulation of the pathway by phosphatases and 
other factors interacting with the JNK activity.
Activation of JNK may or may not play a critical role in Fas-mediated apoptosis (see later 
discussion with JLW cells in chapter 4) but these results demonstrated that JNK activation 
occurred following Fas engagement in the CHO-Fas transfectant system. With the 
development of specific pathway inhibitors and dominant negative inhibitors the CHO- 
Fas system may prove useful for introduction of individual genetic components in an 
attempt to dissect the various influences on the JNK pathway and to work out its 
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Figure 3.1.9: Jun kinase (JNK) signalling in CHO-Fas transfectants.
Autoradiographs o f in vitro kinase reactions electrophoresed on SDS-PAGE gels. GST-cJun was used as 
phosphorylation substrate for measurement o f JNK activity in whole cell lysates. The assay was established in 
T cell blasts (gel a) where activation o f JNK can be seen with anti-Fas stimulation (CH 11 lug/m l in lane 2 
and sFasL 1:10 in lane 3) compared to unstimulated T cells (lane 1). Activation o f JNK was also seen with 
ceramide in the T cell blasts (lane 4). Gel b represents the JNK assay in CHO-Fas transfectants which 
displayed elevated GST-cJun phosphorylation when activated by CH 11 (gel b lane2) as compared to mouse 
IgM (gel b lane 1).
Gel b
Thus the first stage of this project was achieved with the cloning and expression of a 
human Fas cDNA. The transfection of human Fas into CHO cells resulted in expression 
of a functional protein and apoptosis was inducible in a Fas-specific manner in these 
transfectants. In addition the CHO-Fas transfectants were able to use some of the known 
signalling pathways following Fas activation. Successful cloning and expression of the 
human Fas cDNA therefore provided the confidence to proceed with further molecular 
manipulation of the Fas cDNA as described in the following section.
3.2) GENERATION OF RECOMBINANT FAS-Fc
Recombinant Fc fusion proteins provide useful tools for identification of surface counter- 
receptors and the soluble fusion protein could also serve a useful role as a receptor decoy 
in functional experiments, as was elegantly shown in the case of CTLA4-Ig (Linsley et al, 
1991). In the same vein, a Fas-Fc protein would be potentially helpful in probing for Fas 
ligand and also serve as a blocking reagent in functional experiments. Fc fusion proteins 
comprise a hybrid of the protein of interest and the immunoglobulin constant region (Fc). 
The species from which the Fc domain can be chosen is wide but mouse and human Fc 
regions are useful because of the ready availability of secondary antibody reagents. We 
therefore employed this approach to generate a soluble Fas-Fc fusion protein comprising 
human Fas and mouse IgG. Mouse IgG was chosen because of the ready availability of 
secondary anti-mouse IgG reagents. We also reasoned that the use of a mouse 
immunoglobulin Fc region in such a Fas-Fc protein would facilitate identification of 
human Fas co-receptors without the problem of excessive non-specific Fc binding to 
human Fc receptors. In order to make a Fas-Fc fusion protein in vitro a cDNA comprising 
the appropriate genetic components was required.
I l l
3.2.1): Generation of Fas-Fc cDNA
3.2.1.1) G eneration of cDNA by PCR
To create a fusion protein of Fas-Fc in vitro it was nesessary to generate a recombinant 
cDNA molecule comprising the extracellular domain of human Fas and the Fc region of 
mouse IgG. The successful cloning of a functional Fas cDNA described above provided 
the impetus to design new oligonucleotide primers from the Fas coding region to generate 
a truncated Fas molecule containing only the extracellular domain (EC). In addition 
primers were designed to generate a mouse immunoglobulin Fc cDNA. In order to 
facilitate annealing of the Fas extracellular cDNA and the mouse Fc cDNA the primer 
design incorporated an overlap sequence of twenty bases. Figure 3.2.1.1 shows an 
outline of the strategy that was employed to generate the Fas-Fc cDNA using a 
recombinant PCR technique. Cell lines expressing Fas were previously identified for the 
Fas cDNA cloning as described and the same RNA template from H9 T cells was used in 
this experiment. An RNA template for the mouse immunoglobulin PCR reaction was 
obtained from a hybridoma cell line (UCHT4) which was used in our laboratory for 
production of antibody (UCHT4 hybridoma produces a mouse IgG2a subclass of anti- 
CD8 antibody). An initial PCR using the H9 and UCHT4 RNA was carried out using 
primers A and B in reaction 1 and primers C and D in reaction 2, in order to generate the 
human Fas extracellular encoding region and the mouse Fc region, respectively. The 
agarose gel in figure 3.2.1.1 shows the Fas EC domain cDNA (lanes 3, 4, and 5 ± 560bp 
product) and the mouse IgG Fc domain (lanes 6, 7, and 8 ± 890bp product) as well as the 
recombinant Fas-Fc cDNA (lane 10 ± 1300 bp product) which was obtained by 
amplification of a mix of the two cDNAs with the flanking primers A and D. Therefore 
the initial PCR products generated by the primer design above appeared to be of the 
correct predicted size and the overlap PCR reaction also produced the predicted ±1400 bp 
product representing a Fas-Fc hybrid cDNA.
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PCR products purified of unbound 
oligonucleotides and a secondary 
PCR amplification carried out with 
primers A and D.
Human Fas - muFc recombinant cDNA.
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5’ A: CGGAGGATTGCTCAACAACCATGCTG 3
B: AATGGGCCCGCTGGGCCCCAAGTTAGATCTGGATCCTTC 
C : CCAGATCTAACTTGGGGCCCAGCGGGCCCATTTC 
D: GGGTGCC AGTGTCTCTT AGG
Figure 3.2.1.1 : Strategy for generation of Fas-Fc cDNA.
Line drawings above outline the strategy employed to create a recombinant Fas-Fc 
cDNA by PCR. An overlapping primer sequence (21 nucleotides as underlined) 
facilitated the fusion of the human Fas extracellular (EC) domain to the mouse IgG 
Fc domain. The agarose gel shows the Fas (lanes 3, 4, and 5) and Fc (lanes 6, 7, 
and 8) PCR products as well as the recombinant Fas-Fc PCR product (lane 10). 
Molecular weight markers (<J)X-174 Hae III DNA) are shown in lanes 1 and 9.
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3.2.1.2) Cloning the Fas-Fc cDNA into pT7
To validate the Fas-Fc PCR sequence a cloning procedure was undertaken. To achieve 
this an approach similar to the previous Fas cloning was adopted with the vector pT7 
because of the advantages of TA cloning and colour selection of recombinant clones. 
Following selection, four Fas-Fc clones in pT7 were identified. Restriction mapping was 
carried out to confirm that the cloned fragment had all the predicted restriction enzyme 
sites (shown in figure 3 .2 .1 .2 ) . A Kpn l-Xba 1 digest removed the insert of Fas-Fc 
from within the multiple cloning site of pT7 as shown by the ± 1300 bp fragment in lane 
6 of the agarose gel. Bam HI was chosen for its restriction sites in the Fas sequence and 
the multiple cloning site of pT7. The clear fragment of ± 523 bp rather than ±895 bp in 
lane 5 orientates the Fas-Fc product in an anti-sense direction (ie, in relation to the T7 
promoter of the pT7 plasmid).
Similarly Acc 1 cuts in the Fc region and the multiple cloning site and the ± 530 bp 
fragment removed from the clone orientates it in an anti-sense direction within pT7 (lane 
7). A Bgl II restriction site was unique to the overlap sequence of Fas-Fc so that a linear 
fragment of ± 4300bp as seen in lane 4 confirmed the presence of an appropriate Fas-Fc 
insert in the pT7 vector (the additional band seen in all lanes at around 2000bp represents 
partially digested DNA).
The presence of the appropriate sized restriction products on mapping thus confirmed the 
presence of a Fas-Fc sequence of cDNA within the pT7 vector, albeit in an anti-sense 
orientation. The orientation was not critical at this stage because expression of the protein 
was not possible in the pT7 vector. However the orientation within pT7 was exploited for 
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Predicted restriction sites in 
Fas-Fc / pT7 clones:
Kpn 1 + Pst 1 = removes insert
of 1358 bp + 2847 bp
Bgl 11 = linearise within the 
overlap to 4305bp
Bam  HI = Cuts in Fas and pT7 
to give: 
sense: 895bp + 3410bp 
anti-s: 523bp + 3782bp
A cc 1 = Cuts in Fc and pT7 
to give: 
sense: 946bp + 3359bp 
anti-s: 532bp + 3773bp







1 = X Hind III
2 = <J>X-174
3 = clone a uncut
4 = clone a Bgl II
5 = clone a Bam HI
6 = clone a Kpn 1 + Pst 1
7 = clone a Acc 1
Figure 3.2.1.2 : Cloning Fas-Fc into pT7.
A cloning diagram of Fas-Fc in pT7 is shown with selected restriction sites and the 
predicted fragment sizes. The agarose gel shows a restriction map o f a Fas-Fc / pT7 
clone where the predicted ±4300 bp fragment o f D N A  can be seen for Bgl II (lane 4). 
A Kpn 1+ Pst 1 digest removes the ± 1300 bp insert (lane 6) and Bam HI (lane 5) 
and Acc 1 (lane 7) remove ± 500bp fragments. Molecular weight markers are shown 
(lanes 1 and 2).
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3.2.1.3) Cloning Fas-Fc into a mammalian cell expression vector 
(pcDNA3)
In order to express the recombinant protein in eukaryotic cell culture Fas-Fc was 
subcloned into an appropriate mammalian expression vector. The eukaryotic vector 
chosen for Fas-Fc cloning was pcDNA3 which allowed an advantage over pEe6 in that it 
had within its sequence a gene encoding resistance for neomycin. This allows selection 
pressure to grow transfected cells in culture medium containing neomycin hence enriching 
for cells expressing the gene of interest.
In order to subclone Fas-Fc in the correct orientation into pcDNA3 a Kpn l-Xba 1 
fragment was excised from Fas-Fc/pT7 and ligated into the complementary sites of the 
pcDNA3 as shown in figure 3 .2 .1 .3  . Miniprep analysis and restricion mapping was 
used again to confirm that the correct DNA was inserted into the mammalian expression 
vector pcDNA3. A Kpn \-Xba 1 digest shown in lane 7 shows the removal of the ±1300 
bp Fas-Fc insert from the pcDNA3 clone. Bam HI (cutting in the Fas sequence and 
pcDNA3) and Apal (cutting in the Fc sequence and pcDNA3) gave the predicted 
restriction fragments of ±523 bp (lane 8) and ± 850bp (lane 6), respectively. A Xho 1 
digest was used to linearise the cloned DNA within the Fc region to produce a ± 6864bp 
fragment (shown in lane 9 as a larger band compared to the adjoining lanes 6, 7, and 8).
Thus this demonstrated that the Fas-Fc cDNA was cloned in a sense orientation within the 
pcDNA3 plasmid and was therefore suitable for expression.
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Fas-Fc insert removed 
from pT7 by Kpn 1 -Pst 1 
and ligated into pcDNA3 pcDNA3 
5446 bp
Predicted restriction sites for FasFc/pcDNA3 :
Kpn 1 + Xba 1 = insert removed ±1300bp
A pa\ = 850bp + 6014 bp
(cuts in Fc region)
BamH 1 = 523bp + 6341bp
(cuts in Fas)
Xho 1 = linear 6864bp fragment









1 = X Hindi 11
2 = <|)X-174
3 = Fas / pT7 uncut
4 = Fas/pT7 R1 +Pst 1 
5-9 = FasFc-pcDNA3 
clone:
5 = uncut
6 = Apa 1
7 = Kpn 1 + Xba 1
8 = Bam HI
9 = Xho 1
Figure 3.2.1.3: Subcloning Fas-Fc into pcDNA3.
The line drawings demonstrate the strategy o f the sub-cloning o f Fas-Fc. A Kpn 1- Xbal insert 
was excised from pT7 and ligated to pcDNA3 prepared with a Kpn 1 - Xbal digest. The agarose 
gel shows a restriction map o f a clone o f Fas-Fc / pcDNA3 (lanes 5-9). A Kpn \-Xbal digest 
removes the ± 1300 bp insert (lane 7). Apal cuts in the Fc region and pcDNA3 to yield 
a ± 850bp fragment (lane 6), whilst Bam HI cuts in the Fas region and pcDNA3 to give a 
± 530 bp fragment (lane 8). Xho 1 linearises the clone within the Fc region to give a larger 
± 6800 bp band (lane 9, additional band due to a partial digest).
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3.2.2) Production of Fas-Fc fusion protein
3.2.2.1) Expression of Fas-Fc in COS-7 cell culture
In order to achieve in vitro expression of the Fas-Fc fusion protein the DNA clone above 
had to be introduced into a mammalian cell line. COS-7 cells were transfected with 
Fas-Fc / pCDNA3 by electroporation and cell culture supernatants were used for affinity 
purification of the secreted Fas-Fc protein.
To purify Fas-Fc protein from the pooled culture supernatants of the transfected cell lines, 
500ml of the culture medium was concentrated using saturated ammonium sulphate and 
dialysed against PBS before affinity purification was carried out with protein G-sepharose 
columns. The eluted protein was electrophoresed on SDS-PAGE and a Coomassie 
Brilliant blue stain carried out. The gel revealed a 50 Kd protein which was purified by 
affinity chromatography as shown in figure 3.2.2.1 lane 2. This was consistent with 
the predicted molecular weight and is shown in comparison to mouse IgG in lane 4. No 
protein could be purified from untransfected cell culture supernatants (lane 3).
Therefore this result reflected the successful expression of Fas-Fc cDNA in COS cells and 
purification of the protein from pooled culture supernatants by affinity chromatography. 
Further characterisation of the protein was now necessary to test for immune reactivity.
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Figure 3 .2 .2 .1 : Coomassie stain of Fas-Fc protein.
ACoomassie stained SDS-PAGE gel demonstrates the affinity-purified Fas-Fc protein 
of 50 Kd (indicated by arrow) (lane 2). Mouse IgG derived from the original 
hybridoma used for the Fc component of Fas-Fc is shown in lane 4, and molecular 
weight markers are shown in lane 1. Controls are shown in lane 3 where no protein 
could be affinity purified from supernatants of untransfected cells. Affinity purification 
was carried out with Protein G-Sepharose using concentrated cell culture supernatants 
from Fas-Fc transfectants (lane2) and a UCHT4 hybridoma (lane 4).
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3.2.2.2) Immunoreactivity of the purified Fas-Fc protein
To test the purified protein for immunoreactivity both dot blots and western blotting was 
carried out. The Fas-Fc protein was expected to have immunoreactivity to both anti-Fas 
and anti-mouse IgG antibodies because of the constituent parts of the fusion protein. This 
immunoreactivity was tested with Fas-Fc in native (dot blot) and denatured forms 
(western blot).
Figure 3.2.2.2 shows that both the individual Fas and immunoglobulin components of 
the fusion protein had specific antibody reactivity. In the native non-denatured form of the 
protein as tested by dot blotting both the Fas and mouse Fc components were 
immunoreactive (figure 3.2.2.2a). Control staining of IgM and mouse IgG, as well as 
concentrated supernatants from non-transfectants are shown.
The denatured form of Fas-Fc was tested by western blotting (figure 3.2.2.2b). Again 
both the Fas and Fc components demonstrated specific immunoreactivity with 
immunoblotting anti-Fas and anti-mouse IgG2a antibodies, respectively. These results 
therefore demonstrated that the Fas-Fc protein displayed immunoreactivity of its 




























Figure 3 .2 .2 .2 : Immunoreactivity of Fas-Fc protein.
Immunoreactivity o f the recombinant Fas-Fc protein is demonstrated on both dot blot 
(a) and Western blotting (b). The blots demonstrate immunoreactivity o f both the Fas 
and the Immunoglobulin (Fc) components separately as detected by peroxidase 
conjugated anti-mouse IgG (Fc component) and peroxidase conjugated anti-mouse IgM 
(for Fas CH 11 antibody). Control positive antibodies are shown for each isotype and 
concentrated supernatants from untransfected cells was used as a negative control for 
the blots.
To further test for immunoreactivity of the Fas-Fc protein we devised a FACS-based 
assay. This was based on the use of the Fas-Fc to competetively bind anti-Fas antibody 
thereby preventing the binding of antibody to Fas positive cells. A shift on FACS staining 
indicated this competetive binding of anti-Fas antibody by Fas-Fc and figure 3 .2 .2 .3  
demonstrates this result. H9 Fas-positive cells were used in the FACS immunoassay and 
stained with anti-Fas antibody which showed a log fluorescent shift to the right (shaded 
histogram in figure 3.2.2.3), but preincubation of the H9 cells with 50ug/ml Fas-Fc 
resulted in an inhibition of anti-Fas antibody binding as seen by a shift of the log 
fluorescence toward baseline control stained cells (dotted histogram in figure 3.2.2.3).
The above results thus provided further evidence that the 50 Kd protein purified from the 
transfected Cos cells was immunoreactive. That is, the human Fas component of Fas-Fc 
was binding anti-Fas antibody thereby preventing the antibody binding to Fas on the 
surface of H9 T cells. This FACS experiment also suggested that the Fas-Fc molecule 
was potentially capable of acting as a soluble receptor decoy to prevent Fas receptor 
engagement on cells expressing Fas. The functional use of Fas-Fc as a receptor decoy 
will be discussed later.
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Figure 3.2.2.3 : Fas-Fc competetively inhibits binding of anti-Fas 
antibody.
A FACS analysis showing immunoreactivity of the Fas component of the Fas-Fc 
protein. Fas-expressing H9 cells bind anti-Fas antibody causing a log shift in 
fluorescence as shown by the shaded histogram. If the H9 cells are pre-incubated with 
50 ug/ml Fas-Fc (dotted line) there is a marked reduction in the binding of anti-Fas 
antibody, indicating competition for binding of the anti-Fas antibody between the 
surface Fas on H9 cells and the Fas-Fc protein. Negative control staining of H9 cells 
with an IgM antibody is shown on the left (pink line).
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3.2.3) Functional assays to test the Fas-Fc fusion protein
3.2.3.1) Detection of surface expression of hum an Fas-Ligand
3.2.3.1 a) Establishing FcR status and FACS staining with Fas-Fc
Clues from the published literature suggested that the natural ligand for murine Fas was a 
cell surface protein (Rouvier et al, 1993). However, the isolation and characterisation of 
Fas ligand was proving to be more difficult than anticipated. We postulated that if the Fas- 
Fc protein bound a "cell surface ligand" it could then be located on FACS analysis using a 
FTTC-conjugated anti-mouse antibody. Using this strategy we tested various cell lines and 
peripheral blood mononuclear cells with the purified Fas-Fc protein. Cells were incubated 
with the Fas-Fc protein as a “primary antibody” for FACS analysis and secondary anti­
mouse FITC conjugated antibody was used to localise the Fas-Fc binding. A dose 
dependant increase in Fas-Fc binding was seen on activated T cell blasts with the best 
staining on FACS analysis seen at 50ug/ml (figure 3.2.3.1a).
To ensure that the Fas-Fc staining was not via nonspecific Fc receptor binding a number 
of control measures were introduced. All samples for analysis included negative control 
samples stained with equivalent concentrations of isotype matched mouse IgG antibody. 
Fc receptor expression was tested on the various cell types and none was detectable on 
Jurkat T cell lines nor on activated T cell blasts (figure 3.2.3.1a), whilst large amounts 
of FcR staining was detectable on neutrophils and monocytes. In addition all FACS 
analysis was conducted after saturating amounts of human IgG were used to bind any Fc 
receptors that may have been present in low amount.
Therefore these results demonstrated that the Fas-Fc protein was binding activated T cells 
via its Fas component and not by Fc binding to Fc receptors.Thus the Fas-Fc protein was 
functioning in effect as a "Fas ligand probe" as predicted and could consequently be used 
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Figure 3 .2 .3 .1 a  : T cell blasts - Fas-Fc binds specifically to activated 
T cells but not via Fc binding to the FcR.
The histograms show FACS analysis of T cell blasts four days after activation with 
PMA / ionomycin.
i) Fas-Fc binding to activated T cell blasts was seen in a dose-dependant manner (green 
histogram = lug/ml, pink dotted histogram = 10 ug/ml, blue dotted histogram = 50 
ug/ml). Negative control staining of cells (black histograms) was carried out with 
lOug/ml mouse IgG. FITC-labelled anti-mouse IgG was used for secondary detection.
ii) There was no evidence of FcR expression on T cell blasts (green histogram ii) using 
anti-human FcR antibodies, therefore also supporting the results that Fas-Fc binding 
was not via the FcR but rather by specific Fas binding to a putative ligand.
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3.2.3.1 b) Fas-Fc staining of various cell types for Fas ligand (FasL)_
In order to search for expression of FasL the Fas-Fc protein was used as a primary 
antibody on a variety of cell types. Fas-Fc staining and FACS analysis showed the 
presence of a “putative Fas ligand” on the surface of Jurkat T cells and activated T cell 
blasts, but no detectable surface FasL was found on neutrophils, monocytes, B cells, 
transformed B cell lines, nor on the T cell line H9 (figure 3 .2 .3 .1 b ). The absence of 
nonspecific cell binding and also the fact that no universal T cell staining was found (no 
FasL on H9 cells or resting T cells) gave us confidence that we were seeing a putative 
FasL identified by the Fas-Fc fusion protein.
These results therefore suggested specificity of staining with the Fas-Fc and a restricted 
expression of FasL on T cell blasts and Jurkat T cells.
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Figure 3.2.3.1 b: Fas-Fc binding on a variety of cell types.
FACS analysis was carried out following staining of cells with lOug/ml Fas-Fc protein 
and a secondary FITC-conjugated anti-mouse IgG. All negative control cells were 
incubated with lOug/ml mouse IgG (black histograms). Fas-Fc binding to a “putative” 
FasL was seen on Jurkat cells but not on the H9 T cells (green histograms). Also there 
was no evidence of FasL expression on an activated B cell line, monocytes, or 
neutrophils using the Fas-Fc protein. Results are representative of five independent 
experiments.
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3.2.3.1 c) Fas Ligand expression on activated T cells
To investigate if the T cell staining with Fas-Fc was evident on resting T cells PBMCs 
were purified and T cells were isolated as described (methods chapter 2.1.3.2). Fas-Fc 
staining was carried out and FACS analysis showed no "FasL" expression on the surface 
of resting T cells but only on activated T cells from peripheral blood of normal volunteers 
(figure 3.2.3.1c). It was therefore evident that resting T cells did not express surface 
FasL as detected by the Fas-Fc protein.
Kinetics of expression of FasL
To assess the kinetics of expression of FasL following activation of T cells Fas-Fc 
staining was carried out at daily time points on purified T cells.T cells were activated by 
mitogenic stimulation with PMA and ionomycin and kept in culture with IL-2 for up to 
seven days. Figure 3.2.3.1c shows the FACS analysis where ligand expression was 
seen by day one after activation and continued to increase up to day three before returning 
to baseline by day five. Thus the Fas-Fc protein has demonstrated specificity in binding to 
a putative FasL only on T cells and has also revealed a pattern of expression of FasL 
following activation of T cells. The FasL expression on the T cell surface following 
mitogenic activation appeared to be transient, returning completely to baseline after five 
days. However, FasL expression was seen on resting Jurkat T cells and this may reflect 
other factors operative in these transformed cells. These findings have been subsequently 
confirmed by others using monoclonal antibodies developed after the cloning and 
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Figure 3.2.3.1 c : FasL expression on activated T cells as detected with Fas-Fc.
FACS analysis o f T cells with Fas-Fc showed no resting ligand expression (a). FasL 
expression increased following activation of T cells with PMA /  ionomycin (b). There 
was a time dependant increase in FasL expression upto day 3 following T cell activation 
(c) (negative = shaded histogram, green unshaded histogram = day 1, pink dotted 
histogram = day 3). Results reflect more than five independent experiments.
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3.2.3.1 d) Variability of staining with Fas-Fc
The above experiments were reproducible on at least five occasions but showed a 
considerable decrease in sensitivity when using a subsequently-prepared batch of Fas-Fc 
(figure 3.2.3.Id). There was no evidence for any alteration in the immunogenicity of 
subsequent batches (compared on western blotting) nor any evidence of change in the 
mRNA expression of Fas-Fc in transfected cell lines. It has been suggested that 
expression in COS cells is associated with the development of mutations over time (Calos 
et al, 1983) but we did not pursue sequence analysis of the various transfectants from the 
batches shown in figure 3.2.3.Id.
The loss of sensitivity did limit subsequent use of the Fas-Fc protein for FACS analysis 
of Fas-L expression, however the protein continued to show functional activity in the 
inhibition of Fas-mediated apoptosis (see later). Other groups using a similar approach 
with Fas-Fc have experienced similar problems with low level binding to Fas-L. One 
possible explanation may be the nature of Fas-ligand and its variability in expression on 
the cell surface. It became evident following the cloning of the ligand and development of 
antibodies that other factors influence surface expression of FasL, amongst these are 
included the metalloproteinase inhibitors which were shown to influence TNF cleavage 
from the cell surface (Kayagaki et al, 1995). At the time we were not able to test for the 
possible influence of metalloproteinase inhibitors on the highly sensitive Fas-Fc batch.
To summarise, the results presented in this section have therefore shown the successful 
generation of a recombinant Fas-Fc cDNA and the validation of the construct in a number 
of experiments. The recombinant Fas-Fc protein was produced in cell culture supernatants 
and demonstrated immunoreactivity both on dot blots and western blotting. In addition, 
Fas-Fc displayed the ability to block anti-Fas antibody binding to Fas-expressing H9 
cells. Specific binding by the Fas-Fc protein helped identify potential FasL expression on 
the surface of activated T cells and Jurkat T cells. It was therefore time to test if Fas-Fc 
could inhibit Fas-mediated apoptosis by acting as a receptor decoy.
130
FL1-Height
Figure 3.2.3.1 d: Variability of Fas-Fc binding.
FACS analysis o f Jurkat cells is shown with various batches o f Fas-Fc. The level 
o f binding seen with the original batch (orange histogram) could not be 
reproduced with any subsequent batches (light green unshaded, blue dotted and 
pink dotted histograms). The latter batches showed consistent but reduced levels 
of binding to Jurkat cells when compared to the negative control cells (dark 
green shaded histogram).
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3.2.3.2) Inhibition of Fas-mediated apoptosis by Fas-Fc in 
vitro
3.2.3.2 a) JAM assay of apoptosis in Ju rk a t cells expressing Fas
Given the immunoreactivity of the Fas-Fc protein we investigated whether the Fas-Fc 
could be used as a receptor decoy to block Fas-mediated apoptosis in vitro. In order to 
test this it was necessary to establish a number of apoptosis assays in the laboratory to 
measure Fas-mediated apoptosis. Jurkat cells normally express large amounts of Fas on 
their surface and die by apoptosis on engagement of Fas by its natural ligand or 
monoclonal anti-Fas antibodies. Jurkat cells were thus largely chosen for the functional 
apoptosis assays but we also tested similar effects in activated T cells blasts and also in 
the previously generated CHO-Fas transfectants. A JAM assay (chapter 2.5.1) is shown 
in which apoptosis of Jurkat cells was measured following Fas engagement. The results 
in figure 3 .2 .3 .2 (a ) show how monoclonal CH11 antibody resulted in apoptosis 
(reflected as a decrease in cell survival). Control Jurkat cells without antibody stimulation 
had a 100% survival and Fas-Fc protected from CHI 1-mediated killing of the Jurkat cells 
to maintain cell survival up to 95% in the presence of CH11. In addition Fas-Fc was 
tested in a Jurkat apoptosis assay using soluble ligand instead of CH11. The soluble 
ligand was generated as part of this project and will be described later (chapter 4). Fas-Fc 
was seen to inhibit sFasL-induced apoptosis of Jurkat cells in a manner comparable to an 
inhibitory anti-Fas antibody (ZB4) which is also shown in figure 3.2.3.2(b).
The results confirmed previous findings of Jurkat cell apoptosis following Fas 
engagement but in addition they demonstrate the ability of the Fas-Fc protein to inhibit 
Fas-induced killing with both monoclonal CH11 and sFasL. Therefore our hypothesised 








Figure 3 .2 .3 .2  a: Fas-Fc inhibition of Fas mediated apoptosis.
This figure shows a JAM assay in Jurkat T cells with Fas-induced apoptosis by 
monoclonal anti-Fas antibody CH 11 in (a) and soluble Fas-Ligand (sFasL) in (b). In 
both cases Fas-Fc pre-incubation improved the % cell survival, and in the case of sFasL 
(b) the inhibition of apoptosis by Fas-Fc was seen to be comparable to a Fas-blocking 
antibody ZB4. In all cases the % cell survival was calculated from the change in 3H- 
Thymidine incorporation compared to unstimulated Jurkat cells. The results represent 
four independent experiments.
3.2.3.2 b) Fas-Fc inhibition of apoptosis in bioassays
To test whether Fas-Fc was active in a more physiological system two bioassays were 
established. These were designed to test if Fas-Fc could inhibit cell-mediated killing via 
FasL.
Superantigen (Staphylococcal enterotoxin B, SEB) induced cell death is 
inhibited by Fas-Fc.
Fas-Fc inhibition was tested in an SEB blast bioassay. To achieve this superantigen 
(SEB) stimulation of T cells was carried out (section 2.1.3) to produce activated T cell 
blasts. Prior to re-exposure of the eight day old blasts to SEB for 6 hours, 3H-thymidine 
labelling was conducted on the blasts as for a standard JAM assay (section 2.5.1). The 
percentage death by apoptosis measured on re-exposure to SEB was then calculated as in 
a JAM assay. This process of cell death following restimulation by superantigen has been 
described as “activation-induced cell death” (Ettinger et al, 1995) and was thought to be 
related to upregulated expression of Fas and FasL with consequent ligation of Fas and 
death by apoptosis.
Figure 3.2.3.2b (i) shows in the histogram (a) the percent cell survival in the control
3H-thymidine-labelled day 8 SEB blasts left overnight in culture medium alone without 
SEB. With reexposure to SEB (lOug/ml) however, the blasts underwent ±50 - 60% 
apoptosis (histogram b) which was prevented by preincubation of the T cell blasts with 
Fas-Fc prior to rechallenge with SEB (histogram c).
This bioassay thus demonstrated that Fas-Fc inhibited "activation-induced cell death" 
induced by the superantigen SEB.
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Figure 3.2.3.2 b (i): Fas-Fc inhibiting Fas-mediated “activation-induced cell 
death” .
One in vitro bioassay in which Fas-Fc inhibition was seen is represented here. In 
histogram b, SEB rechallenge of T cell blasts previously stimulated with SEB 
resulted in apoptosis (activation induced cell death). Histogram a shows the T cell 
blasts which did not receive restimulation with SEB. Fas-Fc pre-incubation before 
SEB rechallenge protected from apoptosis (c) by blocking the FasL-Fas interaction. 
All histograms represent the mean and standard error of the mean from triplicate 
samples. The result above is representative of three independent experiments.
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Jurkat cell bioassay to assess Fas-Fc inhibition of Fas-FasL interactions.
Fas-Fc inhibition was tested in another bioassay using Jurkat cells as Fas-positive targets 
which could be killed by activated T cells expressing an upregulated Fas ligand. Apoptotic 
death of Fas-positive Jurkat cells was measured by the JAM assay (section 2.5.1) and 
FasL upregulation on the effector cells was achieved by SEB restimulation of T cell blasts 
(Boshell et al, 1996). In such a bioassay the FasL expressed on the activated T cell blasts 
engages Fas receptors on the Jurkat T cells in order to induce apoptosis via a cell-cell 
interaction of the ligand-receptor pair.
To test the activity of Fas-Fc, it was used in this bioassay to block Fas-mediated 
apoptosis of the Jurkat cells. Figure 3 .2 .3 .2 b (ii)  shows the Jurkat bioassay. 
Histograms b and a show the baseline survival of Fas-positive Jurkat cells with and 
without Fas-Fc, respectively. In the presence of unstimulated (day 8 after initial SEB 
stimulation) T cell blasts there was some altered survival of Fas-positive Jurkat cells as 
seen by a reduction in cpm in histograms c and d (compared to a and b) but no significant 
protection was offered by Fas-Fc preincubation (compare d and c). However, when the T 
cell blasts were restimulated with SEB for six hours prior to incubation with Jurkat cells 
there was significant apoptotic death of the Fas-positive Jurkat cells (compare histogram e 
to a and c), indicating an upregulation of FasL on the T cell blasts induced by SEB. In the 
latter situation Fas-Fc protected from SEB blast-induced Jurkat cell apoptosis (compare 
histogram f to e).
The results of this second bioassay thus also demonstrated the ability of Fas-Fc to act as a 
receptor decoy to prevent Fas-mediated apoptosis. In addition this assay also confirmed 












Figure 3.2.3.2 b (ii): Fas-Fc inhibiting Fas mediated cell-cell killing.
A second in vitro bioassay in which Fas-Fc inhibition was seen is represented here. 
Jurkat T cells were used as Fas-positive target cells to measure cell-cell mediated 
death induced by FasL on activated T cell blasts. Unstimulated day-8 T cell blasts 
only had a minor death inducing effect on Jurkat cells (c compared to a). Fas-Fc in the 
latter situation did not have a noticeable effect (d compared to c). However, SEB 
stimulated day-8 T cell blasts did induce significant apoptotic death o f Jurkat cells (e 
compared to a) which was inhibited by pre-incubation o f Jurkat cells with Fas-Fc 
lOug/ml (f compared to e).
The results represent the mean / standard error o f triplicate samples from one o f three 
independent experiments.
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The ability of Fas-Fc to block Fas-related apoptosis thus gave us a reagent that was useful 
in defining the role of Fas in functional assays in future experiments. It was also intended 
to use the purified Fas-Fc protein as an immunogen in a rabbit to attempt to produce a 
polyclonal anti-Fas antibody for use in the laboratory, but limitations on time and 
resources precluded this from being achieved. Other groups have since used a similar 
approach to produce various monoclonal and polyclonal anti-Fas antibodies (Alderson et 
al, 1994). With the availability of a variety of anti-Fas antibodies as a result it seemed 
unnecessary to spend any more time pursuing this.
3.2.3.3) Immunoprecipitation of a putative Fas ligand from Jurkat cells
Since the Fas-Fc protein appeared to identify a putative FasL on the surface of activated T 
cells and Jurkat cells it was decided to test if it could be used to immunoprecipitate the 
“putative ligand” from Jurkat cell lysates. Figure 3.2.3.3 shows a Coomassie stained 
gel from such immunoprecipitates which demonstrates a specific 37-40 Kd 
immunoprecipitated protein.The immunoprecipitated protein was only evident in Jurkat 
lysates (lane 2) and not on Cos cell lysates nor on H9 T cell lysates (lanes 4 and 3 
respectively). The latter would be consistent with our previous FACS analysis which 
failed to reveal FasL expression on H9 T cells. Isotype matched mouse IgG coupled to 
sepharose beads also failed to immunoprecipitate any protein (lane 1).
This experiment therefore clearly demonstrated a specific band of protein (a putative 
FasL) immunoprecipitated by Fas-Fc coupled to sepharose beads.The precipitated protein 
was remarkably similar in size to the mouse and rat Fas-L described by Suda and Nagata 
(1994) a few months later. Subsequent descriptions in the literature following the cloning 
of human Fas-L have confirmed that Jurkat cells express Fas-ligand (Martinez-Lorenzo et 
al, 1996).With the subsequent development of anti-FasL antibodies we tested if FasL
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could be detected on Jurkat cells. As seen in figure 3 .2 .3 .3  FasL was found on the 
surface
of Jurkat cells with the Nokl antibody but much more ligand was seen with intracellular 
staining. Therefore the results showing FasL expression with Fas-Fc have been 
confirmed with the antibody staining. In addition the finding of increased levels of 
intracellular FasL despite low levels on the surface may explain why the Fas-Fc was able 
to immunoprecipitate the FasL in Coomassie-stainable quantities.
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Figure 3 .2 .3 .3  : Immunoprecipitation of “Fas ligand” .
The Fas-Fc protein was used to immunoprecipitate “FasL” from Jurkat cells. 
Immunoprecipitates were electrophoresed on SDS-PAGE gels and stained with 
Coomassie Blue. Lane 2 shows the presence o f a ±40 Kd band which co- 
immunoprecipitated with Fas-Fc but not with control mouse IgG (lane 1). H9 T cells 
(lane 3) and COS cells (lane 4) did not reveal any co-precipitate with Fas-Fc. All lanes 
show the 50 Kd Fas-Fc protein which was used as the immunoprecipitating antibody at 
lOug/ml (coupled to proteinG-sepharose).
FACS analysis was conducted on Jurkat T cells when anti-FasL antibodies became 
available.The FACS histograms show surface staining (a and b = negative and positive 
staining respectively) and intracellular staining (c and d = control negative and positive 
respectively ) with N okl antibody.
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3.2.3.4) Jurkat cells kill each other in culture
The finding that Jurkat T cells expressed both Fas and FasL led us to speculate at the time 
that activated T cells may have the ability to kill each other in order to regulate cell number 
and maintain lymphocyte homeostasis. It was noted that when Jurkat cells were grown to 
high density in culture there was a high rate of cell death. We needed to determine if this 
was due to Fas-mediated apoptosis.
To test this we established an assay based on a 5 Chromium cytotoxicity method (section 
2.1.6). Jurkat cells expressed FasL as shown from the evidence above, and PMA/ 
ionomycin was seen to induce FasL expression on activated T cell blasts, so we 
postulated that if we stimulated Jurkat cells with PMA / ionomycin they may upregulate 
FasL and thereby kill Fas-positive Jurkat cells within the same culture. In order to obtain 
cell - cell contact the assay was established in U-bottomed 96 well culture plates where
stimulated 51Cr-labelled Jurkat cells were left overnight under various conditions (figure
3 .2 .3 .4 ).
The results of this experiment showed that a Fas-mediated mechanism was operative in 
the Jurkat cell death that was seen under these culture conditions. Jurkat cells stimulated 
with PMA / ionomycin had a high level of spontaneous death as measured by chromium 
release (histogram a), which was very nearly as high as the total induced chromium 
release with detergent (histogram b). Inhibition of cell death was evident when the Jurkat 
cells were incubated with both blocking Fas antibodies (M3 and M33) and our Fas-Fc 
protein (histograms c, d and e, respectively). Control mouse antibody did not inhibit 
Jurkat cell death when compared to Fas-Fc (histogram f). These results therefore support 
the concept of expression of FasL on Jurkat cells and may explain the phenomenon of cell 
death in culture especially when Jurkat or T cell blasts are grown to very high density. In 






Figure 3.2.3.4: Jurkat cells kill each other via a Fas-mediated mechanism.
Jurkat cells were labelled with si Cr and stimulated with PMA / ionomycin before 
incubation in 96 well plates overnight. Cell death was measured in a standard 
chromium release assay. Cell death was seen in Jurkat cells left in close proximity 
in a well overnight (a), which was inhibitable by pre-incubation with blocking Fas 
antibodies (c and d) or Fas-Fc (e), but not with isotyp-matched mouse IgG (f).




A major aim of the initial work was the generation of a number of reagents for the study 
of Fas biology in humans. Accordingly the human Fas gene was successfully cloned.
The cloning of human Fas cDNA from a cell line found to express large amounts of 
surface Fas was a good starting point in a project that was to involve a substantial amount 
of molecular biology. It provided experience with many of the molecular techniques 
required later for the cloning, characterisation and expression of the recombinant products 
generated both for Fas and also FasL (chapter 4). In addition it provided a useful handle 
for PCR conditions and oligonucleotide primer design for the SSCP analysis of the Fas 
gene (chapter 5).
The cloned Fas gene was functionally expressed under the control of a heterologous 
promoter in CHO cells. This development of a transfectant model of Fas in a CHO 
system was achieved through a number of selection processes. We speculated at first that 
it would be difficult to achieve stable transfectants of Fas given the nature of the molecule 
as a death protein. Hence it was expected that transfectants would die during the selection 
process as a result of exposure to anti-Fas antibodies. An explanation as to why this did
not occur may be that the antibody incubations were taking place at 4°C rather than the
requisite 37°C for Fas-mediated apoptosis. Why the cells did not die on returning to
37°C after the selection process is still unexplained. It may be possible that the dynamic 
cellular changes on re-warming allowed cleavage or disposal of antibody complexes thus 
preventing the required four to six hour exposure for apoptosis to occur. It may be argued 
that the selection processes favoured the propagation of cells resistant to Fas-mediated 
apoptosis. However, the CHO-Fas transfectants maintained sensitivity to Fas-mediated
apoptosis when challenged with anti-Fas antibody under appropriate conditions (37°C for 
4 - 6  hours), with a death rate of 30 - 50 %. It has been reassuring to note that other
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groups working with murine Fas have also been able to establish stable Fas expressing 
cell lines without the problem of excessive ceil death during the selection process (Itoh et 
al 1991). These also appear to have maintained sensitivity to Fas-mediated apoptosis in 
the range of 30 - 50%. A retrospective analysis of these early experiments shows that the 
cell death was still relatively heterogeneous, which may be explained in the light of 
current knowledge about the need for recruitment of other death domain proteins like 
FADD and FLICE (discussed below). Essentially this early finding of cellular survival 
under conditions where we expected almost certain and total apoptosis should have 
alerted us that not all Fas exposure leads to cell death. This theme will be explored further 
in the next chapter.
In any event the stable expression of human Fas in the CHO cell line has provided a 
useful transfectant model for in vitro analysis of Fas-mediated apoptosis. One reason for 
this is that negative control cells were easy to come by in the form of either untransfected 
cells or mock transfected CHO cells, unlike the situation with lymphocyte cell lines where 
all cells express Fas. Therefore the CHO-Fas transfectants allowed identification of Fas- 
specific mechanisms of apoptosis and this became particularly useful with the validation 
of the soluble FasL reagents generated later in this project. Also, the successful 
expression of Fas on the CHO cells confirmed that the original cDNA for Fas which was 
cloned from the H9 T cells was the correct fragment of DNA.
The CHO-Fas transfectant model could also serve a useful purpose in dissecting the 
individual protein interactions identified more recently. For example, it is now known that 
in order for an apoptotic signal to be transduced following surface Fas engagement, a 
number of other death domain associating interactions must occur (Cascino et al, 1996). 
Death domain proteins like FADD and FLICE have been shown to be essential for Fas- 
mediated apoptosis (Chinnaiyan et al, 1995 and Muzio et al, 1996) but other proteins also 
interact with these and the exact role of each needs to be defined. What is the influence of 
FLIP or FAP (Irmler et al, 1997 and Su et al, 1995) on the interactions of the death
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domain proteins and can these be influenced in any way by dominant negative mutants? 
These interacting proteins first need to be identified within the CHO-Fas system which 
we have established before we can proceed to appropriate step-by-step introduction of the 
relevant genes to study their influence on the outcome of Fas engagment on the surface. It 
may then be useful to study the death-domain-associating proteins by targeted 
mutagenesis and introduction into the Fas transfectant system. One shortcoming of the 
CHO-Fas transfectant system may be that the CHO cells may not necessarily reflect the 
exact physiological and protein components involved in lymphocyte apoptosis.
Initial steps were taken towards defining Fas-mediated signalling in the CHO-Fas system. 
We investigated the role of the MAPK/SAPK pathways and found that the MAPK and 
JNK pathways of signalling were intact in the CHO system. JNK was stimulated via Fas 
in the CHO-Fas transfectants, but not in negative CHO controls. This provided an 
example where negative CHO controls were useful in identifying a Fas-specific effect on 
JNK signalling in the transfectant system. Similar effects were observed in the CHO-Fas 
transfectants with regards to sphingomyelinase signalling. It is known that ceramide 
(which can be generated by sphingomyelinase activity) can also stimulate JNK activity 
(Verheij et al, 1996).However it remains unclear if this is a critical step in a cascade of 
enzyme activation leading to apoptosis or if it is another independant pathway for JNK 
activation. In addition, the actual role of JNK activation in Fas-mediated apoptosis 
remains in question (Nishina et al, 1997). Whilst JNK activation is seen with Fas surface 
engagement it appears that apoptosis may occur independant of JNK activity, and that 
apoptosis is more critically dependant on Caspase activation (Chen et al, 1996). There is 
also evidence of JNK activation following T cell activation with CD3 and CD28 (Su et al, 
1994), which is clearly a proliferative signal rather than a death trigger. Thus it appears 
that JNK activation does not necessarily equal death, and further research is required to 
clearly define the role of JNK signalling following Fas engagement. The balance of Fas 
effects on multiple signalling pathways may determine the ability of a cell to undergo 
apoptosis under given conditions and the CHO-Fas system should prove to be a useful
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model for dissecting out the components of these pathways if we can introduce the 
various genes and / or inhibitors under controlled transfectant conditions as we have done 
with the Fas gene.
Another major objective was achieved through the generation of the Fas-Fc protein. An 
approach with recombinant PCR technology was used to generate a hybrid cDNA 
comprising human Fas and mouse IgG. The successfully engineered DNA was cloned 
and validated by restriction mapping and also limited sequence analysis. Subcloning was 
carried out in order to express the Fas-Fc in a mammalian cell culture system using COS- 
7 cells. The transfected COS cells were found to express a soluble protein which was 
characterised for immunoreactivity in a variety of experiments. The soluble Fas-Fc protein 
which was thus successfully produced in the culture system was put to use in 
predominantly two types of experiments. Firstly it was used as a primary “antibody” for 
binding and identifying a putative FasL on the cell surface by FACS analysis, and 
secondly it was used as a receptor decoy to identify Fas specific mechanisms of 
apoptosis.
The Fas-Fc protein was used successfully to identify a putative FasL which was found to 
have restricted surface expression on activated T cells and Jurkat T cell lines. We could 
not detect any expression of FasL on H9 T cells suggesting that the Fas-Fc was not 
binding non-specifically to a T cell marker. In addition the absence of binding to other cell 
types including B cell lines and PBMC's confirmed that the Fas-Fc identified a specific T 
cell ligand for Fas. Rigorous efforts were made to ensure that we were not seeing non­
specific binding of Fas-Fc via its Fc component to Fc-receptors (FcR) on the cells. In any 
case all FACS staining was carried out in the presence of saturating amounts of human 
IgG even though we did not detect any human FcR expression on the Jurkat and T cell 
blasts which expressed the FasL. We were also able to explore the expression kinetics of 
FasL using the Fas-Fc and showed that resting T cells did not express FasL but 
upregulation of FasL expression occurred by day one after stimulation with PMA /
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ionomycin. The upregulation continued up to day three and returned to baseline by day 
five after the initial stimulation. This finding of a T cell restricted expression of FasL and 
its regulation by mitogenic stimulation was very interesting at the time especially because 
there were no data on FasL except for speculation from the gld mouse model (which is 
discussed later in chapter 4).
Our findings also turned out to be consistent with data on murine FasL expression 
described by Suda and Nagata (1994). The latter group first cloned the FasL gene which 
was the rat ligand for Fas using a very similar Fas-Fc construct. However the 
fundamental difference was that our construct comprised human Fas and therefore 
identified a human ligand on Jurkat cells and activated T cell blasts. Suda et al also found 
a T cell restricted expression of the rat FasL (Suda et al, 1993). Another important 
difference in the approach of Suda et al was in the use of a cytotoxic cell line that was 
heavily sorted (sixteen times) before they could see good murine Fas-Fc binding. The 
sorted cytotoxic cell line was used to clone the Fas ligand which turned out to be the rat 
ligand derived from the rat hybridoma originally used to create the cell line.
FasL expression was thought to be restricted to activated T cells and cytotoxic T cells for 
some time after the publications of Suda and Nagata (1994), thus supporting our findings 
with the Fas-Fc protein. However, more recently with the development of anti-FasL 
antibodies FasL expression has been found on a variety of cell types (to be discussed 
further in the next chapter). Amongst the more intriguing findings have been the 
demonstration of FasL expression on non-lymphoid immune privileged sites (Griffith et 
al, 1995 and Bellgrau et al, 1995, and discussed in chapter 4) such as the eye and testis. 
Therefore our identification of a human ligand for Fas on activated T cells and Jurkat cells 
using the Fas-Fc construct proved to be correct at the outset, and only more refined 
detection systems have been able to identify other cell types with FasL expression. These 
latter methods of detection of FasL expression still depend very heavily on mRNA 
expression and intracellular expression of ligand. Unfortunately, our efforts to progress
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rapidly in this field were somewhat hampered by less potent batches of Fas-Fc as 
discussed.
As a result of the identification of a FasL on Jurkat and T cell blasts we proceeded to 
attempt to immunoprecipitate the ligand using Fas-Fc as an immunoprecipitating antibody. 
Consequently a protein was successfully immunoprecipitated specifically from Jurkat cell 
lysates with a molecular weight of approximately 40 Kd. Before we could proceed further 
with protein sequencing and an attempt at cloning the ligand, Suda et al (1993) published 
results on the rat and mouse ligand for Fas. It was interesting that the 40Kd protein 
immunoprecipitated by Fas-Fc from Jurkat cells had a striking resemblance to the mouse 
and rat ligand described by Suda et al (1993). We thus were able to use the Fas-Fc protein 
not only to identify a putative surface ligand for human Fas on Jurkat and activated T cells 
but also to immunoprecipitate the ligand specifically from Jurkat T cells.
The problem that prevented rapid progress was the difficulty in consistent identification of 
surface FasL with new batches of Fas-Fc and this proved to be an obstacle at the time. 
Also, considering that our best staining with Fas-Fc was seen at concentrations of 
50ug/ml this suggested that the affinity of Fas-Fc and FasL was not very high. However 
we needed to pursue rigorously the possibility of non-specific binding as described 
above, and at the end of that analysis it appeared that the Fas-Fc was specifically detecting 
a putative FasL on activated T cells and Jurkat cells. One explanation for some of our 
difficulties was provided by recent evidence that the FasL protein is unstable by nature 
and requires metalloproteinase inhibitors to keep it on the cell surface. Most researchers 
working with FasL have found difficulty in identification of FasL on the surface of cells 
because of the cleavage by metalloproteinases (Kayagaki et al, 1995). At the time of 
preparation of the first "super-batch" of Fas-Fc we had no idea nor any means of testing 
for contamination of the Fas-Fc sample with metalloproteinase inhibitors. Our attempts to 
define the batch problem was limited to an analysis of transfectant mRNA expression and 
protein immunoreactivity, both of which proved to be normal. There is also the
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possibility that gene mutations within the cloned expression plasmid may have accounted 
for an altered level of binding without affecting the immunoreactivity of the Fas-Fc 
protein. Other authors have previously described a phenomenon of gene mutations in long 
term COS cell expression systems (Calos et al, 1983). Despite the reduced intensity of 
surface staining of FasL we were able to use the protein to immunoprecipitate a putative 
FasL from lysates of Jurkat cells. This may be explicable by our later results of FasL 
staining of Jurkat using monoclonal antibodies to FasL which became available after the 
cloning of FasL. Using the monoclonal antibodies we could confirm that abundant FasL 
expression was seen on intracellular staining (figure 3.2.3.3) as compared to the cell 
surface of Jurkat cells probably because FasL requires metalloproteinase inhibition for 
FasL to remain on the cell surface. In addition, another explanation may be provided by 
recent evidence suggesting that transfer of intracellular FasL to the cell surface varies 
according to the nature and intensity of the stimulus and occurs in a calcium dependent 
manner (Anel et al, 1994; Vignaux et al, 1995). It was reassuring to see that we were not 
alone in having problems with consistent identification of surface FasL, but in any case 
the T cell expression data and immunoprecipitation of FasL by Fas-Fc all proved to be 
confirmed by later work (Suda et al, 1994 and Lynch et al, 1994).
The second major use of the Fas-Fc protein was as a receptor decoy to inhibit Fas- 
mediated apoptosis. Our hypothesis that the soluble Fas-Fc protein would act as an 
inhibitor by binding anti-Fas antibodies thus preventing Fas receptor engagement proved 
to be correct in a number of assays. After testing the ability to block anti-Fas staining of 
cells in the FACS immunoreactivity assay the Fas-Fc was tested in apoptosis assays and 
found to block Fas-mediated apoptosis. We were able to exploit the latter use to show the 
role of Fas-mediated apoptosis in the SEB system and also in other bioassays presented in 
the results above. Subsequently, we have shown that apoptosis of SEB-activated T cells 
occurred on rechallenge with SEB in a Fas-specific manner (Boshell et al, 1996). This 
“activation-induced cell death” which occurs following various stimuli including CD3, 
superantigen, and phorbol esters has been ascribed largely to Fas-mediated mechanisms
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with some minor role for TNF-mediated pathways in some cases (Tucek-Szabo et al 
1996, Sytwu et al 1996). Of particular note is our findings of a Fas-based "fratricide" 
system in Jurkat cell culture. This idea was supported by later research showing FasL 
expression on Jurkat and the release of soluble FasL from Jurkat cells under stimulated 
conditions (Dhein et al 1995). The Fas-mediated death of Jurkat cells and T cells in 
culture may have some relevance in vivo particularly in lymphoid tissue such as the spleen 
and lymph nodes where lymphocytes are in close proximity to each other. Here activated 
cells may undergo death under appropriate conditions via a Fas-mediated fratricide or 
suicide pathway (Brunner et al 1995 and Ju et al 1995). Thus the Fas-Fc protein has 
fulfilled its potential in defining biological systems in which Fas-mediated apoptosis is 
operative.
The potential use of Fas-Fc as an immunogen for generation of our own supply of anti- 
Fas antibodies was also considered. However with the rapid rise in interest in Fas related 
research a number of commercial biomedical companies have used a similar approach to 
prepare a large variety of anti-Fas antibodies (Alderson et al 1994). It therefore seemed 
unnecessary to pursue antibody production given our limited time and resources. It was 
interesting to see a similar Fas-Fc protein used in very recent research relating to directed 
mutagenesis based on the crystal structure of Fas to show two critical ligand binding sites 
(Starling et al 1997), suggesting that the Fas-Fc protein could be used for epitope binding 
analysis of newly developed anti-Fas antibodies.
In summary this chapter has demonstrated the generation of a number of reagents which 
have contributed to our understanding of human Fas biology and the identification of a 
human FasL. Much of this work has been confirmed in mouse models of Fas but new 
questions arise including the concept of resistance to Fas-mediated apoptosis. The next 
chapter will attempt to address some aspects of this in addition to the generation of 




Generation and validation of a soluble human FasL
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INTRODUCTION
After the cloning of Fas and identification of its critical role in disease pathogenesis in the 
Ipr mouse, a worldwide search ensued for the counter-receptor to Fas. The elusive nature 
of the ligand earned it the title of an "immunological holy grail". We made attempts to 
isolate the gene for human FasL from Jurkat cells following our finding that Fas-Fc 
identified and immunoprecipitated a putative "FasL". However, during this time the rat 
and mouse ligand were cloned and sequence data became available (Suda et al, 1994; 
Takahashi et al, 1994; Lynch et al, 1994). We therefore took an approach using 
oligonucleotide primers designed from conserved regions of the sequences for mouse and 
rat FasL, with the premise that the sequence conservation may apply across species to 
humans. This approach proved unsuccessful and with the cloning of the human FasL by 
other groups it soon became apparent that the sequence chosen because of its conservation 
between mouse and rat was not conserved in the human ligand (Takahashi et al, 1994). 
We eventually obtained the human FasL cDNA from Dr D. Lynch of the Immunex 
corporation, which allowed us to embark on a project to generate a recombinant FasL 
protein not very dissimilar in design to the Fas-Fc protein. The aim was to generate 
reagents to enable further study of functional aspects of Fas engagement, using the natural 
ligand as compared to monoclonal antibodies to Fas. In our experience with other 
molecules like CD28, it was known that different effects could be observed when natural 
ligand was used rather than monoclonal antibodies (Nunes et al, 1994).
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RESULTS
4.1) FasL-FLAG: cDNA construct and protein production
In an attempt to generate a soluble ligand a molecular approach was used to generate a 
cDNA comprising the extracellular region of the FasL without the transmembrane and 
cytoplasmic domains. We reasoned that the protein produced by such a gene expressed in 
vitro would be shed into the cell culture medium because of the lack of a transmembrane 
domain to anchor it onto the cell membrane. Since no antibodies were available against 
FasL at the time we incorporated a nucleotide sequence encoding an eight amino acid 
FLAG peptide, to enable identification by anti-FLAG antibodies (Kodak).
4.1.1) Generation of Fas ligand-FLAG cDNA (sFasL) by PCR
In order to generate the recombinant soluble epitope-tagged FasL (sFasL), oligonucleotide 
primers were designed from the C-terminal extracellular encoding region of the FasL 
sequence (genbank accession no: UO3470) as shown in figure 4.1.1. From the cloned 
FasL seqence it was predicted by Suda and Nagata (1994) that the FasL protein was a 
type II transmembrane protein with the extracellular region encoded by the C terminal 
domain and the cytoplasmic portion by the N terminal domain. The sequence encoding 8 
amino acids of the FLAG peptide (Kodak) was incorporated into one of the FasL primers 
as shown in the figure. A PCR reaction was used to generate the recombinant Fas-ligand- 
FLAG (sFasL) cDNA. Figure 4.1.2 outlines the molecular steps involved in the 
production of the sFasL and shows the gel fragments generated by PCR. The agarose gel 
in figure 4.1.2 shows the ± 600bp FasL-FLAG cDNA compared to the full length FasL 
cDNA of ± 1000 bp. Therefore this PCR reaction produced the predicted truncated cDNA 
fragment comprising the extracellular region of the human FasL. In order to check the 
cDNA it was cloned into a plasmid vector (pCR3) using a TA cloning method, and then 
restriction mapped. Thus the experiment designed to generate and clone a DNA construct 
comprising the extracellular domain of human FasL with an epitope tag was successfully 
completed as indicated by the restriction mapping information. It remained to test whether 
a soluble protein would be produced by expression of the sFasL cDNA in vitro.
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Figure 4.1.1: Human Fas ligand (FasL) Gene Sequence
The sequence for human FasL is shown (Genbank accession no: UO3470). The 
transmembrane domain is indicated as a boxed area and the untranslated regions shown in 
lower case. The 842 bp coding region is shown in upper case, and the sites for binding of the 
oligonucleotide primers used to amplify the soluble FasL (sFasL) sequence are underlined. A 
sequence for the Flag peptide was incorporated into primer A as shown below:
5’ primer (A):
cccatggactacaaggacgacgatgacaagCAGCTCTTCCACCTACAGAAGGAGCTGG 
(Flag sequence in lower case, FasL sequence in upper case)
3’ primer (B): GGAAAGAATCCCAAAGTGCTTC
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PCR reaction with primers A 
and FLAG - B.
Fas-L-FLAG cDNA
CCCATGG ACTACAAGG ACG ACG ATG ACAAG
392 978
1
Recombinant cDNA product of ± 600bp 
(see gel inset) generated for cloning into 
mammalian expression vector.
Figure 4 .1 .2  : Strategy fo r the generation of Soluble FasL.
The line drawings outline the general strategy employed to generate a cDNA for sFasL 
by PCR. Essentially, the -COOH terminal extracellular domain encoding region of the 
gene was amplified together with a sequence for the FLAG peptide as shown. The 
agarose gel shows the sFasL-FLAG PCR product ( ± 616 bp in lane 3) in relation to the 
cDNA for the coding region of FasL ( ±  842 bp in lane 2). Molecular weight markers
are shown ((J)X-174 Hae III digest in lane 1).
Tm = transmembrane region, Cyt = cytoplasmic region , EC = extracellular region.
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4.1.2) Expression of sFasL in culture
In order to achieve protein expression in cultured cells, the cloned sFasL cDNA was 
introduced into COS-7 cells using electroporation. Transfected cells were selected in 
Neomycin and cell culture supernatants were tested for apoptosis-inducing acdvity (see 
section 4.2). The results in figure 4.1.3 shows that COS-7 cells mock transfected with 
the plasmid vector not containing the sFasL sequence produced no apoptotic activity in 
their culture supernatants, whilst a dose dependant increase in apoptotic activity was seen 
with the sFasL transfectant supernatants. In addition it was possible to test that the 
apoptosis was induced in a Fas-specific manner by using the previously generated Fas- 
Fc. As shown in chapter 3 section 3.2.3.2, Fas-Fc inhibited Fas-mediated apoptosis 
induced by both CH11 and sFasL in a variety of assays. Therefore these results suggest 
that the sFasL was appropriately expressed in culture supernatants of transfectants as 
predicted and was biologically active. Fas-Fc inhibition of the sFasL-induced apoptosis 
supported a Fas-specific mechanism of action.
Despite the tagged FLAG sequence there was technical difficulty with the isolation and 
demonstration of the sFasL protein on gels as well as immunoblots. This was ascribed to 
small quantities of protein produced, which may have been insufficient to see on a gel but 
which retained potent and Fas-specific apoptosis-inducing activity. Also post-translational 
protein modification through incorporation of the FLAG sequence may have altered the 
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[supernatant]
Figure 4 .1 .3 : sFasL supernatants induce apoptosis (dose response).
Apoptosis of Jurkat cells was measured in a JAM assay and expressed as % cell 
survival versus dilution of cell culture supernatant. Apoptosis of Jurkats occurred in 
response to increasing concentrations of sFasL supernatants (red curve) but 
supernatants from mock transfected cultures did not induce Jurkat cell apoptosis (black 
curve).
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4.1.3) Incorporation of a signal sequence onto sFasL by recombinant PCR
Due to poor protein production and the resultant difficulty with isolation of the sFasL, 
further modification of the sFasL was undertaken using a molecular approach to 
incorporate a signal sequence onto the sFasL cDNA.
In an attempt to improve protein production, it was decided to incorporate a signal 
sequence 5’ of the FasL encoding region. With the signal sequence for the B7 molecule 
which was already in use in the laboratory, a strategy was planned as outlined in figure 
4.1.4. Using specifically designed primers as indicated the B7 (CD80) signal sequence 
was amplified using PCR, as was the sFasL cDNA using newly designed primers. 
Unbound oligonucleotides and dNTP’s were removed and the two fragments annealed in 
an overlap PCR reaction using the flanking primers. In the agarose gel of figure 4.1.4 the 
various PCR products are shown. In this figure it can be seen that the overlap PCR 
produced the predicted larger ±840 bp fragment comprising the added signal sequence. 
Hence this PCR based approach to attach a signal sequence of CD80 5’ of the sFasL 
cDNA was successful. Further mapping and expression of the signal sequence FasL 
(ssFasL) was necessary.
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B7 DNA in Fas ligand DNA
plasmid CDM8 in plasmid pBSKS+o 5
B7 signal sequence sFasL cDNA
ssFasL cDNA
Primer A: CTCCAATCTCTGTGTGTTTTG
Primer B: CTTGTCATCGTCGTCCTTGTAGTC catgggaccagccagcaccaagag
Primer C: ctcttggtgctggctggtcccatg GACTACAAGGACGACGATGACAAG
Primer D: GGAAAGAATCCCAAAGTGCTTC
Figure 4.1.4: Attaching a Signal Sequence to sFasL.
The line drawings outline the recombinant PCR approach used to generate a signal 
sequence onto the sFasL cDNA. Primers used are shown above with the complementary 
sequences for the overlapping primers (B and C) represented in lower case (B7 
sequence) and upper case (sFasL sequence). The inset shows an agarose gel of the PCR 
products of PCR 1 (±270bp B7 signal sequence, lane 2), PCR 2 (±600 bp sFasL product, 
lane 3) and the overlap PCR 3 (± 834 bp signal sequence sFasL, lane 4). Molecular 
weight markers are shown in lane 1 (<|)X-174 Hae III digest).
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4.1.4) Cloning and restriction mapping of ssFasL
In order to confirm the appropriate splicing of the signal sequence the recombinant ssFasL 
cDNA was TA-cloned and mapped as described in figure 4 .1 .5 , Details are provided 
because the vector chosen was different from those in previous cloning experiments. In 
this case the pCR3 vector provided the opportunity for TA cloning directly into a 
mammalian expression vector. The miniprep screen with Eco R1 digests shown in gel A 
(figure 4.1.5) revealed a number of clones with inserts (lanes 4-10 and 14, 15) which 
were then selected for restriction mapping. Apa 1 cuts in the FasL sequence and the 
multiple cloning site of pCR3 to reveal a clear difference between sense (±209bp 
fragment) and anti-sense (± 728 fragment) clones and gel B of figure 4.1.5 shows this 
clearly (sense refers to the correct 5’ to 3’ orientation of the cloned insert in relation to the 
CMV promoter of the plasmid vector). Of the nine clones depicted all were sense clones 
except three (lanes 6, 7, and 8 gel B, figure 4.1.5).
Similar findings were seen with Nco 1 restriction mapping to support the data with the 
Apa 1 digests (see figure 4.1.5, lanes 12-20). Thus the results suggested a high cloning 
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+ 5100 bp linearised vector
Apa 1 : sense = 209 bp + 5723 bp
anti-s = 728 bp + 5204 bp
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3 = pCR3/ EcoRl
4 - 15 = miniprep 
clones 1 - 12  with 
EcoRl
GEL B
1 2 3 -11 12 -20
Lanes:
1 = MWM (X Hind III / 0X-174)
2 = pCR3 uncut
3-11 = Apa  1 digests of clones 1-7,11,12. 
12-20 = N col digests of clones 1-7,11,12.
Figure 4.1.5: Cloning of Signal Sequence FasL (ssFasL) into pCR3.
A cloning map and predicted restriction sites are shown for ssFasL in pCR3. Agarose gel 
A shows randomly selected miniprep clones digested with EcoRl to reveal positive 
clones in 9 of the 12 selected (lanes 4-10 and 14, 15 in gel A). Further restriction 
mapping using Apal and Ncol revealed that clones 1, 2, 3, 7, 11 and 12 were in the 
correct orientation for mammalian cell expression whilst clones 4, 5 and 6 (lanes 6, 7, 8 
and 15, 16, 17 in gel B)were anti-sense clones.
MWM = molecular weight markers (A Hind III / <|>X-174), MCS = multiple cloning site, Amp = ampicillin 
resistance gene, Neo = neomycin resistance gene, Pcmv = cytomegalovirus promoter sequence for in vitro 
expression , anti-s = antisense clones.
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4.1.5) Expression of ssFasL in culture
In order to produce the ssFasL protein in COS-7 cell supernatants one sense clone of 
ssFasL/pCR3 was chosen for expression in mammalian cell culture. After electroporation 
and selection under neomycin, COS cell supernatants were harvested and pooled.
To test the efficiency of the ssFasL produced in culture comparitive assays of apoptosis 
were established for the sFasL (no signal sequence) and the ssFasL (with signal 
sequence) proteins. Figure 4.1.6. shows the results. The addition of a signal sequence 
appeared to enhance the apoptotic activity of the ssFasL (as compared to sFasL) produced 
in culture supernatants as seen in both the JAM assay as well as the Annexin assay shown 
in figure 4.1.6. In the JAM assay (i) the killing potential of the FasL was compared to 
vector transfected control supernatant (histogram a), and ssFasL consistently gave 20 - 
25% more apoptosis (histograms d and e representing independant transfectants) 
compared to sFasL (histograms b and c).
Similar observations were made in the Annexin assay (ii) where 20-25%  more apoptosis 
was seen with ssFasL (FACS histograms in figure 4.1.6). Thus the addition of a signal 
sequence to the sFasL enhanced its potential to kill Jurkat cells as observed in two 
independent in vitro assays of apoptosis.
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Figure  4 .1 .6 :  E nhanced effec tiveness o f  s sF asL  com pared  to sF asL .
A comparison of apoptosis induced by the sFasL versus ssFasL is shown in two 
assays. In (i) a JAM assay on Jurkat cells shows 20 - 25% greater apoptosis induced 
by two independent batches of ssFasL (d and e) compared to sFasL (b and c). All 
comparisons were made to mock transfected supernatants at the same concentration 
(1:10 , histogram a). A similar pattern of enhanced apoptosis (± 25%) was seen with 
ssFasL in an Annexin assay for apoptosis in Jurkat cells (ii). In the latter experiment 
percent apoptotic cells are indicated above the Ml marker as determined on FACS 
analysis. All cell stimulations were carried out for 6 hours. Results are representative of 
three independent experiments.
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4.2) Soluble Fas ligand (sFasL) in apoptosis assays
Following the successful generation and production of the soluble ligand as described 
above it was compared to the monoclonal anti-Fas antibody CH 11 (regarded as the gold 
standard for Fas-induced apoptosis). In order to assess this it was necessary to establish a 
number of apoptosis assays.
4.2.1) JAM  assay
In order to assess apoptotic changes induced by sFasL as compared to CHI I the JAM 
assay (method in 2.5.1) was employed on a variety of cell types. Figure 4.2a shows 
the results in the U937 cell line, CHO-Fas transfectants and T cell blasts and Jurkat cells, 
all of which express Fas on their surface. Comparable killing was induced by the sFasL 
in all four cell types with a tendency to increased killing activity in T cell blasts. It is 
unclear if this reflects a true biological difference in response to the "natural ligand" as 
opposed to the antibody. However the results of a second assay of DNA fragmentation, 
namely the TUNEL assay (chapter 2.5.3) did not show an enhanced killing with sFasL 
compared to CH 11 (figure 4.2b). Thus these results suggest that sFasL can induce 
apoptosis via the Fas receptor in a variety of Fas expressing cell types and that the 
apoptosis induced by sFasL is largely comparable to CH 11.
4.2.2) Annexin V-FITC assay
In order to confirm that the apoptosis detected in the JAM assay could be substantiated by 
other methods we used the Annexin-FITC assay (methods 2.5.2). The Annexin-FITC 
assay depends on detection of externalised phosphatidyl-serine (PS) by Annexin V-FITC 
and FACS analysis. PS is a phospholipid molecule usually situated on the inner leaflet of 
the plasma membrane. It is rapidly externalised and exposed on the surface of apoptotic 
cells. Fas-induced apoptosis has also been shown to be associated with a rapid 
extemalisation of PS (Martin et al, 1995). Our results (figure 4.2c) show that Fas- 
induced apoptosis was detected by 4-6 hours using an Annexin-FITC assay and that both
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the CH 11 antibody and the sFas-L induced early annexin changes (histograms d and b 
respectively). The specificity of Fas-mediated apoptosis was demonstrated in blocking 
annexin changes by preincubation of the Jurkat T cells with the ZB4 anti-Fas antibody 
(reduction of apoptotic population from 45.9% to 6.08%).The CHO-Fas transfectants 
generated earlier were also sensitive to sFas-L induced apoptosis when measured by the 
Annexin-FITC assay. Thus these results confirmed by an independent measurement that 
the sFasL was as capable of inducing apoptosis as CH 11.
4.2.3) Cytospin analysis of nuclear morphology
Morphologic changes in apoptotic cells with cytoplasmic shrinkage, nuclear condensation 
and membrane blebbing are best visualised on electron microscopy or confocal 
microscopy. We attempted to study nuclear morphologic change by fluorescence 
microscopy with simple propidium iodide staining of cells stimulated with the sFasL 
(methods 2.5.4). Figure 4.2d shows our results where gross nuclear changes were 
seen with sFasL on Jurkat T cells. Apoptotic cells showed reduced or irregular speckled 
staining with propidium iodide (picture b compared to a). It was also evident that the Fas- 
mediated apoptotic changes could be inhibited by Fas-Fc (picture c). It was of interest that 
the apoptotic changes were also inhibited by chloroquine (picture d), possibly on the 
basis of sphingomyelinase inhibition. As described in figure 3.1.8 we found that 
chloroquine inhibited sphingomyelinase signalling following Fas engagement. Thus the 
cytospin analysis showed that gross morphologic changes of apoptosis could be detected 
by six hours after exposure to sFasL and that the changes were inhibited by Fas-Fc 
blockade of Fas receptors or by inhibition of signalling pathways of apoptosis.
All the above assays essentially measured apoptosis in response to sFasL. However each 
method reflected a different manifestation of the apoptotic process and thereby confirmed 
the activity of the sFasL as an apoptosis-inducing protein. In general the sFasL appeared 
to have comparable activity to the monoclonal anti-Fas antibody CHI 1. We have thus 
successfully manipulated the FasL cDNA by recombinant PCR and expressed a functional 
soluble form of human FasL with pro-apoptotic activity.
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Figure 4.2 a : sFasL induces Fas-mediated apoptosis in a variety of cell types.
JAM assays were carried out on a variety of cell types as represented above. The percent apoptosis was calculated following 
exposure to monoclonal anti-Fas (CH 11 lug/ml) or sFasL (1: 10 supernatant). For CHO-Fas transfectants and U937 monocytic cell 
lines (a and b respectively) the CH 11 and sFasL had comparable effects, whilst it appeared that sFasL was more effective than CH 
11 at inducing apoptosis in the Jurkat T cells (c) and activated T cell blasts (d). Data are representative of three independent 
experiments.
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Figure 4 . 2 b :  TUNEL assay of apoptosis induced by sFasL.
A TUNEL assay showing FACS histograms is depicted here with apoptosis reflected 
by a shift to the right. Both anti-Fas antibody (a ii) and the sFas-L (b ii) induced 
apoptosis of Jurkat T cells (percent cell death is reflected above the M l marker as 
determined by FACS analysis). Negative cells were incubated with isotype-matched 
mouse antibody (a i) or cell culture supernatant from mock-transfected COS cells (b i). 
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Figure 4 . 2 c :  Annexin-FITC assay of apoptosis induced by sFasL.
FACS pictures are shown of an Annexin-FITC assay in Jurkat cells depicting apoptosis 
as a shift in the histogram to the right. Both CH 11 (b) and sFasL (d) induced apoptotic 
changes compared to control cells (a and c). The effect of sFasL was inhibited by a Fas 
blocking antibody ZB4 (e). Apoptosis measured by Annexin was also detectable in the 
CHO-Fas transfectants on exposure to sFasL (g) as compared to mock supernatant (f). 
Gates on the apoptotic population (Ml)of cells are shown with percentages reflected. 
The results are representative of three independent experiments.
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a b
Figure 4.2 d: Cytospin analysis fo r apoptosis by sFasL.
Cytospin pictures (40X magnification) are shown of Jurkat T cells with propidium 
iodide (PI) staining of nuclei following various stimuli. Jurkat cells were incubated with 
control supernatant (a) or sFas-L supernatant (b) for 4-6 hours and centrifuged onto 
slides for PI staining. Intact nuclei stain homogeneously with PI (a) whilst the apoptotic 
nuclei in b can be seen with very irregular speckled staining and much reduced PI 
fluorescence overall. Inhibitors of Fas-mediated apoptosis like Fas-Fc restored normal 
nuclear staining (c) and an interesting inhibition of Fas mediated apoptotic change was 
also seen with chloroquine (d).
169
4.3) Apoptosis in human T cell blasts
4.3.1) Resistance to Fas-mediated apoptosis : Lack of correlation betw een 
Fas expression and Fas-m ediated apoptosis.
Analysis of the apoptosis assays revealed that not all cells were equally sensitive to Fas- 
induced killing. A significant proportion of cells (Jurkat and T cells) survived exposure to 
anti-Fas reagents despite surface Fas expression. It has previously been reported that 
activation of T cells was required for five to six days before Fas-mediated apoptosis was 
seen (Itoh et al 1991, and Trauth et al, 1989). In our activated T cell cultures there was 
clear evidence of variation in sensitivity to Fas-mediated killing (figure 4.3.1).
In an attempt to study the resistance to Fas-mediated apoptosis, another student in the 
laboratory (Lucy Walker) generated a Fas resistant Jurkat T cell line (JLW) by culturing 
Jurkat cells with low concentrations of anti-Fas antibody over time. These cells were 
resistant to Fas-induced killing despite expressing wild type levels of Fas. To see if the 
JLW cells were resistant to the sFasL generated above, a JAM assay was conducted 
comparing wild type Jurkat cells to the JLW cells. Resistance to Fas-mediated apoptosis 
was found in the JLW cell line when using either anti-Fas antibody or the recombinant 
sFasL (figure 4.3.1). From the figure it is apparent that despite equivalent expression 
of surface Fas the JLW cells were not as sensitive to apoptosis as the Jurkat T cells (5% 
death compared to 30 - 35% after 6 hours stimulation).
Activated T cell blasts also vary in their susceptibility to apoptosis by Fas stimulation and 
an example is shown in figure 4.3.1 (iii) of a stimulated T cell culture with good surface 
Fas expression but resistance to Fas-induced apoptosis. The factors influencing resistance 
to Fas-mediated apoptosis were not clear but a number of protein interactions may be 
implicated including anti-apoptotic factors like Bcl-2, Bcl-XL, and the more recently 
identified death-domain-interacting proteins (FADD (Chinnaiyan et al, 1995), FLICE 
(Los et al, 1995) and FLIP (Irmler et al, 1997) or phosphatases like FAP (Su et al, 1995). 
It remains for these interactions to be defined in our JLW cell line and also in the resistant
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T cell blasts. Defects of signalling pathways could also conceivably influence outcome 
after Fas engagement.
Thus whilst our data did not identify the mechanisms operative in Fas resistance, they did 
reveal at an early stage of our investigation that Fas surface expression did not necessarily 
correspond to apoptotic death following Fas receptor engagement. This concept of 
resistance to Fas-mediated apoptosis has now become an intense focus of research efforts 
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Figure 4.3.1: Fas-induced apoptosis does not correlate with surface Fas expression.
FACS analysis of various cell types are shown for Fas surface expression above. No significant differences in surface 
expression of Fas could be seen for Jurkat cells, JLW cells, and T cell blasts (unshaded histograms). In vitro apoptosis as 
measured by a JAM assay is shown below each FACS histogram where it is evident that JLW cells (ii) and T cell blasts (iii) 
did not die as readily as Jurkat cells (i) after exposure to sFasL for 6 hours despite similar levels of surface Fas expression. 
The data are representative of more than six experiments.
4.3.2) Resistance to Fas-mediated apoptosis is not associated 
with defective JNK signalling.
4.3.2.1) Time course for JNK signalling following Fas engagement in 
Ju rk a t cells.
Since we had already established that phosphorylation of JNK ocurred as a signalling 
mechanism after Fas engagement (chapter 3.1.5c) we investigated whether there was any 
abnormality in JNK signalling to account for the Fas resistance of the JLW cells ; i.e., is 
the defect in these cells above or below the level of JNK signalling?
In order to do this an in vitro JNK assay was established using known stimuli of JNK 
activity. However, a time course experiment was necessary to find the optimum duration 
of stimulation necessary following Fas engagement. Figure 4 .3 .2  shows a time course 
experiment for both sFasL and CH 11 and indicates that the JNK activation following Fas 
receptor stimulation was rapid with activity seen by 5 minutes and a decay of activity 
apparent by 60 minutes.
Thus it was decided that JNK signalling would be assessed after fifteen minutes of Fas 
receptor stimulation in order to optimally detect changes within this signalling pathway.
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2 = PMA /  ionomycin
3-6 = CH 11 time course 
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Figure 4.3.2: In vitro Jun kinase (JNK) assay - time course of activation after Fas stimulation
An in vitro JNK assay is shown using Jurkat cell lysates following stimulation by PM A / ionom ycin, CH 11, and sFasL. Fas 
stimulations by CH 11 (0.5ug/ml) and sFasL (1:10) were carried out for the times indicated below the gel lanes (in minutes). Both 
antibody and sFasL stimulated JNK activity as measured by in vitro GST-cJun phosphorylation with upregulation evident by 5 minutes 
(lanes 3 and 7 compared to lane 1) and persisting for upto 60 minutes (lanes 6 and 10. The plotted curves represent the kinetics o f GST- 
cJun phosphorylation for CH 11 and sFasL when the gel bands were quantitated using Phoretix ID gel analysis software, 
abbreviations: unstim = unstimulated, min = minutes.
4.3.2.2) Comparison of JNK signalling in Jurkat and JLW cell lines.
In order to assess the JNK signalling pathway in the Fas-resistant JLW cells an in vitro 
JNK assay was applied using the conditions established above. Fas-mediated activation 
of JLW cells was compared to Jurkat cells and lysates were analysed for in vitro JNK 
activity fifteen minutes after stimulation.
Figure 4.3.3 shows the results of an in vitro kinase assay measuring JNK activity by 
phosphorylation of a GST-cJun substrate. As compared to unstimulated cells both PMA 
alone and PMA/ionomycin induced marked activation of JNK. Both CH11 and sFasL 
also induced JNK activity but to a lesser extent than the phorbol ester stimulation. Whilst 
the resistant JLW cells maintained a Fas-related upregulation of JNK activity (compare 
lanes 4 and 5 to lane 1 for JLW cells) similar to the sensitive Jurkat cells, there appeared 
to be a generally lower overall signalling response to Fas stimulation within the JLW cells 
(compare lanes 4 and 5 for JLW cells to equivalent lanes for Jurkat cells). Similarly, T 
cell blasts that showed resistance to Fas killing still maintained the ability to activate JNK 
on Fas engagement (data not shown).
These results therefore suggested that the JNK signalling pathway, whilst activated by 
Fas stimulation may be somewhat altered in resistant cells with a lower level of activity 
compared to Fas sensitive cells. However, no obvious major defect of JNK signalling 
was evident to account for the resistance to Fas-mediated apoptosis, and therefore other 
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Figure 4.3.3: Comparison of JNK signalling in Jurkat and JLW  cells.
An in vitro kinase assay is shown for both Jurkat and JLW cells with various stimuli. 
Comparisons were usually made with control unstimulated cells as shown in lanes 1 of  
each gel. PMA / ionomycin was used as a positive control (lanes 3) and was consistently 
greater in its stimulation of JNK activity than PMA alone (lanes 2). Both CH 11 (lanes 5) 
and sFasL (lanes 4) stimulated JNK activity in JLW (Fas-resistant cells) as well as 
Jurkat cells (Fas-sensitive), but the phosphorylation of GST-cJun was somewhat reduced 




Having previously identified a human FasL on T cells using our Fas-Fc protein, we were 
also successful in generating a soluble FasL protein as a useful reagent for further study 
of Fas-FasL interactions. The sFasL protein was generated by manipulation of the human 
FasL cDNA which required a recombinant PCR approach, followed by cloning and 
expression in cell culture. The soluble ligand was produced in vitro in a COS-7 cell 
culture system and was shown to be specific and highly effective in mediating Fas 
receptor stimulation and apoptosis. The sFasL was comparable to the gold standard 
monoclonal anti-Fas antibody (CHI 1) in a range of in vitro apoptosis assays. It is unclear 
from our data if the sFasL was more effective than the CH11 antibody because of a 
natural ligand conformation. The enhanced apoptosis seen in Jurkat cells and T cell blasts 
with sFasL was not always consistent but this may also be due to other factors. Firstly, it 
was difficult to quantitate the sFasL which was used as a supernatant from transfectant 
cell cultures, and therefore a dose-for-dose comparison could not be conducted in order to 
compare its effectiveness to the purified CH11 antibody. However despite this the sFasL 
was at least as effective as lug/ml purified CH11 antibody in mediating Fas-specific 
apoptosis. It is interesting that differences in activity of the natural ligand as compared to 
anti-Fas antibody have been described (Suda et al, 1996; Zipp et al, 1997). A second 
explanation for the inconsistency in the killing potency may be in the heterogeneous 
nature of cell sensitivity to Fas-mediated apoptosis, and will be discussed below.
FasL belongs to the TNF family of proteins, of which TNF has been identified to require 
a trimeric structure for effective TNF-R stimulation (Kriegler et al, 1988). Consequently it 
has been hypothesised that the Fas receptor would also trimerise or oligomerise with FasL 
engagement. The requirement for cross linking of a variety of IgG anti-Fas antibodies 
supported this idea (Dhein et al, 1992), whilst it seemed that the CH 11 antibody did not 
require prior cross linking because of its IgM structure. It was interesting to see that our 
sFasL did not require any prior manipulation in order to induce apoptosis. This would
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suggest that the protein was being appropriately translated in a timeric or multimeric form 
in the COS cell transfectants. An alternative model would suggest that the sFasL protein 
was produced in monomeric form and inducing timerisation of the Fas receptor following 
engagement by recruitment of other death domain binding proteins. Unfortunately, 
although we could detect specific and highly effective apoptotic activity in the transfectant 
supernatants we were not able to isolate and purify the sFasL from the supernatants in 
order to define its structure further. Although the epitope tag attached to the sFasL was 
detectable with anti-FLAG antibodies there was difficulty with consistent immuno­
detection of sFasL. In light of the pressures of time and resources further isolation and 
purification of sFasL was not pursued. However, given its potent and specific activity the 
sFasL supernatants were used for a variety of assays in the laboratory. More recently the 
NMR structure of Fas has been identified as being trimeric (Huang et al, 1996).
The role of sFasL in Fas-mediated apoptosis has been investigated by others more 
recently. Soluble FasL has been found to be produced naturally by Jurkat cells (Dhein et 
al, 1995) following metalloproteinase cleavage and may play a role in regulating cell 
survival under appropriate activation conditions. It has been suggested that activation of T 
cells may upregulate not only surface FasL for cell-cell killing via Fas but may also result 
in production of soluble FasL which may then influence cell death through an autocrine or 
paracrine mechanism (Brunner et al, 1995). Our findings with a recombinant sFasL 
would certainly support the idea that cells can die by apoptosis when presented with a 
soluble FasL as opposed to a cell surface expressed FasL. Further research with 
molecules like the sFasL may eventually yield new therapeutic approaches particularly in 
situations where Fas-induced apoptosis needs to be enhanced, as for example in lymphoid 
malignancies.
It was noted that some cells did not undergo apoptosis on Fas engagement despite high 
levels of Fas expression on FACS, and not all activated T cell blasts died after 6 days of 
activation as suggested in the literature (Owen-Schaub et al, 1992). More recently other 
papers, including our own have also suggested that not all activated cells with Fas
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expression are susceptible to apoptosis (McLeod et al, 1998; Ogasawara et al, 1995). One 
important signalling pathway that was thought to be critical for apoptosis was the JNK 
pathway (Chen et al, 1996).An attempt was made to define if JNK was implicated in the 
phenomenon of resistance to Fas-mediated apoptosis in our cultures. Although we 
observed upregulation of JNK activity even in the Fas resistant cells, there appeared to be 
less overall activity of JNK within these cells compared to Fas-sensitive Jurkat cells. 
However the JNK activity may be influenced by other enzymes induced on engagement 
of the Fas receptor, for example sphingomyelinase, and may not necessarily correlate 
with susceptibility to apoptosis. The role of JNK in apoptosis has come into question 
more recently and it may be that JNK plays different roles under different apoptosis- 
inducing conditions. Whilst JNK activation is critical for apoptosis induced by UV 
irradiation or osmotic stress (Chen et al, 1996), the evidence suggests that with Fas 
stimulation JNK activation occurs independently of any susceptibility to apoptotic death 
(Nishina et al, 1997). The exact role of JNK activation after Fas engagement remains 
uncertain. It could be that JNK is not critical for Fas-mediated apoptosis and that it may 
mediate other Fas effects such as transcription factor induction and cell proliferation as is 
the case with its family member, the TNF-R (Ponton et al, 1996; Hsu et al, 1995). 
Another possibility is that JNK activation occurs earlier than the critical apoptosis 
signalling events more recently identified such as activation of Caspases (Chen et al, 
1996), and that the latter may play a part in the resistance to Fas-mediated death in the 
JLW cell line. Other death domain associated factors like FADD (Chinnaiyan et al, 1995), 
FLICE (Los et al, 1995) and FLIP (Irmler et al, 1997) or phosphatases like FAP (Su et 
al, 1995) may also play a role in modulating the Fas death pathway within these resistant 
cells. For example, it is known that inhibitory proteins like FLIP bind to the death- 
effector-domains of FADD and thereby inhibit their association with FLICE which is an 
essential requirement for the formation of the death-inducing signalling complex (DISC) 
(Irmler et al, 1997; Thome et al, 1997). Further characterisation of resistance to Fas- 
mediated apoptosis and the role of inhibitory molecules such as FLIP needs to be 
conducted in our JLW cell system.
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This chapter has therefore shown the generation of a sFasL reagent which has been 
validated and used in a variety of assays in the laboratory. During this analysis we 
observed the phenomenon of resistance to Fas-mediated apoptosis and this was explored 
further. Whilst the preliminary signalling experiments suggested no overwhelming role 
for JNK in Fas-mediated apoptosis, there remains nevertheless a large number of 
questions about the possible interaction of this pathway with other recently identified 
death signalling pathways. We have a good system with the JLW Fas resistant cell lines 
and CHO-Fas transfectants to explore this further in the future.
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CHAPTER 5
FAS in Human SLE
181
INTRODUCTION
There are a number of mouse models of lupus, one of which is the MRL-/pr /Ipr mouse 
which spontaneously develops features very similar to human SLE. The homozygous/pr 
mouse develops accelerated autoimmune features with arthritis, glomerulonephritis, skin 
changes and autoantibody production including amongst others anti-nuclear antibodies 
and antibodies to dsDNA (Cohen and Eisenberg, 1991). Following the identification that 
the Ipr autoimmune phenotype was due to a defect of the Fas gene (Watanabe-Fukunaga 
et al, 1992) the importance of the gene was demonstrated by the dramatic reduction of 
autoimmune features in these mice with transgenic correction of the Fas gene within the T 
cells (Wu et al, 1994). The Ipr mouse has a retrotransposon insertion into intron 2 of the 
Fas gene resulting in altered transcription and production of a non-functional Fas protein 
resulting in an inability to induce apoptotic cell death, particularly manifested in defective 
Fas-mediated peripheral deletion of activated lymphocytes and defective Fas-mediated
cytotoxicity (Adachi et al, 1993). An allelic variant, Ipr c& was discovered which has a 
single base mutation within the cytoplasmic death domain of the Fas gene and manifests 
with a very similar autoimmune syndrome (Watanabe-Fukunaga et al, 1992), 
highlighting the critical function of the cytoplasmic death domain of Fas. Thus, given the 
critical nature of this single gene in murine lupus, it was decided to explore the role of the 
Fas gene in human SLE. To study the role of Fas in SLE, we used an approach of 
looking for Fas gene polymorphism by PCR-SSCP analysis. Functional apoptosis assays 
were also assessed in the context of Fas engagement by both ligand (generated earlier in 
this project) and monoclonal anti-Fas antibody. An analysis of the clinical parameters in 
relation to apoptosis was carried out to see if any correlations were evident.
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RESULTS
5.1) SSCP ANALYSIS OF THE FAS GENE
With the cloning of Fas as described in chapter 3 we had a human Fas cDNA probe which 
could be used for restriction fragment length polymorphism (RFLP) analysis. However 
RFLPs can only be detected when DNA polymorphisms are present in the recognition 
sequences for the corresponding restriction endonucleases. On the other hand, single 
stranded conformational polymorphisms (SSCP) have been shown to be an efficient and 
useful method for detection of point mutations at various positions in a fragment of DNA 
(Orita et al, 1989). SSCP analysis depends on the separation of single stranded DNA's 
of the same nucleotide length by polyacrylamide gel electrophoresis. Altered 
conformations of single stranded DNA as a result of even a single point mutation within 
the DNA gives rise to a different migration pattern on polyacrylamide gel electrophoresis. 
Therefore an approach using SSCP was employed to search for defects within the Fas 
coding region in human SLE.
5.1.1) Optimisation of SSCP gels for the detection of polymorphism.
In order to optimise conditions to be sensitive enough for the detection of minimal gene 
variation a set of Fas primers were designed to generate a mutant Fas cDNA differing 
from normal by only two nucleotide bases. The polyacrylamide gel in figure 5 .1 .1  
demonstrates that with optimum gel running conditions at 4°C, the mutant Fas PCR 
product was readily differentiated from the normal. However standard agarose gel 
electrophoresis was not sensitive enough to detect these minute changes in DNA sequence 
as seen in figure 5.1.1 (b). Thus the technique of SSCP analysis was established 
within the laboratory with sufficient sensitivity to detect point mutations in the Fas cDNA. 
We could therefore proceed with analysis of the Fas gene in human SLE.
183
ai i i
-  P  
-  I I
►  f  • » -
Figure 5.1.1: Optimisation of SSCP gels.
Optimisation o f SSCP gels was achieved by using a mutant Fas product generated by 
PCR. A mutant primer (CATTCTCATTCAAGATCTCATC) was designed to 
produce a Fas PCR product which differed from the normal by two bases (AA  
replacing the normal TT at the position underlined). Identical PCR products o f 270  
base pairs were seen on 2% agarose gel electrophoresis (b) but non-denaturing 
polyacrylamide gel electrophoresis (a) showed a clear difference in mobility o f the 
mutant Fas PCR products (lanes marked ii in both gels). Lanes marked (i) show the 
normal Fas 270 bp product which has a predominant lower band (large arrowhead) 
whilst the mutant has a retarded migration pattern (sm aller arrow). Other 
conformational patterns are often evident with SSCP and can be seen in the upper 
bands as minor differences in DNA migration.
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5.1.2) Analysis of Human Fas cDNA by SSCP analysis
In order to analyse the Fas cDNA, blood samples from patients and normal controls were 
obtained and processed by Ficoll gradient separation. Cells were stimulated with PMA / 
ionomycin to upregulate Fas expression and total RNA was isolated for cDNA generation 
by reverse transcription. Radiolabelled PCR was carried out for the SSCP polymorphism 
analysis under controlled conditions (chapter 2.4). Patients with SLE were chosen at 
random from a Connective Tissue Diseases clinic at the Royal National Hospital for 
Rheumatic Diseases in Bath, and blood from normal volunteers was taken from amongst 
staff at the hospital and the Bath Institute for Rheumatic Diseases. A total of 60 samples 
were analysed comprising 30 SLE patients and 30 normal healthy donors.
In order to study the Fas gene by SSCP polymorphism the cDNA was divided into four 
overlapping fragments as defined by the oligonucleotide primers shown in F igure 
5 .1 .2 . It was necessary to study the ±1000bp cDNA in four fragments because the 
sensitivity of the SSCP technique is reduced at larger fragment sizes (optimum DNA 
analysis on sizes up to ±350 bases).The line diagram in Figure 5.1.2 depicts the four 
regions amplified by PCR with region 1 corresponding to the extracellular domain of the 
Fas cDNA, region 2 comprising extracellular and transmembrane encoding domains and 
the cytoplasmic domain of Fas cDNA was represented within regions 3 and 4. The exact 
nucleotide and amino acid details of the four arbitrarily defined regions are provided in the 
legend to figure 5.1.2.
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Human FAS cDNA


















p r im e rs e t  A: 5 ’ CG G A G G A TT G C T C  A ACA A C C  A T G C T G 
3 ’ T T C A T C C C C A T T G A C T G T G C A G T C C C
(n t 1 7 7 -2 0 2 )  
(n t 4 3 3 -4 0 8 )
p r im e rs e t  B: 5 ’ GGGA C T  G C ACA GT C  A A T GG G G A T GA A 
3 ’ TTG G C A A A A G A A G A A G A C A A A G C C A C
(n t 4 0 8 -4 3 4 )  
(n t 7 4 4 -7 2 0 )
p r im e rs e t  C: 5 ’ C T T T G T C T T C T T C I I I IG C C A A T T C  
3 ’ C A T T G T C A TTC TTG A TC TC A TC
(n t 7 2 5 -7 4 7 )  
(n t 9 9 4 -9 7 5 )
p r im e rs e t  D: 5 ’ G A TG A G A TC A A G A A TG A CA A TG  
3 ’ C A C TC TA G A C C A A G C TT TG G A TTT C
(n t 9 7 5 -9 9 5 )
(n t 1 2 1 0 - 1 1 8 5 )
Figure 5.1.2 : Regions of the Human Fas cDNA defined for SSCP analysis.
A line diagram depicts the cDNA for human Fas. Primer sets were designed for each of 
the four regions which were defined arbitrarily on the basis of size of the DNA fragment 
(250 - 350 bp being the optimum for SSCP analysis). Region 1 corresponds to the 
extracellular (Ec) 77 amino acids of Fas, whilst region 2 includes amino acids 70 - 182 
(AA 70 - 165 of Ec region and the 17 AA’s of the transmembrane region (Tm). The 
cytoplasmic (Cyt) amino acids of Fas were divided between regions 3 and 4 (amino acids 
175-264 and 258-336 respectively) with the “death domain” represented within region 3. 
The /prcg mutation of the mouse localises to region 3 (amino acid transition from Ile-225 
to Asn-225 corresponding with a Val-238 to Asn-238 transition in humans).
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5.1.3) SSCP polymorphism in Human SLE.
The results are shown in representative polyacrylamide gels demonstrating SSCP analysis 
of the FAS cDNA in Figures 5.1.3a, b and c. There was no evidence of 
polymorphism within the regions of the extracellular and transmembrane domains of the 
Fas cDNA (figure 5 .1 .3 a). The proximal part of the cytoplasmic domain (defined as 
region 3, figure 5 .1 .3b) which represents amino acids 175-264 revealed two 
predominant alleles (marked A and B) but there was no difference in the number or 
zygosity of alleles A and B when patients and normal samples were compared. As shown 
in figure 5.1.3b the predominant pattern was that of homozygosity for allele B, but there 
were no differences between normals and SLE patients. Equal numbers of patients and 
controls were also represented in alleles AA and AB.
Only one patient with SLE was found with a polymorphic band (figure 5 .1 .3 c) in 
region 4 which comprised the Fas cDNA encoding the last 78 amino acids of the Fas 
protein (cytoplasmic region). Independent SSCP analysis confirmed the polymorphic 
band as shown in figure 5 .1 .3d  and sequence analysis revealed a point mutation with 
an A to G transition at nucleotide position 1098 (translating to an Asp-300 replacing Asn- 
300). There were no unusual characteristics in the SLE phenotype of this patient. The 
results therefore show that except for the one patient with SLE no other genetic defects 
were evident in the Fas coding region in the sixty samples analysed.
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3 ’ (nt 1185)
REGION 1 REGION 3
259bp 273bp
primer se t A primer se t  C
Regions 1 and 2
SLE Normal
Figure 5.1.3 a: SSCP gel for regions 1 and 2.
Regions 1 and 2 as defined in the line drawing shown above and 
representing both the Ec (extracellular) domain and the Tm 
(transmembrane) domain of Fas cDNA showed no polymorphism by 
SSCP analysis. The SSCP gel shown is a representative 
autoradiograph of the 60 samples analysed, half of which were 
normal controls and half unselected SLE samples. Band patterns were 
identical for regions 1 and 2.
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Figure 5.1.3 b: SSCP gel for region 3 of the Fas cDNA.
A representative SSCP gel for region 3 (as defined in the line drawing above) 
is shown. This region represents the cytoplasmic domain o f Fas (amino acids 
175-264) which contains the “death domain”. Two predominant alleles were 
seen in this region (labelled A and B). Analysis by groups showed no 
differences between normal controls and SLE patients for either the number 
























Sequence change for sample 
in lane 4 :
AAAAAGCCgATCTTTG
A to G transition at nt 1098
Amino acid change from 
Asn-300 to Asp-300.
Figure 5.1.3 c: SSCP gel for region 4 of the Fas cDNA.
SSCP analysis for region 4 (as defined in the line drawing above) revealed 
one patient with SLE (lane 4) who had a polymorphic band as shown. This 
was independantly confirmed on two subsequent SSCP gels (one shown in 
figure 5.1.3d), and sequencing information revealed a point mutation at 
nucleotide 1098 (A to G transition resulting in amino acid change from 
Asn-300 to Asp-300). Further functional characterisation of this patient’s T 
cells was carried out in the JAM assay and is shown in figure 5.1.3d.
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In order to assess if the cytoplasmic mutation resulted in impaired apoptosis as occurs
with the point mutation of cytoplasmic Fas in the mouse, functional analysis was 
carried out on activated T cells of the patient with the SSCP mutation. This was done 
using a JAM assay. Fas-mediated apoptosis was tested using both CH 11 and our sFasL 
on day six after activation of the T cells with PMA / ionomycin. FACS analysis for Fas 
expression was also carried out and did not reveal any defect in surface Fas expression on 
this patient’s T cells.
Results of the in vitro apoptosis (as measured by a JAM assay) did not show any
impaired apoptosis as expected from the Ipi^Z model (figure 5.1.3d). In fact the Fas- 
mediated apoptosis was increased compared to normals. Therefore our in vitro analysis 
showed that the cytoplasmic mutation in our patient with SLE was associated with 
increased rather than decreased apoptosis. As a result, the question that arose was 
whether the enhanced apoptosis was due to the mutation occurring in the terminal 
“regulatory” domain of the Fas molecule. Deletion studies have shown that the terminal 
15 amino acids of Fas have a downregulatory function (Itoh et al, 1993). With this in 
mind we undertook to study further patients and controls with the in vitro apoptosis assay 
to see if the above mutation at nucleotide position 1098 was in fact specifically associated 
with increased apoptosis in this patient.
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Region 4
1 2 3 4 5 6 7 8
T cell apoptosis in vitro
Patient Normal
Stimulus
Figure 5.1.3 d: Functional characterisation of polymorphism from region 4.
An independant confirmation of the SSCP polymorphism is shown in the gel above 
(lane 5 corresponds to the same patient as in lane 4 figure 5.1.3c). An altered band 
migration can be seen (large and small arrows) compared to the surrounding 
normal and SLE samples. A point mutation was found in the cytoplasmic region of 
the patient cDNA (shown in figure 5.1.3c) and the T cells from this patient were 
further tested for in vitro apoptosis using the JAM assay. The results shown above 
suggest enhanced in vitro Fas-mediated apoptosis of the patient’s T cells compared 
to normal.
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5.2) APOPTOSIS IN SLE
Despite the absence of detectable genetic defects in the Fas cDNA of the SLE patients as a 
whole, it could still be possible that Fas function may be altered, and in light of the 
findings of increased apoptosis in the one patient with the cytoplasmic mutation it was 
essential to study the phenomenon in additional SLE patients. In the MRL-/pr mouse 
model the Fas gene abnormality is associated with impaired apoptosis, so that the 
autoimmunity is thought to be related to prolonged survival and function of activated 
lymphocytes. Thus an apparent discrepancy in our findings of increased apoptosis in this 
SLE patient needed to be addressed. We attempted to address the issue by studying the T 
cells from 20 samples (10 normal and 10 SLE). Therefore T cells from patients with SLE 
and normal controls were isolated and expanded as described (chapter 2.1.3) using PMA 
and ionomycin to induce T cell activation.
5.2.1) Upregulation of Fas surface expression on T cells
Published data have suggested that Fas-mediated apoptosis of T cells only occurred 5-6 
days after activation (Owen-Schaub et al, 1992). In order to therefore optimise Fas 
expression for the apoptosis assays we first established a time course of upregulation of 
Fas surface expression using PMA/ionomycin stimulation. The results (Figure 5 .2 .1 )  
confirmed maximal upregulation of Fas expression on T cells by six days after the 
mitogenic stimulus in our culture conditions. Therefore all samples obtained from patients 
and normal controls were handled under the same conditions so that apoptosis analysis 
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Figure 5.2.1: Upregulation of Fas expression on activated T cells.
Following PMA/ionomycin stimulation Fas surface expression was 
upregulated until day 6-7 as shown in this FACS analysis for Fas 
surface expression. Negative controls were stained with isotype- 
matched mouse IgM antibody and secondary detection was with anti­
mouse IgM-FITC.
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5.2.2 a) FACS analysis of T cells for Fas and FasL expression in SLE
In order to assess surface expression of Fas and FasL, T cells from SLE and normal 
controls were obtained as described (chapter 2.1.3). FACS analysis was conducted on 
day six activated T cells using CH 11 and Fas-Fc staining for Fas and FasL, respectively.
The results of the log scale mean fluorescence intensity (MFI) have been presented on a 
box plot in figure 5 .2 .2 . In figure 5.2.2 (a) it can be seen that the Fas surface 
expression on activated-day-six T cells was significantly higher in SLE compared to 
normal controls (p = 0.049, Mann Whitney U test) but there was no significant difference 
in FasL expression (p = 0.85, Mann Whitney U test).
Therefore under the controlled culture conditions established there was increased surface 
expression of Fas on activated T cells from SLE compared to normal T cells.
5.2.2 b) In vitro Fas-mediated apoptosis of activated T cells in SLE
To assess in vitro apoptosis in the twenty samples, DNA fragmentation analysis by JAM 
assay was used. T cells from the cultures were removed on day six for FACS analysis
and labelled with ^H-thymidine for the JAM assay.
The results obtained from each sample have been computed as a box plot in figu re  
5 .2 .2 b . Apoptosis induced by both CH 11 and sFasL showed a tendency to be 
increased in SLE compared to normal T cells. However, the differences did not reach 
statistical significance (p values 0.10 and 0.12 respectively for CH11 and sFasL). This 
may be explained by a relatively small number of samples, and the differences may 
become more significant if larger sample sizes are analysed. Based on an anticipitated 10 -
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15% difference in the rate of apoptosis with a standard deviation of between 5 and 8, a 
sample size of 20 was enough to detect a difference at 5% level of significance. The 
power of such a study was calculated at 80% from standard nomograms. However it 
remains difficult to define what level of difference of apoptosis within such an in vitro 
assay may be biologically and medically relevant, despite statistical significance.
Therefore we can only conclude from these data that SLE T cells have a higher level of 
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Figure 5.2.2 : Analysis of Fas expression and apoptosis in SLE.
FACS analysis revealed significantly increased surface expression of Fas (a)
(p value 0.049) in the SLE patient group compared to normals, but there was no 
difference detectable in FasL expression using the Fas-Fc protein for staining 
(the results are shown as a box plot of the mean fluorescence intensity derived 
from FACS analysis of 10 samples in each group). Although there was a trend to 
increased in vitro apoptosis in SLE mediated by Fas (b) in the case of both 
sFasL and CH 11 there was no significant difference statistically (p values 
shown , using Mann-Whitney U test).
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5.2.3) Correlation of apoptosis and clinical features of SLE:
The degree of in vitro apoptosis is not associated with clinical d isease 
param eters in our group of SLE patients.
In order to assess if the increased apoptosis was associated with any clinical 
manifestations of SLE, statistical correlation analysis was conducted. The SLICC index is 
a validated score of total tissue damage in SLE (Gladman et al, 1992) and it was decided 
to assess if apoptosis as measured in the in vitro assay correlated with the amount of 
tissue damage seen in SLE.
Figure 5 .2 .3  (a) shows the statistical correlation plot for apoptosis versus the SLICC 
index and there was no statistically significant correlation (p = 0.495, Spearman 
correlation). Similarly there was no statistically significant correlation between the degree 
of apoptosis in SLE and peripheral lymphocyte counts (shown in figure 5.2.3 b) or levels 
of double stranded DNA antibodies (dsDNA). The sample size was too small to analyse 
with any confidence the relationship between percent apoptosis and autoantibody status 
(for example ulRNP positivity).
Therefore our data suggested a trend towards an inverse correlation between the degree of 
in vitro apoptosis and lymphocyte counts and to a lesser extent between apoptosis and 
organ damage (SLICC index). However once again the results were not statistically 
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Figure 5.2.3 : Correlation analysis of Apoptosis versus SLE disease parameters.
Statistical analysis of the 20 samples (10 normal and 10 SLE) for correlation between the 
percent in vitro apoptosis and SLE disease parameters was conducted using Spearman 
correlation and regression plots as shown above. No significant relationship was found 
between organ damage (as defined by the SLICC index) and apoptosis in vitro (a). 
Similarly although there was a trend towards an inverse relationship between the degree 




It was very clear from the MRL-lpr mouse model of SLE that the Fas gene played a 
critical role in the development of the autoimmune manifestations within this mouse 
(Watanabe-Fukunaga et al, 1992). The critical nature of the Fas gene defect was 
highlighted by the fact that the autoimmune features were abrogated by a transgenic 
correction of the Fas gene defect within these mice as already mentioned (Wu et al, 1994).
Interestingly the Ipr c§ mouse also developed the same autoimmune features with only a 
single point mutation within the cytoplasmic region of the Fas gene (Watanabe-Fukunaga 
et al, 1992). Consequently, we undertook to study the role of Fas gene defects in human 
SLE. In order to achieve this we established the technique of SSCP analysis. SSCP 
analysis for DNA polymorphism was established for the first time in our laboratory using 
primers designed to generate a PCR mutant of Fas. A comparison of the mutant and 
normal Fas products which differed by only two bases allowed us to establish optimal gel 
electrophoresis conditions for the detection of mutations within the Fas gene. 
Consequently, PCR-SSCP analysis was conducted on sixty samples in total (thirty with 
SLE and thirty normal controls). The results showed no significant polymorphism within 
the Fas cDNA. Despite interesting allelic patterns evident in region 3 (figure 5.1.3b) there 
was no segregation of any particular allelic pattern with disease phenotype. However, one 
SLE patient revealed a band shift in the cytoplasmic region of the Fas cDNA. This SSCP 
band shift was confirmed on two further occasions before sequence analysis was 
conducted. Sequence analysis on the latter patient showed a point mutation within the
cytoplasmic death domain but unlike the Ipr c& mouse there was no impairment of Fas- 
mediated apoptosis. In fact this patient had evidence of enhanced in vitro apoptosis when 
measured by a JAM assay of DNA fragmentation, and its significance in relation to the 
site of the mutation has been discussed with the relevant results (section 5.1.3). 
However, as a result of the finding of increased death of lymphocytes by apoptosis in this 
patient with SLE, it was decided to explore if this occurred in other patients with SLE. 
Thus the apoptosis assays and reagents generated and described in the previous two 
chapters were exploited to study functional aspects of Fas biology in the context of human
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SLE. Contrary to the findings of decreased Fas expression and apoptosis in the MRL-/pr 
mouse, we found increased Fas expression on the surface of activated T cells from SLE 
patients and a tendency to enhanced in vitro Fas-mediated apoptosis. However, we could 
not find any statistically significant correlations with disease manifestations and the 
increased Fas-mediated apoptosis.
Other research groups studying the Fas gene in SLE have found no significant 
polymorphism related to disease, thus confirming our findings of a lack of Fas gene 
polymorphism in SLE (Fiucci et al, 1994). The latter study identified point mutations in 
three patients which proved to be insignificant because they caused no amino acid change 
in the protein. Therefore our approach of SSCP analysis whilst novel in its application to 
the analysis of the Fas gene in human disease, has not revealed any major genetic defects 
in human SLE. It remains to be seen if genetic defects can be identified for other Fas- 
associated molecules like FADD, FLICE, FLIP etc.
Much controversy surrounds the possibility that alternative splice variants producing a 
soluble Fas molecule may be elevated in SLE. The presence of elevated soluble Fas 
molecules could theoretically inhibit Fas-mediated apoptosis and thereby produce an Ipr- 
like phenotype in humans (Cheng et al, 1994). However, the detection of soluble Fas has 
not been consistently reproducible in different laboratories and elevations have been found 
in diseases other than SLE (Hasunuma et al, 1997; Knipping et al, 1995; Goel et al, 
1995). In addition the method of identification of levels of soluble Fas is questionable. 
Cheng et al (1994) first described an ELISA for measurement of soluble Fas but this was 
based on a variant of Fas found in one patient which was subsequently cloned and 
expressed. It would seem inappropriate to base a general population analysis of soluble 
Fas levels on an assay derived from a recombinant mutant Fas variant. There was no 
evidence of splice variants on our SSCP analysis where we would have expected that 
splice variants producing soluble Fas would be detectable as a change in size of the 
cDNA. Now that the genomic structure of the human Fas gene is available (Cheng et al, 
1995) it may be possible to consider an approach of SSCP analysis of genomic DNA
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from our SLE population. This may yield information about defects in the intronic 
sequences of Fas which would not have been detectable with our analysis of cDNA.
In addition to the genetic analysis we pursued functional analysis of apoptosis in an 
attempt to study if Fas was playing a role in the pathogenesis of SLE. We found 
increased in vitro apoptosis in some patients with SLE, but the overall analysis of the 
group (10 patients compared to 10 normals) did not show significantly enhanced 
apoptosis. The trend may however prove to be statistically significant with a larger 
sample size. Enhanced apoptosis in SLE has also been reported by Emlen et al (1994) in 
patients with SLE and subsequently by other authors (Ohsako et al, 1994; Amasaki et al,
1995). However, most conclusions have been extrapolated from the enhanced Fas 
expression seen on FACS. Our study identifies a direct Fas-mediated in vitro assay for 
measuring apoptosis using a natural ligand for Fas and could now be applied to the study 
of more patients with SLE and other autoimmune diseases. The identification of enhanced 
in vitro apoptosis in human SLE appears to be contradictory to the findings of impaired 
apoptosis in the MRL Ipr /Ipr mouse. However in vitro studies in the Ipr mouse have 
also shown increased apoptosis (Van Houten and Budd 1992). Whether these in vitro 
findings of increased apoptosis represent an artefact or not is uncertain. The enhanced 
apoptosis may simply reflect the activated state of lymphocytes from the SLE patients on 
removal from the body and this will need further analysis in the context of other diseases. 
Better in vivo analysis of apoptosis will also be needed to define the relevance of these in 
vitro findings.However, a suggested hypothesis that may explain the increased apoptosis 
and autoimmunity is provided by data from Casciola-Rosen et al (1994). They reported 
specific autoantigen presentation within apoptotic blebs after ultraviolet exposure of skin 
keratinocytes. In addition the ulRNP protein and other autoantigens like PARP, Topo-1, 
Ro and La antigens (Casiano et al, 1996) have been found in apoptotic particles following 
Fas stimulation. SLE skin is particularly sensitive to ultraviolet irradiation and it is 
conceivable that the apoptotic blebs containing cleaved autoantigenic products may flood 
the macrophage phagocytic system and allow antigen processing with a resultant 
autoimmune response including the autoantibody production reflected in these disorders.
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In view of our findings of increased apoptosis and the supportive data from the literature 
it was decided to analyse our patient group for any relationship between the level of 
apoptosis and the clinical manifestations of SLE. No significant correlation was detectable 
between the level of in vitro apoptosis and the clinical and serological features of SLE. 
The SLICC index is a validated damage index in SLE (Gladman et al, 1992) which 
reflects systemic tissue damage. Given the exaggerated apoptosis in vitro in the SLE 
samples it appeared reasonable to look for a correlation between the degree of apoptosis 
and tissue damage, but no statistically significant correlation could be found. Similarly 
there appeared to be no significant correlation between the degree of apoptosis and the 
lymphocyte count which is characteristically depressed in SLE. However, the trend of the 
correlation with lymphocytes suggested an inverse relationship and other workers have 
also found an inverse relationship between lymphocyte counts and percentage apoptosis 
(Amasaki et al, 1995). The difference in results may be explained by a difference in 
methods of apoptosis detection. Statistical significance of any relevant correlations may 
only become apparent with a greater sample size. Also subset analysis of larger groups of 
patients with SLE may allow us to identify if any associations exist between autoantibody 
production (such as ulRNP) and the enhanced in vitro apoptosis.
It must be noted that the Ipr gene only causes autoimmune features on certain 
backgrounds in mice (Izui et al 1984). For example the Ipr gene defect only results in 
significant autoimmunity in MRL mice but not in many other strains of mice. This would 
be in keeping with human SLE which is probably a multi-genetic disorder with a strong 
influence of environmental factors. From our analysis so far the Fas gene appears not to 
have any major defects in human SLE, but interesting functional defects may be present 
as outlined above. We have not conducted any analyis on the ligand for Fas, but one 
paper suggests that from a sample of 75 SLE patients only one had a defective FasL gene 
with resulting impaired apoptosis (Wu et al, 1996). It is possible that the Fas / FasL genes 
may play a role in only a subset of patients with SLE having specific features such as 
lymphadenopathy or glomerulonephritis. Given the heterogenous nature of SLE it may
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be necessary to identify particular sub-groups by clinical parameters or autoantibody 
profiles for further analysis of functional Fas-mediated apoptosis defects. This will be 
necessary in order to complete the analysis of the role of Fas as a candidate gene in the 
pathogenesis of SLE.
Increased Fas-related apoptosis has been associated with the development of diseases like 
Hashimoto’s thyroiditis (Giordano et al, 1997), Fulminant hepatitis (Kondo et al, 1997), 
Insulin dependent diabetes (Chervonsky et al, 1997) and graft versus host disease(Baker 
et al, 1997). Apart from the features of autoimmunity in some of these conditions, they 
appear to be unified in their pathogenesis by the process of Fas-mediated destruction of 
tissue. Despite the disappointing lack of evidence so far of a direct role for Fas gene 
defects in human SLE, a very interesting group of patients have been identified with Fas 
gene defects and disease resembling the Ipr mice in that they develop marked 
lymphoproliferative disease. It appears to affect mainly children and has been reported as 
various diseases including Autoimmune Lymphoproliferative Syndrome (AILPS) and the 
Canale Smith Syndrome (Fisher et al, 1995; Rieux-Laucat et al, 1995; Drappa et al,
1996). These probably represent the same disorder which is characterised by non- 
malignant lymphoproliferation with varying grades of autoimmune manifestations, 
associated with a variety of Fas gene defects and impaired apoptosis. Most of the defects 
are associated with dominant Fas gene defects but curiously a number of family members 
with heterozygous Fas gene defects had some in vitro abnormalities without the 
associated clinical features of disease (Rieux-Laucat et al, 1995). Whether or not the 
association with lymphoma development in some of the family members is real needs to 
be defined. There has been an association between SLE and malignancy (Banks et al, 
1979) and it would be interesting to look for Fas-related defects in these subgroups of 
SLE patients. This may have implications in the future identification and management of 
patients at high risk for the development of malignancy either de novo or secondary to the 
immunosuppressive drugs like azathioprine which are used in the treatment of SLE.
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Is there a unifying hypothesis to explain Fas-associated increased apoptosis in the 
pathogenesis of the SLE, whilst simultaneously explaining a possible role of impaired 
apoptosis in the subgroup of patients with malignancy? Given the number of associated 
death domain proteins that determine Fas function it is possible that a link could be found. 
One theory suggests that retroviruses may play a role in the pathogenesis of SLE (Izui et 
al, 1981). Whilst retroviral insertions into the Fas gene of the Ipr mouse have not been 
seen thus far in human SLE, it is conceivable that as yet unidentified viral proteins may 
interact with the Fas signalling mechanisms to increase apoptosis. It is known that the 
terminal 15 amino acids of Fas plays a regulatory role in reducing apoptosis (Itoh et al in 
1993) and viral proteins could theoretically interfere with this death domain function to 
“release the brake” as it were. Lymphotrophic viruses may explain the lymphocyte 
selective effect in SLE. On the other hand, it is possible that other as yet unidentified viral 
proteins resembling CrmA or Baculovirus p35 may block Fas signalling via the Caspase 
pathway leading to impaired apoptosis and the development of malignancy. Very recent 
identification of a viral like protein (FLIP) (Irmler et al, 1997) which inhibits apoptosis 
and another protein (Daxx) (Yang et al, 1997b) which enhances Fas associated apoptosis, 
have shown that the hypothesis is reasonable and other viral interacting proteins may well 
be identified in the future. It is possible that our understanding of the relationship between 




FINAL DISCUSSION and CONCLUSIONS
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In order to place this work in context it must be emphasized that when the project 
commenced essentially no reagents were available for the study of human Fas except 
for the CH 11 and anti-Apo-1 antibodies. Therefore in order to embark on a study 
relating to human Fas one of the primary objectives was the generation of appropriate 
reagents. This was undertaken using molecular and cellular techniques, firstly to 
modify and express a human Fas-Fc protein, and secondly to generate a soluble Fas 
ligand (sFasL) protein, both of which have been demonstrated to have specific effects 
in chapter 3 and 4 respectively. In addition, both reagents have proven useful in 
extending our understanding and contribution to current knowledge of Fas-FasL 
biology in human T cells (Boshell et al, 1996; McLeod et al, 1998; Walker et al, 
1998). These reagents, together with the expertise acquired in doing the DNA 
manipulation to generate them, also allowed us to extend our analysis to the role of the 
Fas gene in human SLE (chapter 5).
As described in chapter 3, the Fas-Fc protein was successfully generated by 
expression of a cloned Fas-Fc cDNA in a COS cell culture system. After validation 
and testing of the Fas-Fc, it was used as a blocking reagent in a variety of Fas 
apoptosis assays and, excitingly, particularly in the context of the time at which this 
work was carried out, Fas-Fc was useful in identifying a putative Fas ligand on the 
surface of activated T cells and Jurkat T cells. Specific immunoprecipitation of a 40Kd 
putative ligand was also carried out at that time when no other information was 
available on FasL. However, as it turned out, we encountered some problems with 
batch variation which took some months to explain, and other research workers using 
a very similar approach with a murine Fas-Fc protein were able to identify and clone 
the first ligand for Fas, albeit from a rat hybridoma (Suda et al, 1995). Subsequent 
data from them confirmed our findings that FasL was expressed specifically on 
activated T cells, but with further study it became evident that mRNA expression of 
FasL could be detected in a variety of other lymphoid and non-lymphoid cells. More 
recently, expression of FasL has also been found on immune privileged tissue such as
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the testis and cornea (Bellgrau et al, 1995; Griffith et al, 1995) and also on certain 
maligant tumours (section 1.3.7). Thus it was established over the recent years that 
FasL-Fas interactions were important in a variety of situations including lymphocyte 
cell death following activation (Nagata and Golstein, 1995), cytotoxicity mechanisms 
(Carter et al, 1995; Podack et al, 1995), NK cell function (Arase et al, 1994), 
neutrophil cell death (Liles et al, 1996) , eosinophil function (Tsuyuki et al, 1995), 
monocyte function (Shinohara et al, 1995), as well as some incompletely defined role 
in the function of hepatocytes (Galle et al, 1995), muscle cells (Seino et al, 1996), a 
variety of brain cells (Dowling et al, 1996; Dsouza et al, 1996), synoviocytes 
(Kawakami et al, 1996; Matsumoto et al, 1996), keratinocytes (Sayama et al, 1994), 
and thyroid cells (Giordano et al, 1997). The implications for therapeutic manipulation 
have therefore become far wider than originally anticipated, where Fas-FasL 
interactions were thought to be solely of importance in the maintenance of immune 
homeostasis.
As regards FasL surface expression, it also became clear that FasL itself was largely 
unstable on the cell surface and required metalloproteinase inhibitors to allow retention 
on the cell surface for detection by FACS analysis (Kayagaki et al, 1995). Besides 
offering some explanation for our findings of heterogenous expression of FasL on T 
cells when using our Fas-Fc construct as a “primary antibody”, this finding that FasL 
could be secreted as well as maintained as a cell surface protein offered a variety of 
possibilities in terms of FasL function. It became clear that FasL could act to mediate 
apoptosis via the Fas receptor not only by cell-cell contact but also by acting as a 
soluble mediator, similar to its prototype family member, TNF (Dhein et al 1995). 
Thus in situations where activated lymphocytes need to be eliminated, cell-cell contact 
such as occurs in the tight compartments of lymphoid tissue, will allow FasL-induced 
killing of sensitive Fas-positive targets cells. Similar cell-cell contact is probably 
responsible for the Fas-mediated apoptosis operative in cytotoxic and NK cell 
function, and in the maintenance of immune privilege (Brunner et al, 1995 and Ju et al,
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1995). In other situations however, where cell-cell contact may not be as evident, 
soluble FasL secreted into the cellular environment may play a role. It is unclear if this 
latter mechanism is the major one responsible for target cell destruction in situations 
like fulminant hepatitis, inflammatory muscle disease, cardiac disease and so on, 
where not as much cell-cell contact may be seen when compared to lymph nodes. As 
an extension of this hypothesis, one needs to consider if the small number of activated 
lymphocytes within these tissues may be responsible for soluble FasL release and 
innocent bystander killing of the Fas positive cells within the environment. Thus our 
findings that a human sFasL generated in vitro could effectively mediate apoptosis is 
consistent with recent descriptions of naturally produced soluble FasL (Dhein et al
1995). Our sFasL may therefore prove even more useful as a reagent for analysis of 
Fas-related cell-cell killing versus non-cognate cellular mediated apoptosis in a variety 
of diseases. With further isolation and purification of the sFasL it may even have some 
role in future for appropriate manipulation of the Fas system to enhance apoptosis 
where defective (e.g. lymphoid malignancies and drug resistance).
In order to manipulate the Fas system for therapeutic benefit, a better understanding is 
required of the signalling mechanisms which are engaged following Fas receptor 
engagement. We have shown that Fas engagement with both antibody and sFasL was 
associated with signalling via the sphingoymelinase and JNK pathways. However, 
both these signalling pathways are also activated by T cell proliferative signals, in 
particular CD28 (Su et al, 1994). It is unclear if these signalling pathways mediate 
multiple effects or whether the activation simply reflects bystander activation 
secondary to activation of other enzymes. Alternatively, activation of 
sphingomyelinase and JNK may reflect cellular activation of a cascade of reactions 
common to a number of stimuli, both proliferative and apoptotic and thereby serve to 
integrate subsequent signalling and cellular outcome. More work is required to 
understand the complex signalling events and their relevance to Fas-mediated 
apoptosis in particular.
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It appears that the Caspase cascade may be more specific to apoptosis signalling, but 
this also does not have specificity for Fas-based signalling (Martin and Green, 1995). 
Other protein interactions have been defined that suggest a hierarchy of protein-protein 
interactions with the Fas death domain (Cascino et al, 1996; Chinnaiyan et al, 1995 
and Muzio et al, 1996). Thus it appears that following Fas engagement, a death- 
inducing-signalling complex (DISC) is assembled on the Fas cytoplasmic death 
domain. This comprises proteins like FADD (Chinnaiyan et al, 1995; Muzio et al,
1996) and FLICE (Enari et al, 1996; Muzio et al, 1996) which may then induce the 
Caspase cascade and mitochondrial changes with committment to apoptosis. Negative 
regulation of this signalling pathway appears to be achieved through other death 
domain interacting proteins like FLIP (Irmler et al, 1997) and Daxx (Yang et al, 
1997b). A number of other signalling mechanisms have now been described following 
Fas engagement, including FAP and other phosphatases, but the exact significance 
within the death signalling cascade is not clearly defined as yet. Our transfectant 
system and reagents generated in this project could prove useful in dissecting some of 
these signalling pathways in order to define their significance. In particular, given that 
single genes regulating each step in the cascade of signalling can be introduced in a 
step by step manner into the CHO-Fas system, we may also be able to define the 
hierarchy of events following Fas receptor stimulation.
One consequence of the multiple interactions required for Fas-induced apoptosis is that 
not all Fas stimulation results in death by apoptosis. It has become evident that the 
appropriate engagement of death domain interactions is required in order to commit a 
cell down the death pathway (Chinnaiyan et al, 1995; Muzio et al, 1996). These 
discoveries shed tremendous light on our findings of resistance to Fas-induced 
apoptosis which were recorded at a very early stage of our investigations. In retrospect 
the original publications relating to Fas/Apo-1 also recorded a sensitivity to Fas 
stimulation of around 30-35% but the excitement of the discovery of Fas as a “death
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molecule” was probably the reason for this observation being overlooked (Owen- 
Schaub et al, 1992; Klas et al, 1993). However, subsequent publications by the same 
authors have now acknowledged the concept of resistance to Fas-induced apoptosis, 
and there is a flurry of activity underway to attempt to explain it. We have described a 
Fas resistant cell line generated from Jurkat T cells (JLW, chapter 4), which displayed 
Fas surface expression whilst demonstrating resistance to Fas-induced apoptosis. Our 
findings of intact but slightly reduced JNK signalling needs to be explored further, but 
an analysis of the role of the other death-domain-interacting proteins is clearly 
indicated. Resistance to Fas-mediated apoptosis may explain some of the diseases 
associated with Fas / CD95, including rheumatoid arthritis (Nishioka et al, 1998), 
Sjogren’s syndrome (Elkon, 1997), and drug resistant lymphoid malignancies. In 
these diseases Fas expression has been noted in lesional tissue but there appears to be 
an obvious survival, if not proliferation of the diseased tissue as is the case in the 
rheumatoid synovium, the lymphoid aggregates in sjogrens exocrine glands, and the 
persistance of Fas-positive lymphoma cells. More research work is clearly indicated 
before we can make any attempts to manipulate the Fas system in these diseases.
In order to test the reagents that were generated a number of apoptosis assays have 
been established and validated. Using one of these apoptosis assays (JAM assay for 
DNA fragmentation) we have been able to apply one of our generated reagents (sFasL) 
to study a prototypic autoimmune disease, SLE. Whilst no significant Fas genetic 
defects have been found in our SLE patients there are some interesting questions that 
arise from the evidence of increased in vitro apoptosis. Other approaches can also still 
be used to complete the analysis of the role of Fas and FasL in human SLE. It should 
be remembered that SLE is much more complex in its clinical phenotype than the MRL 
Ipr /Ipr mouse. Whilst the Fas gene defect in the mouse appears critical to the 
development of disease, this is clearly not the case from our studies thus far in human 
SLE . In order to define if the Fas-FasL system plays any role in the pathogenesis of 
human SLE, it will be necessary to study specific subgroups of patients with features
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of lymphadenopathy, malignancy and autoantibody defined subgroups. The analysis 
must include not only genetics of Fas and FasL but also functional studies of apoptosis 
in these groups of patients especially in light of our results that functional changes can 
occur despite normal genetic sequences.
Future work - a personal perspective.
Research into Fas and FasL biology is progressing at a rapid rate but much remains to 
be learnt about the mechanisms of resistance and sensitivity to Fas. With the 
identification of many new proteins that interact with the Fas signalling pathway, there 
will be many years of work ahead to try to identify key signalling interactions that 
determine cellular sensitivity to Fas engagement. Only with further understanding of 
these mechanisms could the Fas-FasL system be fully exploited for possible 
therapeutic intervention in relevant lymphoproliferative disorders and autoimmunity.
It remains to be seen if subsets of SLE with clinical features more closely resembling 
the Ipr phenotype can be identified to have structural Fas gene defects. Clearly genetic 
studies need to be completed for Fas-L in SLE and other autoimmune diseases. Given 
the data on selective autoantigen presentation within apoptotic blebs it may be 
important to subset patients with SLE and other autoimmune diseases like Scleroderma 
by their autoantibody profiles to see if there is any link between Fas-mediated 
apoptosis and disease.
The question of enhanced apoptosis rather than impaired apoptosis in autoimmune 
pathogenesis needs to be addressed. This may be approached also through an analysis
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of patients by autoantibody subsets but further supportive evidence will be needed for 
this hypothesis in vivo possibly using animal models.
The relevance of apoptosis in vivo in human disease is a difficult issue, but with rapid 
advancement in cellular technology, it is not unreasonable to aim in the future to label 
patient cells in order to track their outcome in vivo with appropriately designed “tools 
of measurement”. This may be very useful for example to define if the lymphopaenia 
of SLE is due to enhanced destruction by apoptosis.
It is the case so often in medical science that the discovery of a new molecule usually 
comes with the expectation that answers and cures will be found. In true fashion also, 
the discovery of Fas has brought with it many more questions that need to be 
answered before the knowledge can be fully applied for the benefit of patients.
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APPENDIX 1
A list of suppliers and contact telephone numbers follows in alphabetical order.
Amersham International pic (Little Chalfon, Bucks, UK)
Appligene (Britley, Chester-le-Street, UK)
BDH (Merck Ltd)
Becton Dickinson UK Ltd (Cowley , Oxford, UK)
Boehringer Mannheim (Lewes, East Sussex, UK)
BIO 101 Inc (La Jolla, California, USA) via Stratagene UK
BioRad Laboratories Ltd
CP Pharmaceuticals Ltd (Wrexham,UK) via Fisons UK.
Dynal (UK) Ltd (Croft Business Park, Bromborough,UK)
Fahrenheit Lab. Supplies (Kingswood, Bristol, UK)
Fisons Ltd (Loughborough, Leics, UK)
Genetic Research Instruments Ltd (Dunmow,Essex,UK)
ICN Biochemicals Ltd (UK)
Kodak (IBI limited)















LKB (see Wallac Ltd)
NBL Gene Sciences Ltd (Cramlington, Northumberland,UK)
New England Biolabs (Hitchin, Hertfordshire,UK)
Novagen (via AMS Biotechnology UK Ltd)
Nycomed UK Ltd (Sheldon, Birmingham, UK)
Pharmacia Biotech Ltd (St Albans, Herts,UK)
Phoretix International
Promega Ltd (Enterprise Road, Southampton,UK)
Sigma Aldrich Ltd (Poole, Dorset,UK)
Skatron Ltd (Newmarket, Suffolk, UK)
Stratagene
Unipath Ltd (Basingstoke, Hants,UK)





01993 706 500 
0121 7422444 
01727 814000 
0191 230 2121 
01703 760225 
01202 733114 
01638 660600 
01296 714 071
01509 231166 
01622 692022
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